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1. Abstract/Resumo 
1.1. English Version 
Both neuropathic and inflammatory chronic pains are associated with the lack 
of successful treatments and, consequently, are highly detrimental for the patients’ 
quality of life. Depression and anxiety disorders may emerge as a consequence of the 
long-term exposure to such painful conditions. This will not only have repercussions in 
the psychological state of the patient but will also potentiate the mechanisms 
underlying the negative effects of chronic pain. However, nowadays, such assumptions 
are still mainly hypothetical as the mechanisms underlying the association of pain with 
the development of mood disorders are still barely known. The Locus coeruleus-
noradrenergic system is an important candidate orchestrating the neuronal circuitries 
lying behind chronic painful conditions, and also has an exceptional role in the 
regulation of anxiety and depression disorders.  
In the first publication of this thesis (Publication I), we studied the activation 
pattern of extracellular signal-regulated kinases (pERK1/2, a marker of activation and 
plasticity) in the spinal cord and brainstem nuclei including several noradrenergic 
clusters like the A5, Locus coeruleus (LC) and A7, following seven days after chronic 
constriction injury (CCI) and/or after noxious mechanical stimulation. Associated with 
previous behavioral, electrophysiological and molecular data already existent in this 
pain model, these data led us to hypothesize that the noradrenergic system, and its 
main supplier nucleus, the LC, could be playing an important role mediated through 
ERK1/2 signaling. Moreover, the underlying mechanisms could be different for pain 
types of distinct origins. Thus, in Publication II, we also quantified the expression of 
pERK1/2 in the spinal cord and in the circuitry comprising the LC, the 
Paragigantocellularis nucleus (PGi, the main excitatory LC afferent), and the Prefrontal 
Cortex (PFC, the LC’s main projection), but now in the monoarthritis (MA) model of 
chronic joint inflammation, using an early- and a late-phase of the disease 
development. On the contrary to the neuropathic pain model, where it was detected a 
decreased pERK1/2 expression in LC upon seven days of CCI, in Publication II we 
described a late-phase activation of ERK1/2 accompanied by the emergence of anxiety 
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and depressive behaviors. These changes were reversed by topical anti-inflammatory 
therapy in the affected hind paw, suggesting a cause-effect relation. Thus, in 
Publication III, we also studied the electrophysiological activity of LC neurons in the 
same MA model at prolonged time-points of the inflammatory condition. The results 
obtained led us to hypothesize that ERK1/2 increased activation was related with an 
increased sensory-evoked response of the LC neurons to noxious mechanical 
stimulation, as well as with pain-related anxiety. This was confirmed by the 
administration of an ERK1/2 inhibitor (SL327) in the LC of rats submitted to chronic 
inflammation, which resulted in the reversion of the anxiety-like behavior, reversion of 
the electrophysiological changes and normalization of the ERK1/2 activation levels in 
the PFC. Additionally, we also found significant increases in the expression of tyrosine 
hydroxylase enzyme (a rate-limiting enzyme in the synthesis of noradrenaline) in the 
LC, in prolonged MA conditions. Finally, as most of the electrophysiological and 
biochemical characteristics observed in chronic inflammatory conditions were 
indicative of a stress component in this model, we evaluated the hypothesis of 
corticotropin-releasing factor (CRF)-mediated neurotransmission, a neuropeptide 
deeply implicated in the regulation of stress, being a precursor event triggering ERK1/2 
activation in the LC. Indeed, using a CRF antagonist, which blocks the activity of the 
endogenous CRF through CRF receptors, we observed the reversion of both the 
anxiety-like behavior and pERK1/2 levels in the LC of the animals with prolonged 
monoarthritis but no effects on the nociceptive behavior, strongly indicating that the 
CRF neuropeptide is as possible molecule triggering ERK1/2 activation in the LC in 
response to prolonged joint inflammatory conditions (Publication IV). 
In conclusion, neuropathic and inflammatory pains have different patterns of 
ERK1/2 activation in the LC at early time-points of disease duration. Particularly in 
chronic inflammatory pain, we showed that increased ERK1/2 activation in the LC plays 
a role in the increased perception to noxious stimuli and it is related with the 
emergence of pain-related anxiety. The CRF neurotransmission may act as precursor in 
these ERK1/2-mediated events. 
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1.2. Portuguese Version 
Tanto a dor neuropática como a dor crónica inflamatória estão associadas à 
falta de tratamentos bem-sucedidos e, consequentemente, são altamente prejudiciais 
à qualidade de vida dos doentes. A depressão e a ansiedade podem surgir como 
consequência da exposição, a longo-prazo, a essas condições dolorosas. Tal efeito não 
terá apenas repercussões no estado psicológico do doente mas também irá potenciar 
os mecanismos subjacentes aos efeitos negativos da dor crónica. No entanto, 
atualmente, tais suposições são hipotéticas pois os mecanismos subjacentes à 
associação da dor com o desenvolvimento de transtornos de humor são, ainda, pouco 
conhecidos. O sistema noradrenérgico-Locus coeruleus é um importante candidato a 
orquestrar os circuitos neuronais implicados nas condições dolorosas crónicas, tendo 
também um papel excecional na regulação da ansiedade e da depressão.  
Na primeira publicação desta tese (Publicação I), nós estudámos o padrão de 
ativação das cinases reguladas por sinais extracelulares (pERK1/2, um marcador de 
atividade e plasticidade) na medula espinhal e em núcleos do tronco cerebral incluindo 
vários grupos noradrenérgicos como o A5, o Locus coeruleus (LC) e o A7, após sete dias 
da cirurgia de constrição crónica do nervo ciático (CCI), e/ou após estimulação nóxica 
mecânica. Associados a dados prévios de comportamento, eletrofisiologia e 
moleculares para o modelo CCI, os resultados obtidos permitiram-nos supor que o 
sistema noradrenérgico e a sua maior fonte, o LC, pudessem estar a exercer um papel 
importante mediado pela sinalização via ERK1/2. Para além disso, o mecanismo 
subjacente poderia ser diferente para tipos de dor com diferentes origens. Assim, na 
Publicação II, também quantificámos a expressão de pERK1/2 na medula espinhal e no 
circuito compreendendo o LC, o núcleo Paragigantocelular (PGi, o aferente excitatório 
do LC mais significativo), e o Córtex Pré-frontal (PFC, a mais representativa projeção do 
LC), mas agora no modelo de inflamação articular crónica induzida pela monoartrite 
(MA), usando uma fase inicial e uma fase tardia do desenvolvimento da doença. Ao 
contrário do que foi verificado no modelo de dor neuropática, onde foi detetada uma 
diminuição significativa dos níveis de expressão de pERK1/2 no LC após 7 dias de CCI, 
na Publicação II nós descrevemos uma ativação tardia de ERK1/2 que foi 
acompanhada pelo aparecimento de comportamentos típicos de ansiedade e de 
depressão. Estas alterações foram revertidas por terapia anti-inflamatória tópica na 
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pata afetada, sugerindo uma relação causa-efeito. Assim, na Publicação III, nós 
também estudámos a atividade eletrofisiológica dos neurónios do LC no mesmo 
modelo da MA em tempos prolongados da condição inflamatória. Os resultados 
obtidos permitiram supor que o aumento de ativação de ERK1/2 estaria relacionado 
com um aumento da resposta evocada dos neurónios do LC à estimulação nóxica 
mecânica, bem como com a ansiedade associada com a dor. Isto foi confirmado pela 
administração de um inibidor de ativação de ERK1/2 (SL327) no LC de ratos 
submetidos à inflamação crónica, a qual resultou na reversão do comportamento 
típico de ansiedade, na reversão das alterações eletrofisiológicas e na normalização 
dos níveis de ativação de ERK1/2 no PFC. Aparte disto, também encontrámos um 
aumento significativo da expressão da enzima hidrólase da tirosina (a enzima limitante 
da síntese de noradrenalina) no LC, em condições de monoartrite prolongada. 
Finalmente, como grande parte dos resultados eletrofisiológicos e bioquímicos 
observados em condições de inflamação crónica eram indicativos de uma componente 
de estresse neste modelo, também avaliámos a hipótese da neurotransmissão 
mediada pelo fator libertador da corticotropina (CRF), um neuropéptido 
profundamente implicado na regulação da resposta ao estresse, poder ser um evento 
precursor da ativação de ERK1/2 no LC. De facto, usando um antagonista de CRF, um 
composto que bloqueia a atividade do CRF endógeno através dos seus recetores, 
observámos a reversão tanto dos comportamentos típicos de ansiedade como dos 
níveis de pERK1/2 no LC dos animais com monoartrite prolongada, mas sem alteração 
do comportamento nociceptivo, claramente indicando que o neuropéptido CRF é 
possivelmente uma molécula percursora que desencadeia a ativação de ERK1/2 em 
resposta a condições prolongadas de inflamação articular (Publicação IV).  
Em conclusão, a dor inflamatória e neuropática apresentam diferentes padrões 
de ativação de ERK1/2 no LC em tempos iniciais da doença. Particularmente na dor 
crónica inflamatória, nós mostrámos que um aumento da ativação de ERK1/2 no LC 
desempenha um papel na perceção aumentada a estímulos nóxicos e está relacionada 
com a manifestação de ansiedade relacionada com dor. A neurotransmissão pelo CRF 
parece atuar como percursor nos eventos mediados por ativação de ERK1/2. 
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2. Introduction 
 In a healthy person, pain sensation is an alert against a threat capable of 
damaging the body and, therefore, it is undeniable that the pain feeling has an 
important survival function. However, for reasons not completely understood so far, a 
painful condition may become permanent, even when there is no apparent threat, 
lacking its physiological function. In this case, the body turns into a state where the 
endogenous pain-controlling mechanisms are disrupted. This shift originates a 
condition that, nowadays, it is recognized as a disease by itself: Chronic Pain (Tracey 
and Bushnell 2009).  
 Chronic pain is highly prevalent in developed countries (Breivik et al. 2006; 
Azevedo et al. 2012). In Portugal, a recent study estimated that about 37% of the 
Portuguese population suffers from chronic pain (Azevedo et al. 2012). Moreover, 
13% of the chronic pain patients were diagnosed with depression and a huge 
percentage claimed interference with their job performance (Azevedo et al. 2012; 
Agaliotis et al. 2014). Logically, such unpleasant condition is accompanied by high 
disability in what regards to the performance of normal daily tasks, affecting the 
family and social environment, producing not only depressive symptoms but also 
anxiety and stress disorders (Reid et al. 2011; Gorczyca et al. 2013). The emergence 
of these disorders deteriorates the clinical diagnosis in chronic pain patients and, 
thus, it is common the recognition of a negative self-perpetuating pain cycle (Figure 
1). From an economic perspective, it represents considerable costs to health-related 
governmental services (Reid et al. 2011; Breivik et al. 2013). Indeed, in 2011 and just 
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in general indirect costs related with chronic pain in the lower back and joints, 
Portugal spent almost 750 million euros (Gouveia and Augusto 2011). More recently, 
it has been estimated that chronic pain in the Portuguese population is associated to 
a total of 2,000 million euros per year in direct costs that include visits to physicians 
and other health care professionals, pharmacologic and non-pharmacologic 
treatments and medical tests, while the total annual indirect costs, which have been 
underestimated, amount to 2,600 million euros, mostly related to early retirement 
due to chronic pain as well as job loss and absenteeism (Azevedo et al. 2014). In 
order to overcome such a problematic and complex disease, the comprehension of 
the possible causes and consequences of chronic pain is a justifiable need.  
 
Figure 1: Diagram representing some of the aspects leading to a negative self-perpetuating pain cycle. 
Pain leads to a guarding posture, which, at long-term, and potentiated by the presence of the painful 
stimulus, promotes a restricted mobility which leads to muscle weakness and decreased activity. 
Consequently, depression and anxiety emerge, aggravating pain diagnosis. 
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2.1. Pain definition 
 The most accepted and complete definition has been provided by the 
International Association for the Study of Pain (IASP), which postulates that pain is "an 
unpleasant sensation and an emotional experience associated with a real or a potential 
tissue damage or described in terms of such damage" (Merskey and Bogduk 1994). This 
definition indicates that pain is a multifaceted phenomenon, which can be dissociated 
in various dimensions. Thus, as being an experience, it is implicit that pain is always 
subjective, with each individual interpreting his pain according to previous 
motivational feelings and/or other painful experiences. In addition, it is undeniable 
that the unpleasantness associated to pain sensations prompts emotional distress. 
Accordingly, it is recognized that pain has well established components: the sensory-
discriminative, the cognitive-evaluative and the motivational-affective (Figure 2). As 
indicated by its designation, the temporal and spatial localization, as well as the 
physical characteristics and intensity quantification of the stimulus originating pain 
(noxious stimulus) are conveyed by the sensory-discriminative component. Similarly, 
the emotional perspective associated to such painful experience and its assimilation is 
provided by the cognitive and affective components, which are also responsible for the 
behavioral responses to pain (Melzack 2001; Handwerker 2002; Melzack and Katz 
2013).  
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Figure 2: Factors that contribute to the pain experience according to the dimensions of pain (Cognitive-
Evaluative, Sensory-Discriminative and Motivational-Affective). As a result, the output consists in pain 
perception as well as other body-self actions. Adapted from Melzack and Katz (2013). 
 
2.2. Pain classification 
Pain can be divided in several types according to its duration, etiology, 
localization or others, contributing to its complexity. Therefore, regarding the duration, 
pain can be acute or chronic, although this differentiation is, admittedly, artificial. 
Acute pain is defined as a short duration, phasic and intense physiological event which 
normally resolves immediately or a few hours/days after the phenomenon which 
initially originated pain is healed. It should be noted that several acute stimuli may 
produce pain, being therefore called noxious (e.g. strong pinch, a deep cut, heat/cold 
burn), but there are also several stimuli that, in normal conditions, are non-painful 
(innocuous; e.g. soft touch). Contrarily to acute pain, chronic pain is a long-lasting, 
tonic, persistent pathological pain that is present even when there is no apparent 
biological reason. In this case, it is characterized by its spontaneous nature (not elicited 
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by external stimuli), and by the presence of hyperalgesia and/or allodynia (Sandkuhler 
2009) (Figure 3). 
 
 
Figure 3: Graphic representation of the 
concepts of hyperalgesia, defined as an 
increased pain sensation due to a normal 
noxious stimulation (top), and allodynia, 
which is pain sensation following innocuous 
stimulation (bottom). This representation 
covers the changes made by IASP in 2008. All 
forms of pain amplification are now 
considered as hyperalgesia. Only in the case 
that pain is produced by activation of low-
threshold fibers (e.g. soft touch), the use of 
the term allodynia is correct. T0 represents 
the normal threshold for the correspondent 
sensation and Ts represents the time were 
the stimulation was performed. Illustration 
modified from Sandkuhler (2009). 
 
 
Chronic pain is the most problematic and challenging form of pain and 
represents a paradigm from the clinical perspective, mostly because there are several 
types of chronic pain in what respects to their etiology: visceral, inflammatory, 
neuropathic and/or mixed pain. Visceral pain arises from the viscera and is quite 
diffuse and difficult to localize, often producing what is called referred pain, where 
pain sensation is felt away from the site of the originating painful stimulus. Although 
viscera are not sensitive to cuts or burns, they are highly sensitive to distension, 
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ischemia and inflammation. Inflammatory pain is a response triggered by the 
activation of the immune system and it is included in the IASP description of 
nociceptive pain, which is defined as pain arising from the activation of nociceptors in 
non-neural damaged tissue. Although visceral and inflammatory pain may become 
chronic afterwards, they both have an evident acute component. On the contrary, 
neuropathic pain is caused by an injury of the central or peripheral somatosensory 
nervous system. Finally, mixed pain is a broad term which includes, for example, 
cancer pain. Thus, when these several types of pain overlap in the same patient the 
treatment is difficult due to the complex etiologies. This thesis will focus mainly on the 
chronic inflammatory pain process but will also address neuropathic pain, as justified 
in the following sections. 
 
2.3. Chronic inflammatory pain 
An inflammatory reaction is a normal response of the immune system to 
infection and injury. Besides being an unpleasant process, it is normally characterized 
by the presence of typical signs in the inflamed area, such as redness, heat, swelling 
and pain. This acute phase of inflammation has a beneficial effect that, hopefully, will 
lead to problem solving and to repair of the affected tissue. However, the imbalance of 
this process generates a predisposition to autoimmune disorders, excessive tissue 
damage, and other pathological conditions (Nathan 2002). Consequently, long-term 
inflammation triggers adaptive changes in the central nervous system (CNS) that 
originate exacerbated pain sensation (Ji et al. 2011). As mentioned above, such pain is 
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defined by IASP as nociceptive pain which categorizes the type of pain arising from the 
activation of nociceptors in non-neural damaged tissue. Several clinical conditions are 
associated with chronic inflammation. A representative example is arthritis which 
includes the highly prevalent autoimmune condition known as rheumatoid arthritis 
(RA, World Health Organization website: www.who.int/chp/topics/rheumatic/en/). 
Arthritis, and particularly RA, is a severe inflammatory condition and a common 
autoimmune disease characterized by high disability and systemic complications. Its 
causes are mainly unknown, although it is recognized the involvement of a complex 
interaction between genetic susceptibility and environmental risks (McInnes and 
Schett 2011). It produces synovial inflammation and hyperplasia (swelling), cartilage 
and bone destruction (deformity), which are perpetuated by positive feedback loops 
(Teramachi et al. 2011) (Figure 4). In RA, pain is the most prevailing symptom 
demanding medical assistance and immediate treatment (Phillips and Clauw 2013). 
Although the currently available pharmacological strategies, such as opioids and non-
steroid anti-inflammatory drugs (NSAIDs), are effective for pain relief, they are also 
quite limited due to their well-known adverse side effects (Ong et al. 2007). 
Additionally, a severe RA condition leads to the development of secondary symptoms 
such as anxiety, depression and stress (Covic et al. 2012) that not only burden the 
disease in itself, but that also enhance the negative emotional perspective regarding 
pain sensation and interpretation, as well as deeply affect the psychosocial 
environment of the patient (Gafvels et al. 2014). Despite the relevance of the 
emotional component of pain in RA patients, this has been neglected both in the 
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clinical practice and pre-clinical research. Indeed, from a molecular and mechanistic 
point-of-view, how these negative feelings, which are mostly a consequence of the RA 
(such as depression and anxiety), worsen the diagnosis of the disease is barely 
understood. One model that mimics the RA condition is the monoarthritis model, 
described by (Butler et al. 1992), but others are also available (Asquith et al. 2009). 
Monoarthritis is induced by a single unilateral injection of a complete Freund’s 
adjuvant (CFA) solution in the tibio-tarsal joint. Basically, the CFA solution contains 
killed/inactivated Mycobacterium, usually the Mycobacterium butyricum, in a water-in-
oil emulsion, and causes a slow release of antigens at the site of inoculation. The 
Mycobacterium is recognized by the immune system and triggers the innate adaptive 
immune response. This model is widely used mainly because it is easy to induce and 
has high reproducibility, it allows to predict the efficacy of therapeutic agents in 
humans, and lastly, because its pathogenesis and pathology are similar to what 
happens in the human condition (Bendele 2001). Additionally, the monoarthritis model 
has the great advantage of being restricted to the site of inoculation, therefore 
avoiding all the effects caused by systemic inflammation, such as in the polyarthritis 
model, which would, certainly, mask or interfere with the results.  
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Figure 4: Development and progression of rheumatoid arthritis. Left panel – synovitis is initiated and 
potentiated by positive feedback loops, promoting systemic responses that pop up the disorder 
(adapted from McInnes and Schett, 2011). Right panel: X-ray and histological staining of the rat’s hind 
paw in a control and a CFA condition, where inflammation and bone destruction are evident. Ti, tibia; 
Ta, tarsus; SM, synovial membrane. Scale bar: 200µm. Adapted from Teramachi et al (2011). 
 
2.4. Neuropathic pain 
According to IASP, neuropathic pain can be defined as “pain caused by lesion or 
disease of the somatosensory nervous system” (definition updated from Merskey and 
Bogduk 1994 – IASP). An example of a lesion or damage that may lead to neuropathic 
pain is amputation (stump pain; Jackson and Simpson 2004). Likewise, several diseases 
may be also in the origin of neuropathic pain. Exemplifying, autoimmune (e.g. multiple 
sclerosis), metabolic (e.g. diabetes), infectious (e.g. herpes zoster) and oncologic 
diseases are some of the conditions that may lead to deep changes in the nervous 
system generating neuropathic pain (Woolf and Mannion 1999; Cohen and Mao 2014).  
The treatment of neuropathic pain syndromes is commonly based on the use of 
several pharmacological approaches such as antidepressants, opioids, calcium-channel 
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alpha 2 delta ligands (gabapentin and pregabalin), topical capsaicin and lidocaine 
(Jefferies 2010). Although the number of clinical trials has been increasing in the last 
years, the efficacy of the pharmacological treatments in promoting pain alleviation is 
quite variable and, for countless patients, it is highly unsatisfactory (Attal et al. 2006; 
Attal et al. 2010). Similarly to what is observed in chronic inflammatory pain, 
neuropathic pain deeply affects the quality of life of the patients suffering from this 
condition. In addition, if it is accompanied by several unsuccessful attempts for getting 
an acceptable pain relief, the worst consequence is the development of secondary 
symptoms such as mood disorders (Yalcin et al. 2011; Alba-Delgado et al. 2013; Radat 
et al. 2013; Yalcin and Barrot 2014). 
The number of preclinical studies focusing on neuropathic pain has increased 
significantly in the last few years. According to Jaggi et al. (2011), the most used rat 
model of neuropathic pain is the one described by Bennett and Xie (1988). These 
authors demonstrated that the constriction of the sciatic nerve of the rat, achieved by 
tying four chromic catgut sutures around the nerve with 1mm apart, leads to 
persistent pain with significant mechanical and thermal hypersensitivity, as well as 
recurrent spontaneous pain, mimicking what occurs in human neuropathic conditions. 
Although the constriction injury is recognizably the main cause of pain in this model, 
an inflammatory component may not be discarded. The first indications that 
inflammation might be playing a role in the CCI model were raised by the fact that 
greater hyperalgesia is produced by the chromic suture than by the silk suture (Maves 
et al. 1993), suggesting that a chemical irritation produced by this suture is the basis of 
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pain symptoms development in the CCI model. Indeed, gene expression of 
inflammatory cytokines was detected in the CCI model of neuropathic pain in rats 
(Okamoto et al. 2001). Additionally, neuroinflammation was also observed in the 
sciatic nerve following CCI surgery (Vasudeva et al. 2014). Nevertheless, this 
inflammatory phenomenon resembles a special case of neuropathy, neuritis, which is 
defined by IASP as an inflammatory event affecting nerves. 
 
Figure 5: Illustration of the constriction of the sciatic nerve in rodents. The constriction is produced by 4 
chromic catgut sutures with 1mm apart. The muscle and the skin are sutured and pain is evident few 
days after the surgery.  
 
2.5. The processing of pain 
Despite their recognized complexity, the mechanisms by which the nociceptive 
inputs are transmitted from their point of origin to central supraspinal encephalic 
structures are reasonably well studied. However, nowadays there is an increased 
interest in other pain-related features that not only interfere with nociception but that 
may even potentiate it. Thus, for better therapeutic strategies enclosing all the pain-
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related components, it is fundamental to understand the neuroanatomical pathways 
implicated in noxious input sensing, transmission and processing, but it is also 
important to recognize the structures more susceptible to be involved in all the pain-
related spheres (sensorial, emotional, cognitive, etc.). 
Pain transmission is initiated by the activation of specific physiological 
receptors widely distributed throughout the body called nociceptors. These receptors 
are free nervous endings of the first-order afferent neurons. Usually, the nociceptors 
have a high activation threshold, which means that only intense stimuli are able to 
activate them, initiating the transduction and encoding of noxious stimuli into action 
potentials. Once activated, they display a response that gradually increases with the 
intensity of the stimulus, which can be mechanical, thermal or chemical (Dubin and 
Patapoutian 2010). Under certain pathological circumstances, these receptors may 
become sensitized, resulting in lower activation thresholds and even in their ongoing 
spontaneous activity (Dubin and Patapoutian 2010). 
The cutaneous first-order or primary afferent fibers can be classified into three 
types: A-Beta, A-Delta and C-fibers. All of these are capable of transmitting sensory 
information and have their soma localized at the dorsal root ganglion (DRG), but 
almost only the A-Delta type (small-diameter myelinated; 12-30 m/s) and C type 
(unmyelinated; 0.5-2.0 m/s) are specialized in noxious stimuli conduction (Treede et al. 
1998; Ringkamp 2008; Basbaum et al. 2009). In the skin, these afferents are present in 
the proportion of 70% and 10%, respectively. When a painful stimulus reaches the 
skin, A-Delta fibers propagate modality-specific information with marked intensity and 
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short-latency, promoting a quick pain sensation and triggering withdrawal actions, 
while C fibers conduct the information slowly. The information regarding the painful 
stimulus reaches the spinal cord level, particularly the dorsal horn of the spinal cord 
(Figure 6).  
 
 
Figure 6: Schematic representation of the primary afferent fibers organization and their specific inputs 
into the grey matter of the dorsal horn (left, adapted from Millan (1999)). It is important to note that 
the fibers specifically responsible for the transmission of noxious information overlap their areas of 
innervation in lamina I and II, being this region of the spinal cord the most common target in pain 
studies. Lamina VII, VIII and IX (mostly motor neurons) only receive innervations from spinal 
interneurons or from supraspinal centers. Distribution of Rexed laminae in the L4 segment of the spinal 
cord (right, adapted from Paxinos and Watson (2009)). 
 
 
At the spinal cord, the nociceptors establish synapses with second-order 
neurons distributed along the dorsal horn of the spinal cord. The grey matter of the 
spinal cord is organized in a ten laminae system known as the Rexed laminae 
(Molander et al. 1984) (Figure 6). This organization is based on the fact that each spinal 
cord lamina has its own predominance of neurons with a specific size and shape, and a 
particular cytological density and characteristics (Rexed 1952; Rexed 1954; Molander 
et al. 1984). Laminae I to VI constitute the dorsal horn, with lamina VI being only well 
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differentiated in the cervical and lumbar-sacral enlargements. Lamina VII corresponds 
to the intermediate zone, lamina VIII and IX compose the medial and lateral ventral 
horn, respectively, and lamina X comprises the area surrounding the central canal 
(Rexed 1952; Rexed 1954; Millan 1999). Lamina I (also known as the marginal zone or 
layer) and lamina II constitute the superficial dorsal horn and receive the nociceptive 
inputs from the primary afferents. In lamina I, most of the neurons are interneurons 
classified as fusiform, multipolar and pyramidal (Lima and Coimbra 1990). It contains 
very few projection neurons (about 5% in segment L4), that reach the brainstem, 
particularly the lateral parabrachial nucleus (LPB), and the thalamus (Lima and Coimbra 
1988). The lamina II neurons own their main classification to Ramón and Cajal’s (1909) 
work (Ramón y Cajal 1909). There are two main cell types: the central cell, which is 
widespread throughout the lamina, and the limitroph cell, that occurs in an outer band 
close to the lamina I-II border (lamina II outer; Paxinos 2004). In lamina III, 5 main cell 
types can be found: islet, central, radial, medial-lateral and vertical (Lu and Perl 2003; 
Lu and Perl 2005). Again, a small number of neurons in lamina III project to higher 
centers such as the thalamus, lateral cervical nucleus or pontine-medullary junction 
(Willis 1978). On the contrary to what is observed in laminae I and II, in lamina III, most 
of the neurons project diffusely to supraspinal levels (Todd et al. 2000; Todd et al. 
2009). In the dorsal horn, the neurons are differentiated according to the type of input 
they receive, being classified into three groups: the nociceptive neurons, the Wide 
Dynamic Range (WDR) neurons, and the non-nociceptive neurons (Grant 2004; Heise 
2009). The nociceptive specific neurons respond exclusively to stimuli with a painful 
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nature and are mainly localized in lamina I, II, V and VI. These neurons are implicated 
in the discrimination of the stimulus’ physical quality and localization (Grant 2004; 
Heise 2009). The WDR neurons receive inputs from the A-Delta and A-Beta fibers, are 
localized in lamina I, II, IV-VI and X, and have a higher ability to discriminate the 
stimulus intensity. Finally, the non-nociceptive neurons are activated by innocuous 
stimuli propagated by A-Delta and A-Beta fibers and can be found in lamina I, II and IV 
(Grant 2004; Heise 2009). Taking this into consideration, a great part of the spinal 
neurons that respond to nociceptive inputs from the periphery are localized in the 
superficial layers/laminae, which are, very often, the subject of study in several pain 
conditions.  
Most of the axons of the second-order dorsal horn neurons decussate to the 
contralateral side of the body and ascend through the anterior or posterior fascicle, 
forming bundles that allow the flow of the nociceptive information, which had been 
integrated in the different laminae of the spinal cord, until it reaches important 
supraspinal structures implicated in the modulation of the pain response. Afterwards, 
the nociceptive information is processed in order to trigger a response via the 
descending pain pathways. 
 
2.5.1. Ascending pain pathways 
It has been described that ascending bundles form tracts that can be named 
according to the most important brain areas where the axons end (Lima 2008). The 
most studied ascending tracts are the spinothalamic tract, the spinoreticular tract and 
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the spinomesencephalic tract. The spinothalamic tract neurons ascend majorly by the 
contralateral side (67-81%). In the lumbar segment of the spinal cord, the 
spinothalamic neurons are located in the medial part of lamina V and their axons 
terminate either in the lateral or medial thalamus. Projections to the lateral thalamus 
(lateral spinothalamic tract) target the ventroposterolateral and ventroposteromedial 
nuclei, collectively known as the ventrobasal complex of the thalamus, and the 
posterior complex, all of them involved in the sensory-discriminative aspects of pain 
(Albe-Fessard et al. 1985). The medial spinothalamic tract projects to the intralaminar 
nuclei and the central lateral nucleus of the thalamus, and plays an important role in 
the motivational-affective responses to pain. Collaterals of the spinothalamic tract 
reach the medullary reticular formation, the periaqueductal gray (PAG) and accumbens 
nucleus.  
The spinoreticular tract neurons originate mainly in laminae I, V, VII and VIII, X 
and lateral spinal nucleus. They ascend contralaterally from the spinal cord and reach 
the lateral, dorsal and gigantocellularis reticular nuclei, the oral and caudal pontine 
reticular nuclei, the dorsal and lateral paragigantocellularis nuclei (PGi), the Locus 
coeruleus (LC), the raphe magnus nucleus (RMg) and the median raphe nucleus 
(Kayalioglu 2009). Neurons in this tract respond to innocuous and noxious radiant heat 
and light tactile stimuli.  
The spinomesencephalic tract includes projections from the spinal cord to the 
midbrain, namely the PAG, dorsal raphe nucleus (DRN), cuneiform nucleus, deep layers 
of the superior colliculus, the red nucleus, the Edinger-Westphal nucleus (EW), among 
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others (Willis 2007; Kayalioglu 2009). Neurons in this tract respond to noxious and 
innocuous stimulation from cutaneous or deep structures such as joints and muscles. 
The projections to PAG are responsible for the motivational-affective responses to pain 
and for the descending control of nociception (Paxinos 2004). 
Although the main ascending pathways described originate in the spinal cord 
and have main targets in specific supraspinal regions, it is nowadays, recognized that 
they are not independent but, instead, they are interconnected with each other as 
they send to and receive collaterals from other nuclei. Thus, the nociceptive 
information is not processed in a single and isolated brain structure, and neither that 
brain structure receives information from only one area but, instead, it appears to be 
organized in a “pain matrix”. As proposed by Ossipov (2010), in this “pain matrix” there 
is constant interaction between brain structures, assuring that pain encompasses 
aspects like unpleasantness, anxiety, stress and emotion, contributing, undoubtedly, to 
the complexity of the pain experience (Ossipov et al. 2010; Tracey and Johns 2010). 
The “down-top” transmission originated by the painful signal is responsible for the 
pain perception at the cortical areas and it initiates the “top-down” mechanisms, 
which will be responsible for the motor-behavior responses. 
 
2.5.2. Descending pain pathways 
 After the information has been processed by the supraspinal centers of pain 
modulation, the balanced response to pain is achieved by the activation of descending 
pain pathways. In this “top-down” transmission, there are several nuclei implicated, 
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either directly (whose neurons send projections to the spinal cord) or indirectly (whose 
neurons send projections to other structures that are directly connected with the 
spinal cord), and some of them also participate in the ascending pain transmission. 
Included in these descending modulatory pathways are the corticospinal tract 
(originated in the cerebral cortex) and smaller descending tracts like those originated 
in the hypothalamus (paraventricular nucleus, PVN), in the midbrain (superior 
colliculus, PAG, supraoculomotor nucleus, interstitial nucleus of Cajal and cuneiform 
nucleus), and hindbrain (nucleus gigantocellularis, DRN, solitary tract nucleus, LC, 
subcoeruleus nuclei) (Paxinos 2004). Some of these structures are particularly 
interesting as they are part of the “endogenous pain inhibitory system” (Ossipov et al. 
2010), which results from the interconnectivity of several nuclei, mostly located in the 
brainstem. An important contributor to this inhibitory system is the noradrenergic 
system, through the activation of adrenergic receptors in the spinal cord (Ossipov et al. 
1990; Ossipov et al. 1990; Eisenach et al. 1998; Pertovaara 2006). Spinal noradrenaline 
(NA) is supplied by three main noradrenergic clusters in the brainstem, namely the A5, 
LC (or A6) and the A7 (the LC-NA system is described in detail in section 2.6). Besides 
the inhibitory effects, it is also known that the descending pain circuitry may be 
responsible for some facilitation of pain transmission, which may occur through the 
activation of the on-cells in the rostral ventromedial medulla (RVM; Kaplan and Fields 
1991; Morgan and Fields 1994), among other mechanisms. 
 At the end, pain is a consequence of a global effect where the facilitatory 
descending mechanisms exceed the inhibitory mechanisms, while analgesia (absence 
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of pain to painful stimulation) represents a state where the inhibitory mechanisms 
triumph.  
 
2.6. The noradrenergic system 
The noradrenergic system comprises a vital circuitry based on the action of NA 
on different and strategically located adrenergic receptors. In this way, NA exerts many 
important autonomic functions in the CNS, such as in sleep, arousal, vigilance and 
cognition, among others. Noradrenaline is a neurotransmitter biosynthesized by 
sequential enzymatic reactions starting with the amino acid tyrosine. The first and the 
most important step in this cascade is the conversion of tyrosine into 
dihydroxyphenylalanine (L-DOPA) through the enzymatic action of tyrosine 
hydroxylase (TH). After this step, the L-DOPA is converted into dopamine through the 
action of the aromatic L-amino acid descarboxylase. It is only in the noradrenergic 
neurons that dopamine is converted into noradrenaline by the dopamine β-
hydroxylase enzyme (Figure 7). The step catalyzed by TH is known as a rate-limiting 
step, as it directly interferes with the availability of dopamine and noradrenaline in the 
body, and the immunodetection of TH expression is often used as marker of 
dopaminergic/noradrenergic neurons as well as is indicative of these 
neurotransmitters synthesis demand (Bacopoulos and Bhatnagar 1977). After being 
synthesized, NA is stored in vesicles in the synaptic terminal of the axon. Following a 
specific electrical input, these vesicles attach to the neuronal membrane through the 
vesicular monoamine transporter, and their content is released into the synaptic cleft. 
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Then, NA binds to post-synaptic adrenergic receptors and, subsequently, activates 
intracellular signaling cascades that will translate the signal according to the type of 
adrenergic receptor activated (facilitatory or inhibitory receptor). After exerting their 
signaling function, the NA molecules can follow two different pathways: either they 
undergo reuptake by the presynaptic NA transporters and are recycled, or they 
undergo degradation by enzymes in the synaptic cleft and nerve terminal (Figure 7).  
The noradrenergic neurons are organized in seven clusters or groups, classified 
from A1 to A7 and located in the brainstem (Pertovaara 2006). From these, the A5 and 
A7 are responsible for the noradrenergic innervations of the spinal cord and the A6 
(also known as LC) innervates almost the entire forebrain and projects to the spinal 
cord as well. Pain regulation is one of the functions played by the noradrenergic 
system and, in particular, by the LC (Pertovaara 2006; Pertovaara 2013). However, to 
understand how NA modulates pain, it is important to know how the adrenergic 
receptors work. 
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Figure 7: Schematic representation of a noradrenergic synapse. Noradrenergic neurons, here 
represented as a pre-synaptic neuron, are the source of NA for the entire CNS. NA is synthesized from 
the aminoacid tyrosine through a cascade of events. After the synthesis, NA is stored in vesicles at the 
axon terminal. Following specific electrical inputs, these vesicles attach to the membrane and release 
the NA content into the synaptic cleft. In the extracellular space, NA exerts its function by binding to 
adrenergic receptors in the post-synaptic membrane. When the flow of NA in the synaptic cleft is high, 
α2-adrenoceptors in the pre-synaptic membrane (auto-receptors) are also activated and inhibit/cease 
NA release. At the same time, the extracellular NA content that is not binding to any receptor or already 
exerted its function may be recycled upon reuptake at the pre-synaptic membrane or may follow 
degradation. L-DOPA – L-dihydroxyphenylalanine; MAO – Monoamine oxydase; TH – Tyrosine 
hydroxylase. 
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2.6.1. Adrenergic receptors 
Two main categories divide the adrenergic receptors: type α- and type β- 
adrenoceptors. Although both categories have been found to be implicated in pain 
modulation, the α-adrenoceptors play a key role by mediating the pain regulatory 
effects of noradrenaline. Within each type, several subtypes are recognized. Thus, the 
α-adrenoceptors can be found as α1A, α1B, α1D, α2A, α2B, α2C and α2D (Ruffolo and 
Hieble 1994). In general, the action of these receptors is mediated by guanine 
nucleotide-binding regulatory proteins (G proteins). The α2-adrenoceptors are able to 
decrease the intracellular adenylcyclase activity through the Gi protein or directly 
modify the activity of certain ion channels acting, therefore, as inhibitors of signal 
transmission. In contrast, α1-adrenoceptors are coupled either to phospholipase C 
through the Gq protein or directly to calcium influx (Summers and McMartin 1993), 
being, therefore, excitatory to the transmission of the signal.  
The activation of α2-adrenoceptors localized in the somatodendritic area of 
catecholaminergic neurons (auto-receptors) produces inhibition of the nervous 
impulse discharge and further inhibition of NA release from the adrenergic terminals. 
However, α2-adrenoceptors are also found in non-adrenergic cells, acting as hetero-
receptors and contributing to the regulation of other important functions such as 
sedation (Gyires et al. 2009).  
The α1A, α1B, α2A and α2B-adrenoceptors are, so far, the most studied 
adrenoceptors. The α1A and α2A-adrenoceptors can be found widely throughout the 
supraspinal areas, mostly coinciding with the wide distribution of ascending pain 
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pathways. In contrast, the subtype α2B and α1B are more restricted to the thalamus 
(Pertovaara 2013) and the cerebral cortex, respectively (Nalepa et al. 2005). In the 
particular case of the LC, a large proportion of α2A receptors are inhibitory auto-
receptors located in the cell bodies (Aghajanian and VanderMaelen 1982), highlighting 
their role in a negative feedback mechanism involved in the regulation of LC electrical 
activity. 
 
2.6.2. The Locus coeruleus 
The LC, the main structure coordinating the central noradrenergic system, is 
located in the lateral floor of the fourth ventricle, in the pons of the brainstem. Its 
neuronal noradrenergic terminations reach almost the entire CNS, constituting an 
elaborated network. Although NA is the main neurotransmitter synthesized in the LC 
neurons, it was already shown that other substances are also produced in the nucleus 
as, for example, vasopressin, neurotensin and galanin, or others that are expressed in 
smaller amounts (Olpe and Steinmann 1991; Singewald and Philippu 1998).  
 
2.6.2.1 The Locus coeruleus main pathway 
The LC is strategically localized and establishes important connections in the 
CNS, which, in the particular case of chronic pain modulation, allow the coordination 
of both the sensory, by participating in the ascending and descending pain pathways 
(Figure 8), and the affective components (Renn and Dorsey 2005; Weiss et al. 2005). 
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In what regards to the ascending pain pathways, the LC receives and integrates 
inputs from two major nuclei, the Paragigantocellularis nucleus (PGi) and the 
Prepositus Hypoglossi (PrH; Aston-Jones et al. 1991), whose projections were 
demonstrated to be predominantly excitatory (glutamatergic; Ennis et al. 1992) and 
inhibitory (GABAergic; Ennis and Aston-Jones 1989), respectively. Additionally, the 
noradrenergic neurons in the LC extensively innervate forebrain structures that are 
involved in a wide range of functions, as for example the prefrontal cortex (PFC) 
(Morrison et al. 1979; Porrino and Goldman-Rakic 1982). It is described that the PFC is 
implicated in the cognitive and emotional/affective aspects of pain (Gusnard et al. 
2001; Phelps et al. 2004), and particularly the affective component of pain is 
modulated by the anterior cingulate cortex (ACC) subarea in humans (Rainville et al. 
1997; Wager et al. 2004) and rats (Johansen et al. 2001; Wei and Zhuo 2008; Cao et al. 
2009; Dai et al. 2011). Additionally, retrograde and anterograde labeling studies 
showed reciprocal connections between the LC and PFC (Porrino and Goldman-Rakic 
1982; Jodo et al. 1998; Heidbreder and Groenewegen 2003), establishing an 
interesting and regulatory feedback loop. Another quite important area of projection 
of LC neurons is the amygdala, one of the centers of excellence for the regulation of 
emotion (Asan 1998; Davidson et al. 2000). Additionally the LC receives inputs from 
the Hypothalamus (Reyes et al. 2005), reinforcing the importance of the NA-LC system 
in the affective/emotional sphere. In fact, is important to highlight the reciprocal 
connection between the LC and the PVN of the Hypothalamus, which represents the 
major source of corticotropin-releasing factor (CRF) although PGi neurons also deliver 
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CRF into the LC at a lesser extent (Valentino et al. 1992). CRF is implicated in stress, 
depression and pain and exerts its neuromodulatory function partially by targeting the 
noradrenergic LC pathway (Valentino and Van Bockstaele 2008). Interestingly, pain, 
particularly inflammatory pain, may act as a "stressor" agent modulated by CRF 
(Hummel et al. 2010) which, by itself, increases LC neuronal activity (Kubota et al. 
2012). Curiously, CRF administration into the LC area promoted c-Fos and pERK1/2 
expression in the PFC (Snyder et al. 2012), and glutamate-induced excitation of PVN 
neurons induced an increased activation of the LC neurons and PVN neurons 
containing CRF (Kubota et al. 2012). However, it still is rather unknown how chronic 
pain conditions affect this pathway. 
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Figure 8: Schematic representation of the most important ascending (red) and descending (green) pain 
pathways where the LC is a key structure. Briefly, when a painful stimulus is applied at the periphery, 
the noxious information is transduced and the nociceptive input is transmitted to the spinal cord where 
it triggers specific neurons within the superficial dorsal horn. The ascending axons decussate and ascend 
to several supraspinal structures. Those reaching the PGi nucleus and predominantly excitatory will, in 
turn, activate the LC neurons, and subsequently, the noradrenergic neurotransmission is increased. At 
the same time, descending pain pathways are triggered. These may be originated at the cortical areas or 
directly in the LC. Their axonal terminations are predominantly targeting the superficial dorsal horn, and 
will modulate the quality of the information that will ascend, therefore completing the circuitry. 
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2.6.2.2 The electrical activity of the Locus coeruleus 
As a major modulator of the state of arousal, the activity of LC neurons 
promotes wakefulness, a behavioral attribute whose relevance is undeniable in either 
healthy or unhealthy conditions. When a pathological condition affects the normal 
activity of the NA-LC system, harmful consequences in the normal arousal state may 
emerge. Chronic pain is one of these pathological conditions that, as a result of its 
sensory and emotional components, produce several changes in the normal 
functioning of the NA-LC system (Hirata and Aston-Jones 1994; Pertovaara 2006; 
Pertovaara 2013). 
At least two discharge patterns were identified in LC neurons: the tonic and 
phasic activity (Aston-Jones and Cohen 2005). The LC spikes are action potentials 
presenting long-duration (>2 ms) and positive-negative waveforms. The tonic activity 
corresponds to a spontaneous and regular firing, with a slow rhythm (0.5 and 5 Hz). 
The phasic activity occurs as a consequence of external relevant stimuli such as intense 
sounds or painful stimulation (Aston-Jones and Bloom 1981; Valentino and Foote 
1988). It is characterized by a rapid burst of 2-3 action potentials followed by an 
inhibitory or suppression period (Korf et al. 1974). This sensory-evoked response of the 
LC neurons is correlated with increased arousal and vigilance towards the initiating 
external stimulus (Aston-Jones and Cohen 2005), and it is accompanied by increased 
release of noradrenaline in the terminal areas (Florin-Lechner et al. 1996). 
Mechanistically, it has been shown that noxious hind paw stimulation activates the PGi 
glutamatergic nucleus which, hypothetically, may be responsible for an increased and 
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rapid activation of LC neurons upon external stimuli (Ennis and Aston-Jones 1988; 
Torres-Sanchez et al. 2013). This activation of the LC causes increased release of NA at 
the spinal cord level. Thus, the ascending noxious information will allow the LC 
neurons to engage descending feedback systems that regulate the output from the 
spinal cord. Pharmacological manipulation may act on this sensory-evoked response of 
the LC neurons as is demonstrated by Torres-Sanchez and partners (2013) in a study 
where tapentadol, an analgesic compound, inhibited the LC response to acute noxious 
stimulation (Torres-Sanchez et al. 2013). In normal healthy conditions, innocuous 
stimulation, such as low level auditory stimuli, does not produce this kind of response 
in the LC neurons (Grant et al. 1988), suggesting that the phasic activity is intensity-
dependent.  
As reviewed by Aston-Jones and Cohen, a direct correlation exists between the 
tonic to phasic ratio of the LC activity and the performance of tasks that require 
specific levels of attention (Aston-Jones and Cohen 2005). Animals are inattentive and 
lethargic at very low levels of LC tonic activity, and, on the contrary, they are 
distractible and overactive at very high levels of LC tonic activity (absence of phasic 
activity). These two situations reflect a poor behavior performance. An optimal 
behavior performance is observed when the tonic activity of the LC is moderate and a 
phasic LC activation occurs following a relevant stimuli related with the goal of the task 
(Aston-Jones and Cohen 2005). It was already shown that the tonic to phasic ratio was 
altered in several pathological conditions such as stress, pain and depression (Bravo et 
al. 2013; George et al. 2013).  
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2.6.3. The noradrenergic system in the sensorial and emotional pain sphere.  
Several years ago, it was described that the antinociceptive effect produced by 
electrical stimulation of the PAG or the RVM was accompanied by increased levels of 
noradrenaline in the cerebrospinal fluid and was blocked by the intrathecal 
administration of adrenergic antagonists (Barbaro et al. 1985; Hammond et al. 1985; 
Cui et al. 1999). These were the first findings implicating the noradrenergic system in 
descending pain modulation, particularly at the spinal cord level. In the following 
years, several studies contributed for the establishment of the spinal adrenergic 
receptors, particularly α2-adrenoceptors, as strongly involved in pain inhibition, since 
the use of several agonists, administered mainly at the spinal cord level, resulted in 
antinociceptive behaviors (Ossipov et al. 2010; Pertovaara 2013). Thus, it is well known 
that descending noradrenergic projections to the spinal cord, which are not all 
originated in the LC, result in pain inhibition (Hayashida and Eisenach 2010; Pertovaara 
2013). 
At supraspinal level, a great part of the structures implicated in pain 
modulation also express several adrenergic receptors (MacDonald and Scheinin 1995) 
and consequently, the noradrenergic system acts directly and indirectly in order to 
deal with a specific painful condition. The existence of this network pops out different 
modes of action and processing according to the type of stimulus. This explains why 
the activation of α2-adrenoceptors in the spinal cord is widely accepted as having a 
potent antinociceptive effect (Hayashida and Eisenach 2010; Pertovaara 2013) while at 
supraspinal level such relation is not always true. Indeed, administration of an agonist 
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for α2-adrenoceptors in the LC resulted in spinal antinociception in several pain 
conditions (Guo et al. 1996) but also produced pain behaviors without interfering with 
acute pain (Pertovaara and Hamalainen 1994). In contrast, the administration of an 
antagonist for α2-adrenoceptors in the LC had an anti-allodynic effect in nerve-injured 
rats which was reversed by the intrathecal administration of the same antagonist (Wei 
and Pertovaara 2006). Moreover, no significant effects were observed in control non-
pathological conditions. Overall, these results clearly suggest that, in neuropathic 
conditions, spinal and supraspinal α2-adrenoceptors have opposite effects (Wei and 
Pertovaara 2006). Thus, blocking or antagonizing the supraspinal activity of α2-
adrenoceptors may promote the descending noradrenergic transmission which, at 
spinal cord level, could act, for example, on α2-adrenoceptors present in the primary 
afferents terminals (presynaptic inhibition, Pan et al. 2002; Kawasaki et al. 2003) or 
inhibit excitatory interneurons (Olave and Maxwell 2002).  
Pharmacological manipulation of the α2-adrenoceptors is a widely used 
method for studying the role of these receptors in specific experimental pain 
conditions, and it is an indirect way to test the functionality under specific 
experimental conditions. On the other hand, protein quantification for the expression 
of adrenoceptors provides quantitative data that is also quite important. Indeed, in 
chronic pain conditions it was shown that the α2A adrenoceptor expression in the LC is 
enhanced while, in the spinal cord, it is decreased in the ipsilateral side (Stone et al. 
1999; Alba-Delgado et al. 2013). These results strongly indicate a relevant attenuation 
of the descending pain control at both spinal and supraspinal levels. Interestingly, in 
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post-mortem tissue from depressed patients it was found an elevated number of 
agonist binding sites for α2-adrenoceptors in the LC (Ordway et al. 2003), evidencing a 
similarity between depression and chronic pain conditions. Quantification of the TH 
enzyme expression is also often used as an indication of the noradrenaline synthesis 
demand and several studies addressed it in several experimental conditions. Alba-
Delgado et al. (2013) demonstrated that TH expression is increased in neuropathic 
conditions, when anxiety and depression were also detected. Also, this increase in TH 
expression was higher in comorbid neuropathic and depressive conditions, induced by 
using the CCI model and the chronic mild stress (CMS, model of depression) or social 
stress models simultaneously in the same animals (Bravo et al. 2013; Bravo et al. 
2014). Again, similar results were observed in post-mortem tissue from depressed 
patients (Zhu et al. 1999). Curiously, chronic administration of several antidepressants, 
known for their analgesic effects as well, resulted in a substantial down-regulation of 
the TH messenger ribonucleic acid (mRNA) expression in the LC (Nestler et al. 1990). 
These techniques are quite useful but they do not allow inferring about the role 
of a specific structure in specific conditions. One interesting study was performed by 
Tsuruoka et al. (2012) where the effects of a bilateral lesion in the LC/Subcoerular area 
on the development of peripheral hyperalgesia were evaluated in rats submitted to 
inflammatory pain (carrageenan model; Tsuruoka et al. 2012). They observed that, a 
few hours after induction of the inflammation, the LC-lesioned animals had 
significantly shorter latencies to heat stimuli than those with no lesion in the LC, 
indicating that peripheral inflammation activates the inhibitory pathway from the LC to 
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the spinal cord (the so called coeruleospinal inhibitory pathway, CSIP; Tsuruoka et al. 
2012), and reflecting a delay in the development of hyperalgesia in the acute phase of 
inflammation. In a study focused on the influence of the opioid system, the same 
authors observed that systemic administration of naloxone, a mu-opioid receptor 
antagonist, significantly decreased the paw withdrawal latencies in the LC-lesioned 
rats, in the acute phase of inflammation. This indicates that the opioid pain control 
mechanisms are active and interact with the CSIP. However, as no significant changes 
were observed with systemic administration of naloxone in sham non-lesioned rats, 
the authors concluded that the CSIP is predominant in acute inflammatory conditions 
(Tsuruoka et al. 2012).  
Another work that used a similar methodological approach in a model of 
neuropathic pain was performed by Brightwell and Taylor in 2009. Briefly, they used a 
model of neuropathic pain, the spared sural nerve injury and, two weeks after the 
surgery for the induction of neuropathic pain, they bilaterally administered lidocaine in 
the LC. This procedure reduced the neuropathic pain behaviors (allodynia and 
hyperalgesia), suggesting that, in a chronic pain condition, the LC contributes to pain 
facilitation (Brightwell and Taylor 2009). Additionally, they observed a bilateral 
increase in the expression of activation markers (c-Fos and phosphorylated CREB, 
cAMP response element-binding protein) in the LC after the application of an 
innocuous stimulus to the spared sural innervation territory of the hind paw 
(Brightwell and Taylor 2009). 
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Few studies were performed in order to understand the precise role of the NA-
LC system in pain-related affective disorders. In the CCI model of neuropathic pain, 
Alba-Delgado et al. (2013) demonstrated that some electrophysiological parameters of 
the LC firing, such as the variation coefficient and burst activity, were altered in rats 
following 28 days of CCI, a time-point that was accompanied by anxiety- and 
depressive-like behaviors, increased TH expression, increased noradrenaline 
transporter (NET) expression, and enhanced α2-adrenoreceptor expression and 
sensitivity (Alba-Delgado et al. 2013). Thus, the authors concluded that a 
noradrenergic dysfunction was occurring in the long-term CCI condition.  
Overall, the scientific community studying the role of the NA-LC system in 
chronic pain conditions recognizes that a deeper role may be attributed to this system, 
since inhibition of nociception is not the only function carried out by noradrenergic 
neurons. In this context, a role regarding the modulation of the development of 
secondary traits associated with untreated chronic painful conditions, such as anxiety 
and depression, is one of the hypotheses being tested by pre-clinical research. 
 
2.7. The extracellular signal-regulated kinases 1 and 2 (ERK1/2) 
Extracellular signal-regulated kinases 1 and 2 (ERK1/2) are members of the 
mitogen-activated protein kinases (MAPK) superfamily, ubiquitously expressed 
throughout the body, either in the activated and/or inactivated state (total proportion 
of ERK1/2). Because they have high homology in what respects to their protein 
structure and function, and are often activated together in the Ras-Raf-MEK-ERK signal 
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transduction cascade (Figure 9), they are commonly  referred jointly as ERK1/2 (Ji et al. 
2009). Their activation is achieved by phosphorylation and, therefore, the activated 
ERK1/2 is known as pERK1/2. Then, the main fate of pERK1/2 is the translocation into 
the nucleus in order to activate a wide range of transcriptional factors (c-fos or CREB) 
or remain in the cytoplasm exerting other functions (Figure 9). In normal and healthy 
conditions, the activation of the ERK1/2 cascade upon extracellular stimulation lasts 
between 20 minutes (transient activation) up to 2 to 3 hours (sustained activation). 
After exerting its function, the normal tracking of the ERK1/2 signaling cascade is 
dephosphorylation produced by phosphatases. However, several pathological 
conditions, including pain syndromes (Ji et al. 2002; Wei and Zhuo 2008), cancer and 
depressive disorders, deregulate the normal course of the Ras-Raf-MEK-ERK cascade 
producing either persistent or sustained ERK1/2 activation, by escaping from the 
phosphatases action, and/or by exacerbated extracellular stimulation (Wortzel and 
Seger 2011). 
Several conditions and factors were shown to induce ERK1/2 phosphorylation 
but it is the acknowledgement of their activation in several painful conditions that 
provides an increased interest for this work. Indeed, in the study of chronic pain it is 
imperative the use of good tools and appropriate targets and the activation of these 
kinases have emerged as a valuable and promising biomarker, particularly at the spinal 
cord level (Ji et al. 2009; White et al. 2011). Moreover, another subject where the 
MAPK cascade seems to be implicated is in the regulation of the affective sphere, such 
as in depression (Duric et al. 2010) and anxiety (Wang et al. 2010). This is a great 
Regulation of the activity of the Locus coeruleus-noradrenergic system in 
chronic pain 
Porto, 
2015 
 
49 
advantage considering that pERK1/2 expression may also be used as an activation 
marker when studying prolonged painful conditions where the affective component of 
pain is also triggered. 
Another benefit of the use pERK1/2 is the fact that it can be immunodetected 
in multiple cellular compartments, as neuronal perikarya and dendrites, allowing the 
delimitation of the cell morphology (Figure 9) (Flood et al. 1998; Koh et al. 2002). 
 
Figure 9: Schematic representation of the intracellular ERK1/2 activation/signaling cascade. A) The 
activation of Ras promotes the activity of the kinase RAF serine/threonine protein kinases and, 
subsequently, promotes the phosphorylation of the MEK 1/2 and ERK1/2. Most of the ERK1/2 activation 
inhibitors, such as SL327, act on this last step. The activated/phosphorylated ERK1/2 translocate into the 
nucleus and trigger the translation of many transcription factors. At the cytoplasm activated ERK1/2 
mediate several mechanisms including the phosphorylation of other proteins and receptors 
internalization. Modified from Ji et al. 2009. B) Detailed photomicrograph of a brain section (30μm thick) 
from a naïve rat showing pyramidal neurons in the prefrontal cortex labeled against the pERK1/2 
activated isoforms. The immunolabeling was revealed by using a ABC kit and 3,3’-diaminobenzidine. 
Original photomicrograph from the author. Scale bar =100μm. 
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2.7.1. ERK1/2 in pain 
The expression of ERK1/2 was studied in different pain types and experimental 
models and this has been the focus of several reviews (Ji et al. 2009; White et al. 2011; 
Borges et al. 2015). Indeed, several data suggest that these kinases may be an 
exceptional target for studying the signaling mechanisms underlying the processing of 
noxious stimuli in painful conditions, and that they may even represent a valid 
therapeutic target (Ciruela et al. 2003; Zhang et al. 2005; Ji et al. 2007). Accordingly, 
the use of specific upstream ERK inhibitors resulted in analgesia in several pain models 
(Cruz et al. 2005) and, in the same way, analgesic pharmacological approaches were 
also able to reduce pain-induced increases in ERK1/2 levels in the spinal cord (Cruz et 
al. 2005; Borges et al. 2014).  
In the LC, some studies addressed the expression of pERK1/2 in painful 
conditions. Thus, the formalin injection into the hind paw resulted in increased ERK1/2 
activation in the LC for 1 hour after the injection, while acute ERK1/2 activation after 
hind paw injection of CFA was not that prolonged (Imbe et al. 2009). It was shown that 
a great part (90%) of the cells expressing pERK1/2 were TH-positive neurons (Imbe et 
al. 2009). On the contrary, in the CCI model (7 days), it was shown that pERK1/2 was 
significantly decreased in the LC neurons (Borges et al. 2013). Despite the indication of 
a higher or lesser activation of LC neurons in certain pain conditions, this data is quite 
unsatisfactory when we are looking for the specificity of ERK1/2 role in those 
conditions.  
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2.7.2. ERK1/2 in pain-associated disorders 
Apart from the well-known role in pain signaling, at least at the spinal cord 
level, new roles have been attributed to ERK1/2 pain signaling at supraspinal levels in 
the last few years. Indeed, more than to the sensory component, ERK1/2 has also been 
associated to the affective/emotional component of pain (Borges et al. 2015). 
Important contributions for this knowledge were provided by Bravo and colleagues 
(2012) who showed for the first time that animals submitted simultaneously to the CCI 
model of pain and to a chronic mild stress protocol, as a model of depression, have 
increased aversion to painful experiences (Bravo et al. 2012). Interestingly, this 
behavioral response was accompanied by higher pERK1/2 expression and decreased 
neuronal density in the ACC (Bravo et al. 2012), suggesting that, although this cascade 
is highly activated, there is an evident neuronal loss under these experimental 
conditions. Thus, these studies represent undeniable evidences that depression might 
lead to impairments in pain interpretation in patients suffering from chronic pain, and 
that the ERK1/2 cascade in the ACC has a role on it (Bravo et al. 2012). Another 
important contribution was provided by Cao and colleagues (Cao et al. 2009). They 
reached similar conclusions by demonstrating the engagement of the ACC, which is 
part of the PFC, in the processing of the affective component of pain (Johansen et al. 
2001) and a role for ERK1/2-mediated signaling in these events. They used the formalin 
model of acute pain and observed that ERK1/2 activation in the ACC is needed for the 
induction and expression of the affective pain component (Cao et al. 2009), and that 
the ERK cascade in the ACC plays a central role in managing the pain-related negative 
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emotion and pain-related aversive learning underlying pain-predictive recognition and 
avoidance (Cao et al. 2009). 
The mechanisms associated to ERK signaling during anxio-depressive conditions 
are still barely known. It has been observed that ERK1/2 are involved in CRF receptor 
signaling in neuronal cells (Hauger et al. 2006). Interestingly, increased CRF 
neurotransmission has been associated with depression and anxiety and, more 
recently, its implication in pain was also shown (Hummel et al. 2010). Thus, it is 
possible that ERK1/2 modulate pain perception partly through mechanisms associated 
to CRF-mediated neurotransmission. 
Altogether, these important studies reinforce the fact that the study of ERK1/2 
expression might be an appropriate target in the search of the mechanisms underlying 
chronic pain conditions and/or anxio-depressive phenotypes associated to chronic 
pain. 
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3. Aims 
There is still sparse data regarding the role of LC neuronal activity in chronic 
pain conditions. In addition, it is barely understood the role of this nucleus and how its 
activity is modulated in chronic pain conditions that lead to the development of 
anxiety and depressive behaviors. Moreover, although several evidences implicate the 
activation of the ERK1/2 cascade in pain signaling mechanisms in the spinal cord, at 
supraspinal levels less is known. Particularly in the LC, the associated molecular 
mechanisms are hardly explored, and the possible contribution of ERK1/2 might be 
much more complex, especially when anxiety and depressive behaviors are present as 
a result of the chronic painful condition.  
Considering the above mentioned, the main aim of the present work was to 
understand how chronic pain conditions affect the activity of the Locus coeruleus 
neurons and if the signaling-mediated by the ERK1/2 cascade would be correlated 
with that activity. To achieve this goal several tasks, each devoted to a specific 
objective, were planned. First, to understand how ERK1/2-mediated signaling could be 
implicated in the development of neuropathic pain induced by the CCI model, we 
performed an extensive evaluation of the expression of phosphorylated ERK1/2 in the 
spinal cord, LC and other brainstem nuclei of CCI animals, either submitted or not to an 
acute noxious stimulation protocol (Publication I). To correlate with existing data 
(Alba-Delgado et al. 2011), we used CCI animals with 7 days of disease development 
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(Publication I). Sham (control) rats were submitted to an identical experimental 
protocol. We are planning to repeat the procedures in stimulated and non-stimulated 
CCI animals at a longer disease duration equal to that used in MA animals (Publication 
II), but no additional behavioral or electrophysiological approaches were performed 
because there was already data regarding this in the CCI neuropathic pain model. 
Indeed, the development of anxiety- and depression-like behaviors has also been 
shown in the CCI model at prolonged time-points (4 weeks; Alba-Delgado et al. 2013). 
Additionally, electrophysiological studies had already shown that the tonic and phasic 
activity of the LC neurons was not altered at earlier time-points of the CCI condition, 
namely at 7 (Alba-Delgado et al. 2011) and 14 days (Bravo et al. 2013), but that they 
were significantly altered, particularly the phasic activity, at 28 days after the CCI 
surgery (Alba-Delgado et al. 2013).  
At the time these experiments were performed it was unclear if a prolonged 
chronic inflammatory joint pain condition would also trigger the affective component 
of pain and what was the necessary disease duration for that to occur. Thus, we used 
the monoarthritis model induced by CFA injection into the tibiotarsal joint, and 
assessed the development of anxio-depressive behaviors in that chronic inflammatory 
painful condition (Publication II). Additionally, at supraspinal level, some sparse 
studies suggested the involvement of ERK1/2 signaling in the regulation of 
inflammatory pain (Imbe et al. 2009). To understand if these behavioral changes would 
be somehow associated with changes in ERK1/2 activation in the LC neurons, and in 
the main regions projecting to (PGi) or receiving afferents from (the spinal cord and 
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the PFC) the LC, we then evaluated the level of activation/phosphorylation of ERK1/2 
following different time-points of monoarthritis duration (Publication II). This allowed 
us to correlate with our data in the CCI model and to contribute to the existing 
information regarding ERK1/2 implication in chronic pain processing at supraspinal 
level. Secondly, in order to confirm that the inflammatory nociceptive input was the 
main cause of behavioral and molecular changes, namely in the activation of the 
ERK1/2 cascade, we studied the effect of the application to the inflamed paw of a topic 
anti-inflammatory drug. With this we were able to study the effect of the successful 
blockade of the nociceptive inputs arising from the inflamed paw on the affective 
dimension of pain, as well as on the level of activation of ERK1/2 in the PGi-LC-PFC 
pathway (Publication II). 
The electrophysiological activity of the LC neurons in response to exacerbated 
noxious input is also a hardly studied topic in chronic inflammatory pain models. 
Electrophysiological recordings of the LC neurons provide good quality data and allow 
the study of the two most important and recognized modes of LC function, the tonic 
and the phasic activities, as described (section 2.6.2.), which is a difficult, or even 
impossible, task to attain in studies devoted to the immunodetection of activation 
markers as are the pERK1/2 or the pCREB. Thus, to understand how the LC neurons 
activity is affected by the monoarthritic condition, we evaluated the 
electrophysiological properties of the tonic and evoked phasic activity of the 
noradrenergic neurons in the LC, in control and monoarthritic rats at different time-
points of evolution of the inflammatory pain condition (Publication III). A significant 
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increase in the phasic activity of the LC neurons was observed following long-term 
monoarthritis, which correlated with the pattern of pERK1/2 expression in the LC. 
Consequently, to functionally associate LC neurons electrical activity to ERK1/2-
mediated signaling, additional electrophysiological recordings of the phasic activity of 
the LC neurons were performed after local inhibition of ERK1/2 activation by the LC-
intra administration of the SL327 compound (Publication III). 
To evaluate the behavioral effects of blocking ERK1/2 activation directly in the 
LC, the nociceptive and anxiety-like behaviors were also evaluated in rats submitted to 
prolonged monoarthritis following an intra-LC administration of the same inhibitor of 
ERK1/2 activation (Publication III). Moreover, the expression of pERK1/2 in the ACC of 
the PFC was also addressed in those conditions (Publication III). To understand how 
the signaling mechanisms in the nociceptive system react to the monoarthritic chronic 
condition, the expression of activated/phosphorylated ERK1/2 and the TH expression 
were studied by immunohistochemistry in the LC of one week and four weeks 
monoarthritic rats, as compared to control non-inflamed animals (Publication III).  
Finally, it has been described that CRF activates the ERK1/2 signaling cascade to 
produce internalization of CRF receptors (Bonfiglio et al. 2013). Additionally, there are 
strong evidences supporting a role played by CRF in the LC, particularly in stress-
induced depression and anxiety conditions (Van Bockstaele et al. 2010). Taking into 
account that chronic inflammatory pain has already been considered as a “stressor” 
agent activating the CRF pathway (Hummel et al. 2010), we then explored the role of 
CRF-mediated neurotransmission in the LC in the nociceptive and anxiety-like 
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behaviors associated to prolonged inflammatory conditions by using a CRF receptor 
antagonist. We then evaluated the expression of CRF receptors in the LC as well as of 
pERK1/2 in the PVN, the main CRF supplier in the CNS, and in the LC, in the 
monoarthritic animals at prolonged time-points of disease and after the antagonist 
administration (Publication IV). 
In summary, in order to accomplish the objectives proposed for this thesis, and 
attain the main aim of the present thesis, this study was divided into six aims, each 
with specific tasks, as follows: 
 
 Aim I – To evaluate if the pattern of ERK1/2 activation is altered in the CCI 
model of neuropathic pain, by: 
 a) Evaluating ERK1/2 activation in the spinal cord and brainstem nuclei 
following seven days of chronic constriction injury (Publication I). 
 b) Analyzing if this pattern of ERK1/2 activation is altered following an 
additional mechanical stimulation of the area innervated by the constricted 
sciatic nerve (Publication I). 
 
 Aim II – To evaluate if a monoarthritic painful condition triggers the affective 
component of pain and if is this correlated with changes in ERK1/2 activation in 
the PGi-LC-PFC pathway, by: 
 a) Evaluating the development of anxiety- and depressive-like behaviors at 
different time-points of the monoarthritic disease (Publication II). 
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 b) Assessing if ERK1/2 activation, evaluated by pERK1/2 expression, is altered in 
the PGi-LC-PFC pathway in those pathological conditions (Publication II). 
 
 Aim III – To evaluate if the behavioral and molecular changes observed in the 
monoarthritic animals (Aim II) are reversed by topical analgesia, by: 
 a) Studying the effect of a local maintained analgesia in the anxiety- and 
depressive-like behaviors that had been triggered by the prolonged 
monoarthritic states (Publication II). 
 b) Investigating the effect of a local maintained analgesia in the monoarthritis-
induced increased ERK1/2 activation in the PGi-LC-PFC pathway (Publication 
II). 
 
 Aim IV – To evaluate if the electrophysiological activity of LC neurons is altered 
at an earlier (when only nociceptive behavior is detected) and/or at a late-
phase (when there is also an anxio-depressive phenotype) of the monoarthritic 
condition, by: 
 a) Studying the tonic-spontaneous activity and the phasic-evoked activity of the 
LC neurons in anaesthetized rats bearing a monoarthritic condition 
(Publication III). 
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 Aim V – To evaluate if the increased ERK1/2 activation (observed in Aim II) is 
correlated with an increased phasic activity of LC neurons (detected in Aim IV), 
and how is the noradrenergic demand and pERK1/2 in cortical areas (Aim II) in 
those conditions, by: 
 a) Investigating the effect of inhibiting ERK1/2 activation directly in LC neurons 
(intra-LC injections) on the phasic activity of the LC neurons (Publication III). 
 b) Evaluating if ERK1/2 activation (pERK1/2 expression) in the LC and ACC is 
altered in monoarthritis-induced chronic inflammatory painful condition 
(Publication III). 
 c) Analyzing tyrosine hydroxylase expression in the LC of the same 
monoarthritic animals (Publication III). 
 
 Aim VI - To evaluate if the inhibition of the ERK1/2 activation in the LC in 
prolonged monoarthritis has effects on the nociceptive and anxiety-like 
behaviors, by: 
 a) Investigating the effect of inhibiting ERK1/2 activation directly in LC neurons 
(intra-LC injections) on the nociceptive behavior (Publication III). 
 b) Investigating the effect of inhibiting ERK1/2 activation directly in LC neurons 
(intra-LC injections) on the anxiety-like behavior (Publication III). 
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 Aim VII – To evaluate if the CRF neurotransmission in the LC upon prolonged 
inflammatory conditions plays a role in the nociception and anxiety-like 
behaviors and ERK1/2-mediated signaling, by: 
 a) Evaluating changes in the expression of CRF receptors in the LC during 
monoarthritis (Publication IV). 
 b) Analyzing the activation of ERK1/2 in the PVN of the hypothalamus, the main 
supplier of CRF, during monoarthritis (Publication IV). 
 c) Studying the effect of blocking CRF neurotransmission within the LC (intra-LC 
injection of a CRF receptor antagonist) on the nociceptive and anxiety-like 
behaviors (Publication IV). 
 d) Studying the effect of blocking CRF neurotransmission within the LC (intra-LC 
injection of a CRF receptor antagonist) on the activation of ERK1/2 in LC 
neurons (Publication IV). 
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Abstract
Background: The role of extracellular signal-regulated kinases (ERKs) in
nociception has been explored in the last years. While in spinal cord their
activation is frequently correlated with pain or acute noxious stimuli,
supraspinally, this association is not so evident and remains unclear. This
study aims to evaluate ERK1/2 activation in the spinal cord and brainstem
nuclei upon neuropathy and/or an additional mechanical stimulus.
Methods: Acute noxious mechanical stimulation was applied in the left
hindpaw of anaesthetized SHAM-operated and chronic constriction
injured (CCI, neuropathic pain model) rats. Other SHAM or CCI rats
did not receive any stimulus. Immunohistochemistry against the
phosphorylated isoforms of ERK1/2 (pERK1/2) was performed in lumbar
spinal cord and brainstem sections to assess ERK1/2 activation.
Results: In the spinal cord, stimulation promoted an increase in pERK1/2
expression in the superficial dorsal horn of SHAM rats. No significant
effects were caused by CCI alone. At supraspinal level, changes in ERK1/2
activation induced by CCI were observed in A5, locus coeruleus (LC),
raphe obscurus (ROb), raphe magnus, dorsal raphe (DRN), lateral reticular
and paragigantocellularis nucleus. CCI increased pERK1/2 expression in all
these nuclei, with exception of LC, where a significant decrease was
verified. Mechanical noxious stimulation of CCI rats decreased pERK1/2
expression in ROb and DRN, but no further changes were detected in
either SHAM- or CCI-stimulated animals.
Conclusion: ERK1/2 are differentially activated in the spinal cord and in
selected brainstem nuclei implicated in nociception, in response to an
acute noxious stimulus and/or to a neuropathic pain condition.
1. Introduction
Extracellular signal-regulated kinases 1 and 2
(ERK1/2) are members of the mitogen-activated
protein kinase (MAPK) family, translating extracellular
stimuli into intracellular responses (Ji et al., 2009).
Immunodetection of ERK1/2 phosphorylation/
activation (pERK1/2) is observed in multiple compart-
ments as neuronal perikarya and dendrites, allowing
cell morphology delimitation (Flood et al., 1998; Koh
et al., 2002). pERK1/2 expression in spinal cord dorsal
horn neurons depends on nociceptive activity, there-
fore being used as a marker in pain studies (Ji et al.,
2009). Indeed, spinal ERK1/2 activation was observed
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in the presence of allodynia and/or hyperalgesia (Gao
and Ji, 2010; Han et al., 2011), two types of exacer-
bated nociception characteristic of persistent painful
conditions. ERK1/2 involvement in the signalling of
noxious stimuli has been studied in different pain
models, and its spinal activation has been correlated
with chronic inflammatory pain (Cruz et al., 2005,
2007; Imbe et al., 2009; Ji et al., 2009). Also, ERK1/2
seem to be implicated in neuropathic pain and may
even represent a therapeutic target (Ciruela et al.,
2003; Zhang et al., 2005). Accordingly, the use of spe-
cific upstream ERK inhibitors resulted in analgesia in
several pain models (Ji et al., 2002; Galan et al., 2003;
Cruz et al., 2005).
Despite the numerous studies evaluating pERK1/2
in spinal cord in distinct pain conditions (Song et al.,
2005; Zhang et al., 2005), equivalent knowledge in
supraspinal structures is scarce. Indeed, ERK1/2 acti-
vation in pain-related encephalic areas has been
studied in only a few regions. Exemplifying, in locus
coeruleus (LC or A6), the main source of noradrena-
line (NA) in central nervous system (CNS), high
ERK1/2 activation induced by acute noxious stimula-
tion was shown (Imbe et al., 2009). Spinal cord
receives noradrenergic inputs from brainstem pontine
A5, LC and A7 (Millan, 2002), and all these nuclei are
connected with periaqueductal grey (PAG, Bajic and
Proudfit, 1999), a region involved in descending pain
modulation. Serotonergic nuclei, as the raphe magnus
(RMg), dorsal raphe (DRN) and median raphe, are also
important in pain modulation (Suzuki et al., 2004).
RMg has been proposed as one region responsible for
the increased serotonin (5-HT) release into the spinal
cord verified upon PAG stimulation (Cui et al., 1999).
Interestingly, attenuation of formalin-evoked spinal
ERK1/2 activation was observed upon depletion of
spinal 5-HT (Svensson et al., 2006).
In chronic inflammatory pain, we showed that
spinal ERK1/2 activation requires movement of the
arthritic joint (Cruz et al., 2005). We also reported
increased pERK1/2 expression in spinal cord, paragi-
gantocellularis nucleus (PGi) and DRN in the chronic
constriction injury (CCI, Bennett and Xie, 1988)
model of neuropathic pain (Alba-Delgado et al.,
2012). However, it is unknown if this happens in other
supraspinal structures implicated in cognitive, affec-
tive and sensory functions following neuropathic pain
or if this is altered by additional noxious stimulation.
For effective therapeutic purposes this is important to
check. We evaluated, by immunohistochemistry, CCI-
induced pERK1/2 expression in lumbar spinal cord
and selected brainstem areas, and the effect of a
mechanical noxious stimulation applied in the
hindpaw of anaesthetized rats.
2. Methods
2.1 Animals
Experiments were carried out in 39 adult male Harlan
Sprague-Dawley rats (250–300 g), housed 4 per cage
under controlled conditions of lighting (12 h light/
12 h dark cycle), temperature (22 °C) and humidity
(45–60%), with food and water ad libitum. All efforts
were made to minimize distress and reduce the
number of animals. Procedures followed the European
Communities Council Directive (86/609/EEC), the
Spanish Law (RD 1201/2005) and the ethical guide-
lines for pain investigation in animals (Zimmermann,
1983).
2.2 Neuropathic pain model
Neuropathic pain was induced by sciatic nerve con-
striction (CCI model) following established surgical
procedures (Bennett and Xie, 1988; Berrocoso et al.,
2007) in anaesthetized rats (intraperitoneal sodium
pentobarbital, 50 mg/kg; Sigma, Madrid, Spain).
Briefly, four chromic gut (4/0) ligatures were loosely
tied around the left sciatic nerve, about 1.0 mm apart
(CCI operated) and the surgical wound was sutured.
Control animals (SHAM) experienced similar proce-
dures except for the sciatic nerve ligation. All
animals were used 7 days after SHAM or CCI sur-
geries. Behavioural tests were performed in an addi-
tional set of SHAM and CCI animals to avoid further
paw stimulation.
What’s already known about this topic?
• Expression of extracellular signal-regulated
kinases (pERK1/2) in spinal cord dorsal horn
neurons depends on nociceptive activity.
• The use of specific ERK inhibitors resulted in
analgesia.
• ERK1/2 seem to be implicated in chronic pain
and may even represent a therapeutic target.
What does this study add?
• Acute mechanical noxious stimulation
modulates ERK1/2 activation in the spinal cord;
supraspinally, the CCI is prevailing, in relation to
acute stimulation promoting pERK1/2 increases
or decreases; ERK1/2 activity in descending
modulation pathways is differentially altered.
ERK1/2 activation in the brainstem of CCI rats G.S. Borges et al.
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2.3 Validation of the neuropathic pain model
A parallel set of animals (SHAM n = 8 and CCI n = 8)
was used to evaluate mechanical and thermal hyper-
algesia, as described (Alba-Delgado et al., 2012). Rats
were habituated for 3 days before experiments.
Randall–Selitto’s paw pressure apparatus (Ugo Basile,
Comerio, Italy) was used to evaluate the withdrawal
threshold to paw mechanical stimulation (Randall and
Selitto, 1957). The hindpaw was submitted to an
increasing force (250 g cut-off) until rats vocalized or
withdrew the paw. Reduced withdrawal latency indi-
cates mechanical hyperalgesia.
Withdrawal threshold to paw thermal stimulation
was evaluated by the Hargreaves’ plantar test appara-
tus (Ugo Basile, Hargreaves et al., 1988). Animals
were placed on a 2-mm-thick glass floor with an infra-
red heat generator under the floor targeted at the rat’s
hindpaw. Rats could freely withdraw the paw and the
paw withdrawal latency was recorded automatically.
Reduced withdrawal latency indicates thermal hyper-
algesia. In both tests, three measures taken on each
paw at 5-min intervals were averaged.
2.4 Noxious mechanical stimulation
To evaluate the effect of noxious mechanical stimula-
tion on ERK1/2 activation, SHAM or CCI animals
were anaesthetized by intraperitoneal injection of
chloral hydrate (35%, 350 mg/kg; Panreac, Barcelona,
Spain) to avoid confounding factors resultant from
painful stimulation (e.g., arousal, anxiety or stress)
which, by themselves, could trigger ERK1/2 activa-
tion, and were submitted to mechanical noxious
stimulation. This consisted of 4 pinches/min (1–2 s/
pinch) for 20 min, manually applied with a similar and
constant force with a rat-tooth forceps (Pinto et al.,
2003) in the left hindpaw area innervated by the
sciatic nerve [SHAM-stimulated (SS) and CCI stimu-
lated (CCIS), n = 6 per group]. Other two groups of
anaesthetized rats were not submitted to noxious
stimulation [SHAM not stimulated (SNS), n = 6; CCI
not stimulated (CCINS), n = 5].
2.5 Tissue processing and
immunohistochemistry
After noxious mechanical stimulation (or not), the
anaesthetized animals were transcardially perfused
through the ascending aorta with 250 mL of oxygen-
ated Tyrode’s solution followed by 750 mL of
paraformaldehyde 4% in phosphate buffer, 0.1 mol/L
pH 7.2. Brains and spinal cords were processed for
free-floating immunohistochemistry (Cruz et al.,
2005; Nascimento et al., 2011) against pERK1/2. One
in each five 40-mm brainstem or L4, L5 and L6 spinal
cord sequential transverse sections from each rat went
through washes and incubation in blocking solution
(Cruz et al., 2005), and were incubated in antibody
raised in rabbit against the phosphorylated isoforms
ERK1 and ERK2 (pERK1/2; 1:1000; 48 h at 4–8 °C;
Neuromics, Edina, Minnesota, USA). Immunodetec-
tion was achieved upon incubation in biotinylated
swine anti-rabbit antiserum (1:200; 1 h; DAKO, Glos-
trup, Denmark), followed by ABC solution (1:200,
1 h; ABC Elite kit; Vector Laboratories, Peterborough,
UK) and reaction with 3,3-diaminobenzidine tetrahy-
drochloride (DAB; 10 min) (Cruz et al., 2005).
To evaluate the nature of the pERK1/2 IR cells in
spinal cord sections of CCI rats, double immunolabel-
ling against pERK1/2 and the anti-neuronal nuclear
antigen (NeuN), specific for mature neurons in verte-
brates (Mullen et al., 1992), was performed by incu-
bation (two overnights) in rabbit anti-pERK1/2
(1:1000) and mouse anti-NeuN (1:100; Millipore,
Chemicon, CA, USA) primary antibodies. The immu-
noreaction was revealed using as secondary antibod-
ies biotinylated donkey anti-rabbit (1:200) followed
by incubation in Streptavidin conjugated with
alexa®488 (1:200; Invitrogen, Molecular Probes, USA)
and donkey anti-mouse conjugated with alexa®568
(1:1000; Invitrogen, Molecular Probes). A similar pro-
cedure was used to evaluate the neurochemical
nature of noradrenergic [sheep anti-tyrosine
hydroxylase (TH), 1:2000; Abcam, Cambridge, UK] or
serotonergic [sheep anti-tryptophan hydroxylase
(TrpOH), 1:500; Millipore, Chemicon] areas in
supraspinal adjacent sections. Biotinylated donkey
anti-rabbit (1:200), streptavidin conjugated with
alexa®488, and donkey anti-sheep conjugated with
alexa®568 (1:1000) were used. Specificity was con-
trolled by omitting each primary antibody in various
sets of immunoreactions.
2.6 Data analysis and statistics
pERK1/2 labelling was studied in spinal cord segments
L4, L5 or L6, and in the following brainstem nuclei: A5,
LC (A6), A7, raphe obscurus nucleus (ROb), RMg,
DRN, lateral reticular nucleus (LRt), PGi, gigantocel-
lular reticular pars alpha nucleus (GiA), PAG, lateral
parabrachial nucleus (LPB) and Edinger–Westphal
nucleus (EW). Histological delimitation of brain areas
and respective rostrocaudal extensions was made
G.S. Borges et al. ERK1/2 activation in the brainstem of CCI rats
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according to The Rat Brain Atlas (Paxinos and Watson,
2009) and co-localization with TH or TrpOH, for nora-
drenergic or serotonergic nuclei, respectively. Quanti-
fication of pERK1/2 immunoreactive (IR) cells in
spinal cord was performed, as described (Cruz et al.,
2005), by using an optical light microscope (Axioskop
40; Zeiss, Hertfordshire, UK) and counting the number
of cell bodies with a brownish labelling for DAB in
laminae I–III, IV–VI, VII–IX and X (Molander et al.,
1984; Cruz et al., 2005), in a total of 15 sections per
animal (5 sections of the caudal portion of segment L4
and 10 sections of segments L5 and L6).
At supraspinal level, a similar approach was used to
count pERK1/2 IR cells in all sections containing the
analysed regions, per animal, except for LC and LPB.
The average number of pERK1/2 IR cells/section/
animal was statistically analysed. In LC and LPB, a
distinct pERK1/2 fibre labelling intensity was visually
detected in rostrocaudal extensions, and so separate
quantification was performed. Photomicrographs of
all sections containing the LC or LPB, of regions with
only non-specific labelling, and of the glass in each
slide, per animal, were taken, as described (Alba-
Delgado et al., 2011). Acquisition conditions (objec-
tive amplification, light intensity, contrast and hue)
were maintained constant. Densitometric analysis of
each photomicrograph was performed using free
access software (Image J 1.42). Mean grey densito-
metric values/section/animal were calculated by using
a specific equation as described (Alba-Delgado et al.,
2012), and were averaged. Values of pERK1/2 expres-
sion in LC or LPB were expressed as densitometry
optic units/section/animal and were statistically
analysed. Co-localization of pERK1/2 with NeuN, TH
or TrpOH was evaluated by using an AxioImager Z1
(Zeiss) fluorescence microscope.
Behavioural data were statistically compared by
two-way analysis of variance (ANOVA) for factors
‘surgery’ and ‘time’ followed by the Bonferroni post
hoc. For the immunohistochemistry data, at spinal
level, only data from the ipsilateral side were consid-
ered since contralateral pERK1/2 expression was
insignificant. At supraspinal level, as no statistically
significant differences between ipsi- and contralateral
sides were detected (independent Student’s t-test),
values from both sides were pooled to calculate the
mean number of IR cells or densitometry per section
and per animal. Two-way ANOVA for the factors
‘stimulation’ and ‘surgery’ was performed followed by
the Fisher least significant difference (LSD) post hoc
test. The level of significance accepted was 0.05.
GraphPad Prism 5 and STATISTICA software were
used.
3. Results
3.1 Chronic neuropathic pain
In 7 days, CCI rats developed a stable mononeuropa-
thy in the operated (ipsilateral) paw, characterized by
mechanical and thermal hyperalgesia. Both the
mechanical pressure supported by animals and the
withdrawal latency to thermal stimuli, on the ipsilat-
eral paw, were significantly reduced in CCI when
compared with SHAM animals (p < 0.001 and
p < 0.01, respectively; Supporting Information
Fig. S1). No differences were observed contralaterally.
SHAM rats did not develop any neuropathic reaction.
All animals were healthy (no abnormal behaviour).
3.2 Spinal ERK1/2 activation
pERK1/2 expression in L4, L5 and L6 spinal cord seg-
ments of SHAM or CCI rats either receiving, or not, a
mechanical stimulation is depicted in Supporting Infor-
mation Table S1 and Fig. 1. Positive immunolabelling
to pERK1/2 was observed in perikarya and fibres, and
co-localizes with NeuN indicating that ERK1/2 are
activated in neurons (Supporting Information Fig. S2).
Few (less than 10) pERK1/2 IR cells/section were
detected in SNS rats in every lamina of the lumbar
spinal cord, both ipsi- and contralaterally. Noxious
mechanical stimulation of SHAM rats (SS group)
induced a significant increase of pERK1/2 IR cells/
section in the ipsilateral laminae I–III (p < 0.001),when
compared with the same laminae of SNS rats (Support-
ing Information Table S1 and Fig. 1A). Moreover, in SS
rats, pERK1/2 IR cells were concentrated in the medial
region of the ipsilateral superficial dorsal horn (Fig. 1A,
SS). Additionally, the number of pERK1/2 IR cells/
section in SS was significantly higher than in CCINS
and CCIS animals, in laminae I–III (p < 0.01 and
p < 0.05, respectively, Supporting Information Table S1
and Fig. 1A). Thus, the noxious mechanical stimula-
tion was sufficient to induce a higher ERK1/2 activa-
tion than the CCI condition alone or combinedwith the
stimulus. In CCINS, the number of pERK1/2 IR cells/
section in laminae I–III was higher than in SNS (but
without statistical significance) and positive neurons
were distributed in all superficial dorsal horn (Fig. 1B,
CCINS), contrary to that observed in SS and CCIS.
Noxiousmechanical stimulation of CCI rats produced a
significantly higher number of pERK1/2 IR cells
(p < 0.05) in superficial dorsal horn than that observed
in SNS, but also significantly lesser than that observed
in SS animals (p < 0.05, Supporting Information
Table S1 and Fig. 1A), suggesting a different effect of
ERK1/2 activation in the brainstem of CCI rats G.S. Borges et al.
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the noxious stimulation in SHAM and in neuropathic
animals, confirmed by the significant value (p < 0.05)
obtained for the ‘interaction’ between the factors
‘surgery’ and ‘stimulation’, in laminae I–III (Support-
ing Information Table S1). However, similar to SS rats,
a medial distribution of pERK1/2 IR cells was observed
(Fig. 1B, CCIS).
In laminae IV–VI, VII–IX and X, no changes were
observed between any group (Supporting Information
Table S1 and Fig. 1A).
3.3 Brainstem ERK1/2 activation
pERK1/2 immunolabelling in almost all brainstem
nuclei consisted of a brownish precipitate in perikarya
and dendrites (Supporting Information Fig. S2). In
general, a baseline labelling was observed in all nuclei
analysed in the SNS group (Supporting Information
Table S2). Double immunoreactions confirmed the
localization of the A5, LC and A7 (TH-positive regions)
or ROb, RMg and DRN (TrpOH-positive regions).
Overall, statistical analysis of the factor ‘stimulation’
did not detect significant changes between the experi-
mental groups in any brainstem nuclei studied. Thus,
the mechanical noxious stimulation, per se, did not
seem to induce significant changes in ERK1/2 activa-
tion in brainstem nuclei, either in SHAM or CCI rats.
However, two-way ANOVA for the factor ‘surgery’
indicated that the neuropathic condition induced sig-
nificant changes in ERK1/2 activation in some nuclei,
as subsequently described.
3.3.1 A5, LC and A7 regions
Statistically significant changes between groups were
identified for the factor ‘surgery’ in A5 (p < 0.05) and
LC (p < 0.05, p < 0.01 and p < 0.01 in total, caudal or
rostral portions, respectively, Supporting Information
Table S2). In A5, a significantly increased number of
pERK1/2 IR cells/section in CCINS was observed,
when compared with SNS (p < 0.01) or SS rats
(p < 0.05, Supporting Information Table S2 and
Fig. 2A). In contrast, pERK1/2 IR-fibre intensity was
significantly decreased in LC in CCINS (p < 0.05, for
total LC, LC caudal or LC rostral) or CCIS (p < 0.05 in
total LC or in the caudal extension; p < 0.01 in LC
rostral), when each was compared with SNS animals
(Supporting Information Table S2 and Fig. 2B). No sig-
nificant changes were observed in A7.
3.3.2 ROb, RMg and DRN regions
In rostral ROb, a significant interaction (p < 0.01, Sup-
porting Information Table S2) between the ‘surgery’
and ‘stimulation’ factors was observed, meaning that
noxious mechanical stimulation differently affects
SHAM and CCI animals. The Fisher LSD post hoc test
detected a significant increase in the number of
pERK1/2 IR cells/section in SS (p < 0.05) and CCINS
(p < 0.05) when compared with SNS rats (Supporting
Information Table S2 and Fig. 3A). In contrast, a sig-
nificantly decreased number of pERK1/2 IR cells/
section was observed in CCIS when compared with
Figure 1 Effect of chronic constriction injury (CCI) in the left sciatic nerve and/or application of a noxiousmechanical stimulation to the ipsilateral hindpaw
on the average number of pERK1/2 IR cells/section counted in four different regions of the lumbar spinal cord greymatter. (A) In the superﬁcial dorsal horn
laminae I–III, the CCI condition (CCI not stimulated group, CCINS) induced an increase (not statistically signiﬁcant) in the number of pERK1/2-labelled cells
when compared with SHAM (SHAM not stimulated group, SNS). Acute mechanical noxious stimulation signiﬁcantly increased pERK1/2 expression in the
same region of SHAM (SHAM stimulated group, SS) but had no signiﬁcant effect on CCI rats (CCI stimulated group, CCIS), when compared with the
respective not stimulated groups. No changes were detected in deep dorsal horn (laminae IV– VI), ventral horn (laminae VII–IX) and central canal (lamina
X). (B) Photomicrographs showing that pERK1/2 labelling in the spinal cord from SS and CCIS rats has a medial distribution in ipsilateral superﬁcial dorsal
horn while in the CCINS, this distribution pattern was not observed; scale bar = 100 mm. *p < 0.05; **p < 0.01; and ***p < 0.001 by two-way analysis of
variance followed by Fisher least signiﬁcant difference post hoc test.
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CCINS (p < 0.05) or SS animals (p < 0.05, Supporting
Information Table S2 and Fig. 3A). In RMg, a signifi-
cant value for the factor ‘surgery’ was verified
(p < 0.05, Supporting Information Table S2), and the
Fisher LSD post hoc test revealed a significantly
increased number of pERK1/2 IR cells in CCINS when
compared with SNS animals (p < 0.01, Supporting
Information Table S2 and Fig. 3A). In DRN, the factor
‘surgery’ was significant (p < 0.01, Supporting Infor-
mation Table S2), and a significantly increased number
Figure 2 Effect of chronic constriction injury (CCI) in the left sciatic nerve and/or application of a noxiousmechanical stimulation to the ipsilateral hindpaw
on the average number of pERK1/2 IR cells/section or in the densitometry/section in the noradrenergic nuclei. (A) The CCI condition signiﬁcantly increased
pERK1/2 expression in the A5. No changes were observed following noxious mechanical stimulation of either SHAM or CCI animals. (B) CCI groups (either
stimulated or not) showed signiﬁcant decreases in pERK1/2 expression at all levels of LC (total, caudal and rostral). (C) Photomicrographs showing the
localization or pERK1/2 labelling in A5 and in the caudal part of LC in SHAM not stimulated (SNS), SHAM stimulated (SS), CCI not stimulated (CCINS) and
CCI stimulated (CCIS) rats; scale bar = 100 mm. 7 – facial nucleus, 4V – fourth ventricle. *p < 0.05 and **p < 0.01 by two-way analysis of variance followed
by Fisher least signiﬁcant difference post hoc test.
Figure 3 Effect of chronic constriction injury (CCI) in the left sciatic nerve and/or application of a noxiousmechanical stimulation to the ipsilateral hindpaw
on the average number of pERK1/2 IR cells/section in the serotonergic nuclei. (A) The CCI condition signiﬁcantly increased pERK1/2 expression in ROb, RMg
and DRN. Acute noxious stimulation applied to SHAM animals also resulted in increased pERK1/2 expression in ROb. In RMg, no changes were observed
in stimulated (either SHAMor CCI) groups. In ROb and DRN, acute noxious stimulation of CCI animals induced a decrease in the number of pERK1/2 IR cells.
(B) Photomicrographs showing the localization or pERK1/2 labelling in ROb, RMg and DRN in SHAM not stimulated (SNS), SHAM stimulated (SS), CCI not
stimulated (CCINS) and CCI stimulated (CCIS); scale bar = 100 mm. *p < 0.05 and **p < 0.01 by two-way analysis of variance followed by Fisher least
signiﬁcant difference post hoc test.
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of pERK1/2 IR cells was detected in CCINS when
compared with SNS (p < 0.01), SS (p < 0.01) and CCIS
animals (p < 0.05, Fig. 3A).
3.3.3 Rostroventromedial and ventrolateral
medulla
In LRt [from ventrolateral medulla (VLM)] and PGi
[from rostroventromedial medulla (RVM)], a signifi-
cantly increased number of pERK1/2 IR cells/section
was observed in CCINS when compared with SNS
(p < 0.01 for LRt and p < 0.001 for PGi) or with SS
(p < 0.05 for LRt and p < 0.001 for PGi), or in CCIS
when compared with SNS (p < 0.05 for LRt and
p < 0.01 for PGi) or with SS (p < 0.001 for PGi only,
Supporting Information Table S2 and Fig. 4A). No sig-
nificant changes were observed in GiA.
3.3.4 Other brainstem nuclei
In the ventrolateral PAG (VLPAG), LPB and EW no
statistical significant differences were detected.
4. Discussion
This study shows that in 7-day CCI rats, ERK1/2 are
activated in the spinal cord and in several brainstem
monoaminergic regions implicated in pain modulation
(Pinto et al., 2003; Almeida et al., 2004; Rouwette
et al., 2010). Additionally, mechanical noxious stimu-
lation increased pERK1/2 expression in the superficial
dorsal horn of SHAM but not of CCI rats, while,
supraspinally, the acute stimuli per se did not induce
any change.
The spinal cord laminae I–VI are majorly implicated
in the reception and transmission of nociceptive
information (Rexed, 1952; Willis and Coggeshall,
1991). Few IR cells were observed in SHAM rats, but
pinching the ipsilateral hindpaw promoted an
increase in pERK1/2 IR cells in laminae I–III, indicat-
ing that 20 min of noxious mechanical stimulation is
sufficient to induce ERK1/2 activation in spinal cord.
While mechanical stimulation induced an increase of
pERK1/2 IR cells in laminae I–III of SHAM rats, when
applied to CCI rats no changes were detected, sug-
gesting that the processing of this stimulus is altered
at the spinal cord level, when other nociceptive
inputs, which are probably more deleterious to the
organism, are already being chronically perceived.
Thus, CCI seems to be sufficient to induce some
degree of tonic ERK1/2 activation while additional
noxious stimulation of these animals only provokes a
redistribution of IR cells. Although ERK1/2 activation
in superficial dorsal horn during neuropathic pain has
already been demonstrated (Song et al., 2005; Alba-
Delgado et al., 2011), consistent with an increased
number (although not statistically significant) of
pERK1/2 cells in laminae I–III of CCINS rats, the
effect of noxious stimulation during neuropathic pain
conditions had never been addressed. Actually, the
prevalence of ERK1/2 activation in laminae I–III in
SS and CCIS animals is expected since superficial
dorsal horn neurons have been implicated in acute
pain processing (Coghill et al., 1991; Porro and
Cavazzuti, 1996) and in noxious stimuli response
through pERK1/2 (Cruz et al., 2005; Yanagidate and
Strichartz, 2007). Overall, these data point to a rela-
tion between high levels of pERK1/2 in laminae I–III
Figure 4 Effect of chronic constriction injury (CCI) in the left sciatic nerve and/or application of a noxiousmechanical stimulation to the ipsilateral hindpaw
on the average number of pERK1/2 IR cells/section in the LRt and PGi. (A) The CCI condition signiﬁcantly increased pERK1/2 expression in LRt. Acute
noxious stimulation had no signiﬁcant effects either in SHAM or CCI when compared with the respective not stimulated groups. In PGi, a signiﬁcant
increase in pERK1/2 expressionwas detected in CCI groups (either stimulated or not) in comparison to the respective SHAMgroups. (B) Photomicrographs
showing the localization or pERK1/2 labelling in LRt and PGi in SHAM not stimulated (SNS), SHAM stimulated (SS), CCI not stimulated (CCINS) and CCI
stimulated (CCIS); scale bar = 100 mm. *p < 0.05; **p < 0.01; and ***p < 0.001 by two-way analysis of variance followed by Fisher least signiﬁcant
difference post hoc test.
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and the processing of nociceptive input from the
injured paw.
Supraspinally, changes in pERK1/2 immunolabel-
ling occurred in a few nuclei, mostly in CCI animals
when compared with SHAM, but they were not sig-
nificantly influenced by noxious stimulation in any
region analysed. However, significant interactions
between factors were obtained for some nuclei.
4.1 A5, LC and A7 regions
The A5, LC and A7 provide the main noradrenergic
inputs into the spinal cord (Proudfit, 1988; Kwiat
and Basbaum, 1992). The A5 is involved in pain modu-
lation, playing both antinociceptive (Miller and
Proudfit, 1990; Burnett and Gebhart, 1991) and
pronociceptive roles (Sagen and Proudfit, 1986;
Tavares and Lima, 2002; Marques-Lopes et al., 2010).
Increased pERK1/2 immunolabelling in CCINS sug-
gests an enhanced activity of A5 neurons during neu-
ropathic pain, which may be related with increased
NA synthesis and/or release into the spinal cord. In
fact, an increased activation of cAMP response
element-binding protein (another neuronal activation
marker) and TH (an NA synthesis rate-limiting
enzyme) labelling in A5 upon painful diabetic neur-
opathy was observed along with increased NA at
spinal level (Morgado et al., 2011). In mononeuropa-
thy, as is CCI, this remains to be clarified. The role of
the LC in pain modulation is well established (Tsu-
ruoka et al., 2003; Maeda et al., 2009; Khakpay et al.,
2010) at both ascending and descending pathways. In
LC, both pronociceptive and antinociceptive roles
were described. Hence, lesions of LC’s noradrenergic
neurons resulted in increased thermal hyperalgesia
induced by inflammation and also in increased
responsiveness of dorsal horn neurons (Tsuruoka and
Willis, 1996; Wei et al., 1999; Tsuruoka et al., 2003),
suggesting a role in pain inhibition. Contrarily, similar
lesions in LC neurons also resulted in decreased tonic
behavioural responses to intraplantar formalin injec-
tion (Martin et al., 1999; Taylor et al., 2000), and
reduced mechanical hyperalgesia, tactile and cold allo-
dynia after spared sural nerve injury (Brightwell and
Taylor, 2009), suggesting a role in pain facilitation.
Here, a decreased pERK1/2 labelling was observed in
CCI animals when compared with SHAM, indicating a
general decrease in LC neurons activity following CCI.
In contrast, ERK1/2 were activated in LC for 1 h fol-
lowing formalin injection into the hindpaw (Imbe
et al., 2011), while complete Freund’s adjuvant
(CFA)-evoked chronic inflammation did not induce
prolonged ERK1/2 activation (Imbe et al., 2009).
Thus, different pain modalities might exert unique
effects on ERK1/2 activation in LC neurons. Interest-
ingly, chronic restraint stress produced hyperalgesia
and significantly decreased pERK1/2 IR cells in LC and
the analgesia produced by acute stress is accompanied
by mild pERK1/2 IR cells increase (Imbe et al., 2004).
This suggests that LC responds to acute stimuli by
increasing ERK1/2 activity, probably activating the
descending inhibitory pathway, but when nociceptive
stimulation becomes chronic such activation is com-
promised. Overall data suggest that nerve injury modi-
fied the evoked LC activity pattern leading to an
altered descending modulation of painful stimuli and
contributing to the pain state. In A7, no changes were
detected, indicating that in this region the nociceptive
processing does not involve ERK1/2 activation. Inter-
estingly, no changes in TH expression in A7 during
diabetic neuropathy were observed (Morgado et al.,
2011).
4.2 ROb, RMg and DRN regions
ERK1/2 phosphorylation was also evaluated in ROb,
RMg and DRN. ROb involvement in pain modulation
has been proposed (Aicher and Randich, 1990) but the
underlying mechanisms remain largely unknown.
Increased pERK1/2 expression was observed following
either noxious stimulation of SHAM or CCI animals,
suggesting that ERK1/2 activation is implicated in
nociceptive-related signalling events occurring at ROb.
However, when the stimuli were applied to neuro-
pathic animals, no further increase was produced, sug-
gesting that this extra input is minor when compared
with the input resultant from nerve injury, and that,
its processing does not require ERK1/2 activation.
Interestingly, C-Fos expression, another neuronal acti-
vation marker, is increased in ROb after noxious
mechanical stimulation (Pinto et al., 2003), and this
occurred mainly in neurons expressing gamma ami-
nobutyric acid type B (GABAB) receptors (Pinto et al.,
2003), pointing to the involvement of the GABAergic
system. In RMg, a small increase was detected in
pERK1/2 immunolabelling upon CCI. Others obtained
a similar result upon chronic stress (Imbe et al., 2004),
suggesting some analogy between these two chronic
situations. In DRN, CCI induced an increased ERK1/2
expression, consistent with our previous data (Alba-
Delgado et al., 2011). The DRN constitutes the major
5-HT source in CNS (Dahlstrom and Fuxe, 1964), and
is involved in other (patho)physiological functions
beyond pain processing (Greenwood et al., 2003).
Moreover, the DRN connects directly to the LC (Kim
et al., 2004) providing a potent negative input (Segal,
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1979), which might explain why, in LC, a decreased
ERK1/2 activation was verified during CCI.
4.3 RVM and VLM
In PGi, a nucleus of the RVM, there was increased
pERK1/2 immunolabelling in CCI animals, compared
with SHAM, suggesting a highest neuronal activation
during neuropathic pain consistent with previous
results (Alba-Delgado et al., 2012). The RVM plays an
important role in the nociceptive activity of spinal cord
neurons and in pain transmission (Porreca et al.,
2002). Activation of distinct groups of RVM neurons
results in descending inhibition or facilitation and, in
particular, the PGi constitutes the main excitatory LC
afferent (Carlson et al., 2007; Heinricher et al., 2009).
Additionally, the LC is under the inhibitory control of
the serotonergic DRN (Kim et al., 2004), being puz-
zling how these excitatory and inhibitory drives might
be affecting ERK1/2 activation in LC. Mechanisms still
unknown are probably implicated. Moreover, in LRt,
which belongs to the VLM, another region highly
engaged in pain modulation (Heinricher et al., 2009),
similar data were obtained. The increase in pERK1/2
IR cells during CCI suggests the involvement of
ERK1/2 cascade in neuropathic pain modulation in
those nuclei of the RVM and VLM.
4.4 Other brainstem nuclei
PAG acts in ascending and descending nociceptive
systems and electrical stimulation of its ventrolateral
column produces antinociception (Porreca et al.,
2002). Despite the reasonable pERK1/2 baseline label-
ling found in VLPAG, no significant changes were
observed, indicating a low recruitment of the ERK1/2
signalling cascade in VLPAG for either acute or neu-
ropathic pain modulation. Consistently, few studies
have detected ERK1/2 activation in PAG. Exemplify-
ing, discrete increases in pERK1/2 neuronal density
were found in ether-anaesthetized noxious-stimulated
rats (Gioia et al., 2005). Also in LPB and EW, no
changes in the ERK1/2 activation pattern were
observed in CCI or after acute noxious stimulation,
despite their roles in pain modulation (Basbaum and
Fields, 1979; Gauriau and Bernard, 2002). Therefore,
chronic pain modulation in these nuclei may not
involve the ERK1/2 cascade.
Concluding, we demonstrate that ERK1/2 activa-
tion is involved in neuropathic pain and/or acute
mechanical noxious stimulation processing, in spinal
cord and selected brainstem regions. While in spinal
cord acute noxious stimulation modulates ERK1/2
activation, the same does not happen in most of the
brainstem nuclei analysed. Supraspinally, the CCI con-
dition is prevailing, in relation to acute stimulation,
inducing pERK1/2 increases in some nuclei and
decreases in LC, suggesting that ERK1/2 activity in
descending modulation pathways is differentially
altered, contributing to the pain state. Therefore, the
use of MAPK/ERK kinase (MEK) inhibitors must be
carefully considered in neuropathic pain treatment.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Graphs depicting the effect of chronic constric-
tion injury (CCI) of the left sciatic nerve on the mechanical
and thermal threshold of the ipsilateral paw (A and C,
respectively) and contralateral paw (B and D, respectively).
In the ipsilateral paw, both mechanical (A) and thermal (B)
hyperalgesia was observed at 7 days after the CCI surgery. No
significant changes were observed in the contralateral paw.
**p < 0.01 and ***p < 0.001 by two-way ANOVA followed by
Bonferroni post hoc test.
Figure S2. Photomicrographs showing the co-localization of
pERK1/2 (green) with NeuN, TH or TrpOH (red). Double
labelling was used to evaluate the nature of the cells express-
ing pERK1/2 in spinal cord (neurons, co-localization with
NeuN) and also to facilitate the delimitation of noradrenergic
(A5, LC and A7, co-localization with TH) and serotonergic
(ROb, RMg and DRN, co-localization with TrpOH) popula-
tions. Double-labelled cells are indicated by yellow colour in
the merged figure (arrows). Scale bar = 100 mm in all fluo-
rescent photomicrographs. Note the localization of DAB
brownish precipitate in the perikarya, dendrites and nucleus
of the neuron (right corner of figure). Scale bar = 10 mm.
Table S1. Table depicting the number of pERK1/2 IR cells
per section for each spinal cord region analysed in the ipsi-
lateral side in each experimental group. Values expressed as
mean  SEM p-values were obtained by two-way ANOVA
followed by Fisher LSD post hoc test.
Table S2. Table depicting the number of pERK1/2 IR cells or
the densitometric values (LC and LPB) per section for each
brainstem nucleus studied in each experimental group.
Values expressed as mean  SEM p-values were obtained by
two-way ANOVA followed by Fisher LSD post hoc test.
Appendix S1. Additional discussion.
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Figure S2 
 
Non Stimulated 
(SNS - a)
Stimulated 
(SS - b)
Non Stimulated 
(CCINS - c)
Stimulated 
(CCIS - d) Stimulation Surgery Interaction
Laminae I-III 2.3±1.1 43.6±3.6 9.4±2.0 23.0±9.7 <0.001*** 0.256 0.032* a/b***; a/d*; b/c**; b/d*
Laminae IV-VI 5.7±2.9 6.4±0.3 6.7±2.4 4.3±1.7 0.718 0.812 0.514 _
Laminae VII-IX 5.3±2.8 2.1±0.6 6.6±1.7 3.5±1.3 0.161 0.527 0.986 _
Lamina X 0.4±0.2 0.2±0.0 0.5±0.2 0.4±0.1 0.305 0.305 0.833 _
Note: In the post-hoc  column, a/b*** means that SNS was statistically different from SS with p<0.001.
* p<0.05; ** p<0.01 and *** p<0.001
Table S1 - Number of pERK1/2 IR-cells per section (expressed as mean ± S.E.M.) for each spinal cord region analyzed in the ipsilateral side in each experimental group.
Fisher LSD (post-hoc )Lumbar Spinal Cord
SHAM CCI P Value (Two-Way ANOVA)
Non Stimulated 
(SNS - a)
Stimulated 
(SS - b)
Non Stimulated 
(CCINS - c)
Stimulated 
(CCIS - d) Stimulation Surgery Interaction
TH-positive Regions
A5 (Noradrenergic Cells) Total 12.1±1.2 13.3±2.1 18.7±1.9 15.4±1.0 0.498 0.012* 0.161 a/c**; b/c*
LC (Locus Coeruleus) Total 6.4±1.0 5.6±0.8 4.2±0.4 4.0±0.2 0.489 0.011* 0.601  a/c*; a/d*
CaudalA 6.6±0.9 6.1±0.8 4.2±0.4 4.4±0.3 0.890 0.005** 0.602  a/c*; a/d*
RostralB 7.1±1.4 4.9±0.9 3.9±0.2 3.2±0.3 0.075 0.005** 0.352  a/c*; a/d**
A7 (Noradrenergic Cells) Total 31.2±8.6 50.6±1.6 54.7±13.2 49.7±4.9 0.419 0.216 0.186 _
TrpOH-positive Regions
ROb (Raphe Obscurus) RostralC 5.2±2.2 18.3±7.5 18.8±3.1 2.0±1.2 0.681 0.764 0.005** a/b*; a/c*; b/d*; c/d*
RMg (Raphe Magnus) Total 9.0±0.5 10.6±0.5 13.0±1.0 10.9±0,6 0.815 0.039* 0.076 a/c**
DRN (Dorsal Raphe) Total 9.9±3.2 12.1±3.4 26.4±2.5 15.6±1.9 0.177 0.006** 0.057 a/c**; b/c**; c/d*
RVM and VLM
LRt (Lateral Reticular) RostralD 25.9±3.9 28.1±4.3 48.2±6.9 40.5±3.3 0.567 0.003** 0.302 a/c**; a/d*; b/c*
PGi (Paragigantocellularis) Total 30.±2.2 21.8±6.7 63.0±5.0 55.5±3.8 0.067 <0.001*** 0.751 a/c***; a/d**; b/c***; b/d***
GiA (Gigantocellular Reticular Pars Alpha) Total 18.2±1.8 17.4±3.7 18.0±1.8 16.8±0.5 0.662 0.877 0.940 _
Other Nuclei
VLPAG (Ventrolateral Periaqueductal Grey) Total 32.8±4.2 27.7±6.6 42.5±9.2 29.3±3.6 0.183 0.397 0.541 _
LPB (Lateral Parabrachial) Total 5.8±0.9 6.9±1.1 7.7±2.5 6.5±0.6 0.958 0.618 0.409 _
CaudalE 5.9±0.7 7.1±1.0 8.4±2.9 7.1±0.8 0.991 0.401 0.404 _
RostralF 5.2±1.8 6.3±1.3 6.5±1.9 5.4±0.6 0.988 0.903 0.436 _
EW (Edinger-Westphal) Total 39.7±9.5 45.6±1.9 43.2±3.7 43.7±2.3 0.514 0.869 0.575 _
Note: In the post-hoc  column, a/c** means that SNS was statistically different from CCINS with p<0.01.
Coordinates from bregma: A -9.8 to -10.12mm; B -9.16 to -9.8mm; C -13.68 to -11.60mm; D -13.68 to -13.24mm;  E -9.16 to -10.04mm; F -8.80 and -9.16mm.
Table S2 - Number of pERK1/2 IR-cells or densitometric values (LC and LPB) per section (expressed as mean ± S.E.M.) for each brainstem nuclei studied in each experimental group.
     * p<0.05; ** p<0.01 and  *** p<0.001 
Encephalic Nuclei Fisher LSD (post-hoc )
P Value (Two-Way ANOVA)CCISHAM
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Discussion - Supplementary Material 
 
Spinal ERK1/2 activation 
In the spinal cord superficial dorsal horn, the application of mechanical noxious 
stimulation induced a specific pattern in the distribution of pERK1/2 of IR-cells. In fact, 
in these conditions positive pERK1/2 profiles were confined to a medial zone within this 
region. Interestingly, C-fiber activation by capsaicin also induced pERK1/2 IR-cells in 
the medial part of laminae I-III, where nociceptive inputs from the hindpaw are received 
(Ji et al., 1999; Ji et al., 2009). Additionally, a medial distribution of the pERKs1/2 IR-
cells was also observed in CCIS rats. Conversely, in CCINS rats, pERK1/2 IR-cells were 
numerous but detected along all the superficial dorsal horn, suggesting a distinctive 
spatial distribution depending on the presence of chronic nociceptive stimulation 
(neuropathic pain) or of acute nociceptive stimuli (mechanical noxious stimulation). 
Another relevant observation was that in the remaining spinal cord laminae (IV-VI, VII-
IX, X) studied, pERK1/2 immunolabeling was not changed by neuropathic pain and/or 
mechanical noxious stimulation, suggesting that ERK1/2 activation in these regions is not 
a strategic event in the processing of these noxious stimuli, at least at 7 days of CCI. 
Others showed different regulation of ERK1/2 phosphorylation at both superficial and 
deep dorsal horn after noxious stimulation of 14 days monoarthritic rats (Cruz et al., 
2005). Thus it is possible that a prolonged time of disease is needed to trigger ERK1/2 
activation in the remaining laminae of the spinal cord. 
 
Supraspinal ERK1/2 activation 
In opposition to the spinal cord, at supraspinal level, ERK1/2 phosphorylation occurred 
even in SHAM animals, pointing to a baseline activation of these kinases, as already 
described in some areas (Imbe et al., 2011). This supraspinal baseline ERK1/2 
phosphorylation might be enough to trigger any mechanistic event in response to acute 
noxious mechanical stimulation. This would rather explain the lack of changes upon 
noxious mechanical stimulation of either SHAM or CCI rats. Additionally, unilateral CCI 
induced bilateral ERK1/2 activation in almost all nuclei analyzed (with exception of 
DRN, ROb and EW, the medial nuclei), suggesting that ERK activation in brainstem, due 
2 
  
to noxious input, is not confined to the side somatotopically related to the neuropathic 
paw. In fact, our study is consistent with the finding of bilateral increased metabolic 
activity in many brain regions during CCI (Mao et al., 1993). 
One interesting observation of our study was the fact that in the LC, pERK1/2 expression 
was decreased in the CCI condition. However, it is possible that LC neuronal activity is 
enhanced but without requiring ERK1/2 signaling, since although pERK1/2 expression is 
considered a neuronal activation marker, this does not mean that when ERK1/2 
phosphorylation is not observed, neurons are not activated. Indeed, further studies are 
needed to fully understand the pattern of pERKs expression in LC during CCI conditions. 
 
Methodological considerations 
In CCI rats the source of pain is the constriction of the sciatic nerve. Therefore, as 
mechanical noxious stimulation, we chose to apply a standardized protocol of pinches to 
the limb area innervated by the sciatic nerve. Since ERK1/2 are activated upon different 
types of stimulus (Ailing et al., 2008; Dai et al., 2011; Wang et al., 2010), the animals 
were previously anesthetized to avoid all external confounders (e.g. stress, anxiety) 
caused by noxious mechanical stimulation. However, different anesthetic procedures and 
the duration of anesthesia seem to affect ERK phosphorylation in different brain regions 
(Planel et al., 2007; Springell et al., 2005; Takamura et al., 2008). Additionally, the use 
of anesthetics may also interfere with some of the pain-related responses (such as 
cognition and affection), which could alter/mask the pattern of pERK1/2 expression in 
encephalic nuclei involved in these functions, as is the case of some brainstem regions 
analyzed in this study. Thus, anesthesia might have interfered with the level of ERKs1/2 
activation in some of those regions. However, if that happened, anesthesia affected 
ERK1/2 phosphorylation in a similar way/magnitude in all the experimental groups, as 
all animals were submitted to similar anesthesia protocols and experimental conditions. 
Thus, interindividual variability in ERK1/2 detection has been minimized, and in what 
respects to the relative changes (increases/decreases) in ERK1/2 expression we found in 
each analyzed region in response to CCI and/or acute noxious stimulation, our findings 
remain valid and are important. Since we did not study matched un-anesthetized groups 
of animals, the data obtained does not allow inferring how the anesthetic agents interact 
with ERK1/2 activation in the analyzed regions and in the conditions of this specific 
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experimental protocol (CCI and/or noxious mechanical stimulation). Moreover, to our 
best knowledge, there are no such studies yet and so this is still lacking verification and/or 
comphreension. It would be of great value the evaluation of the effect of anesthesia (in 
what regards to the substance, duration, doses, and other parameters) in respect to ERK1/2 
activation during modulation of the pain experience, in comparison with an anesthetized 
situation, since our data was restricted to studying pERK1/2 expression in supraspinal 
nuclei of SHAM and CCI rats, submitted to a particular anesthesia protocol. Also, both 
anesthetics and pain are able to change cardiovascular and respiratory responses (Guyenet 
et al., 2001; Jin et al., 2008; Pilowsky and Goodchild, 2002; Randich and Maixner, 1984), 
and some of the encephalic areas studied are implicated in the control of cardiovascular 
and respiratory functions. Thus, this aspect must be also considered when interpreting the 
data. Although the respiratory, arterial pressure or heart beat rate were not controlled, all 
the animals were submitted to identical anesthesia and stimulation protocols and so, it is 
expectable that interindividual differences in cardiovascular or respiratory changes that 
may have occurred due to anesthesia or to acute noxious stimulation were 
minimized/standardized. The same rationale is not possible to infer in what concerns the 
autonomic responses that may occur due to the CCI condition, and that may have affected, 
somehow, ERK1/2 activation in regions involved in autonomic control. Studies aiming 
at correlating the cardiovascular and respiratory changes, upon acute or chronic noxious 
stimulation, with supraspinal ERK1/2 activation in nuclei specifically implicated in 
autonomic control would be of great significance. 
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P ATIENTS with arthritis primarily seek medical assis-tance due to persistent pain caused by the inflamma-
tion and destruction of joints.1 This pain results from a 
complex interaction between the peripheral and central ner-
vous systems. In general consensus, chronic pain provokes 
neuroplastic alterations that contribute to the maintenance 
and amplification of painful sensation and to the onset of 
related disorders.2 One of the most common consequences 
of chronic pain is the development of anxio-depressive dis-
orders, manifested as helplessness, pessimism, rumination, 
and catastrophism.3 These affective alterations originate due 
to the disruption of central mechanisms and should be care-
fully monitored, because their presence is directly related 
with pain severity.4 Indeed, such modifications establish a 
vicious circle whereby chronic pain triggers profound emo-
tional changes, which in turn enhance pain perception.4 It is 
therefore critical to determine whether these plastic changes 
are reversible, because this could strongly condition the 
treatment strategies used. One potentially effective approach 
is to explore the effect of topically administering nonste-
roidal anti-inflammatory drug in animal models which are 
among the first-line treatments to alleviate joint pain5 and 
are frequently administered topically to avoid the side effects 
associated with their oral administration.6
We focused on the pathway formed by the spinal cord 
(SC), paragigantocellularis nucleus (PGi), locus coeruleus 
(LC), and prefrontal cortex (PFC). The LC is involved in 
What We Already Know about This Topic
•	 Many	types	of	chronic	pain	 including	pain	related	to	arthritis	
are	associated	with	depressed	mood	and	anxiety
What This Article Tells Us That Is New
•	 Using	a	rat	model	of	arthritis,	diclofenac	reduced	nociceptive	
sensitization	 and	 reduced	 additional	 behaviors	 suggesting	
anxiety-	and	depression-like	changes	in	the	animals
•	 The	activation	of	extracellular	signaling-related	kinase	in	sev-
eral	brain	regions	was	implicated	in	these	changes
Copyright © 2014, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins. Anesthesiology 2014; 120:1476-90
ABSTRACT
Background: Nonsteroidal anti-inflammatory drugs are effective for arthritic pain, but it is unknown whether they also 
benefit anxiety and depression that frequently coexist with pain. Using the monoarthritis model, the authors evaluated the 
activation of extracellular signal–regulated kinases 1 and 2 (ERK1/2) in structures implicated in both sensorial and emotional 
pain spheres, and it was verified whether analgesia can reverse monoarthritis-mediated affective responses.
Methods: Monoarthritis was induced in male rats by complete Freund’s adjuvant injection. Allodynia (ankle-bend test), 
mechanical hyperalgesia (paw-pinch test), anxiety- and depression-like behaviors (elevated zero maze and forced swimming 
tests, respectively), and ERK1/2 phosphorylation (Western blot) in the spinal cord, paragigantocellularis nucleus, locus coeru-
leus, and prefrontal cortex were evaluated at 4, 14, and 28 days postinoculation (n = 6 per group). Changes in these parameters 
were evaluated after induction of analgesia by topical diclofenac (n = 5 to 6 per group).
Results: Despite the pain hypersensitivity and inflammation throughout the testing period, chronic monoarthritis (28 days) 
also resulted in depressive- (control [mean ± SEM]: 38.3 ± 3.7 vs. monoarthritis: 51.3 ± 2.0; P < 0.05) and anxiogenic-like 
behaviors (control: 36.8 ± 3.7 vs. monoarthritis: 13.2 ± 2.9; P < 0.001). These changes coincided with increased ERK1/2 activa-
tion in the spinal cord, paragigantocellularis, locus coeruleus, and prefrontal cortex (control vs. monoarthritis: 1.0 ± 0.0 vs. 
5.1 ± 20.8, P < 0.001; 0.9 ± 0.0 vs. 1.9 ± 0.4, P < 0.05; 1.0 ± 0.3 vs. 2.9 ± 0.6, P < 0.01; and 1.0 ± 0.0 vs. 1.8 ± 0.1, P < 0.05, 
respectively). Diclofenac decreased the pain threshold of the inflamed paw and reversed the anxio-depressive state, restoring 
ERK1/2 activation levels in the regions analyzed.
Conclusion: Chronic monoarthritis induces affective disorders associated with ERK1/2 phosphorylation in paragigantocellu-
laris, locus coeruleus, and prefrontal cortex which are reversed by diclofenac analgesia. (Anesthesiology 2014; 120:1476-90)
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ascending and descending pain pathways and constitutes 
the main source of noradrenaline in the central nervous sys-
tem, a neurotransmitter implicated in pain, emotion, stress, 
depression, anxiety, and other disorders.7 The LC receives 
ascending nociceptive inputs from the SC through the 
PGi8 and it projects to forebrain structures similar to the 
anterior cingulate cortex in the PFC, which is implicated 
in cognition and pain-related emotion.9–13 Although it is 
clear that the anatomical and modulatory link between these 
structures may mediate the integration of pain processing 
at the emotional level, the underlying molecular and cellu-
lar mechanisms remain poorly understood. The extracellu-
lar signal–regulated kinases 1 and 2 (ERK1/2), members of 
the mitogen-activated protein kinase superfamily, have been 
used as markers of activity in the SC after noxious stimula-
tion and tissue injury.14 Beneficial results were demonstrated 
in a clinical trial using a mitogen-activated protein kinase 
inhibitor to treat neuropathic pain,15 suggesting this kinase 
as a target in the treatment of pathological pain.16 Interest-
ingly, ERK1/2 activation is also strongly implicated in the 
regulation of pain-associated disorders. Indeed, recent stud-
ies indicate that ERK1/2 is activated in the anterior cingulate 
cortex of the PFC after tissue or nerve injury,9,10,13 suggest-
ing that ERK1/2 is involved in both the sensorial and emo-
tional aspects of pain.
We hypothesized that an effective treatment of the inflam-
matory condition is able to reverse the emotional and molec-
ular responses produced by this condition. Thus, we used 
an experimental rat model of rheumatoid arthritis (monoar-
thritis) and we assessed the subsequent effects of diclofenac 
treatment on pain-induced anxiety, depression, and ERK1/2 
activation in the SC–PGi–LC–PFC pathway.
Materials and Methods
Animals
Adult male Harlan Sprague–Dawley rats (n = 116) weigh-
ing 250 to 300 g were provided by the Experimental Unit 
of the University of Cádiz, Cádiz, Spain (registration num-
ber: ES110120000210). The animals were housed 2 to 4 
per cage, with an ad libitum access to food and water, and 
they were maintained on a 12-h light–dark cycle at 22°C 
and with 45 to 60% humidity. All experimental procedures 
were carried out in accordance with the European Commu-
nities Council Directive of September 22, 2010 (2010/63/
EC), Spanish Law (RD 1201/2005), and ethical guidelines 
for the study of experimental pain in animals.17 The experi-
mental protocols were reviewed and approved by the Insti-
tutional Ethical Committee for animal care and use (Cádiz, 
Andalucía, Spain).
Inflammatory Pain Model: Monoarthritis
Monoarthritis was induced as described previously.18 In 
brief, anesthesia was induced and maintained with isoflu-
rane (4 and 2%, respectively; Abbott, Madrid, Spain), and 
the rats were injected in the left tibiotarsal joint with 50 μl 
of complete Freund’s adjuvant (CFA) solution containing 
30 mg of desiccated Mycobacterium butyricum (Difco Labo-
ratories, Detroit, MI) diluted in the vehicle solution (3 ml 
paraffin oil, 2 ml saline, and 500 μl Tween-80). Control 
rats were injected with the vehicle solution alone and any 
animal exhibiting sign of polyarthritis was excluded from 
the study.
Inflammation Assessment
After CFA or vehicle injection, all the animals were moni-
tored weekly for 4 weeks, measuring their body weight, 
rectal temperature (Chy 580BR Thermometer; Bioseb, Vit-
rolles, France), paw volume (using a plethysmometer appa-
ratus; Ugo Basile, Comerio, Italy), and inflammation score. 
The inflammation score was a subjective scoring based on 
the signs of inflammation at the injection site and locomo-
tion, whereby: 0 corresponds to the absence of inflammation 
and 4 to severe inflammation with persistent flexion of the 
affected limb and motor activity effects.19
Nociceptive Behavioral Assessment
Each week, nociceptive behavior was assessed in both the 
ipsi- and contralateral paws. Physiological evaluation of 
movement-induced nociception (allodynia) was performed 
using the ankle-bend test,20 which involves the assessment 
of squeak and/or struggle reactions in response to five 
alternate flexions and extensions of the ankle joint. Higher 
scores (score 2) indicate squeak responses to moderate 
manipulations of the inflamed joint, whereas lower scores 
(score 0) indicate the absence of a response to manipula-
tion. The reactions recorded in response to each extension 
or flexion are summed to obtain the ankle-bend score, giv-
ing a maximum value of 20, and a high ankle-bend score 
is indicative of allodynia. In addition, the presence of 
mechanical secondary hyperalgesia was determined using 
the paw-pinch test.21 In brief, increasing pressure was grad-
ually applied to the dorsal side of the paw using a graded 
motor-driven device (Ugo Basile) and beginning at 30 g of 
pressure. Three measurements were taken for each paw at 
5-min intervals and the average value determined, with a 
250 g cutoff applied to prevent damage to the paw. Second-
ary hyperalgesia is indicated by a reduction in the pressure-
provoking withdrawal.
Anxiety- and Depression-like Behavior
Pain-induced emotional and affective changes were assessed 
in a separate set of animals at 4 (monoarthritis [MA]4D), 
14 (MA14D), and 28 days (MA28D) after inducing mono-
arthritis. Anxiety-like behavior was evaluated by using the 
marble-burying and elevated zero maze (EZM) tests.
In the marble-burying test,22 after a 30-min acclimati-
zation, the rats were placed individually in a transparent 
plastic cage (51 × 22 × 15 cm) illuminated by a 100-W light 
and containing bedding (5 cm deep) in which 20 marbles 
were arranged in four columns and five rows. After 30 min, 
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the rats were removed and the number of buried marbles 
was counted, considering the marbles to be buried if they 
were at least two thirds covered with bedding. A larger num-
ber of buried marbles are taken as an indicator of increased 
 anxiety-like behavior.
The EZM consisted of a black circular platform 105 cm 
in diameter that was elevated 65 cm above the floor. This 
maze was divided into four equal length quadrants: the two 
opposing open quadrants had 1-cm-high clear lips to pre-
vent falls, whereas the two opposing closed quadrants were 
enclosed by 27-cm-high black walls. Each 5-min trial was 
carried out under the same lighting conditions and com-
menced with the animal being placed in the center of a 
closed quadrant. Spontaneous Motor Activity Recording 
and Tracking software (Panlab S.L.U., Barcelona, Spain) was 
used to analyze the percentage time spent in the open arms 
and the total distance travelled by each rat. An increase in 
the amount of time spent in the closed areas is correlated 
with anxiety-like behavior.
Depression-like behavior was evaluated by using a modi-
fied version of the forced swimming test (FST), as described 
previously.23 When confined to a limited space, rodents 
engage in vigorous escape behavior. When it becomes clear 
that escape is impossible, these animals adopt an immobile 
posture, performing only the necessary movements required 
to keep their head above the water. Accordingly, in the FST, 
rats were placed for 15 min (pretest) in a clear cylindrical 
plastic container (46 cm high and 20 cm in diameter) filled 
with 30 cm of water (25° ± 1°C). After 24 h, the rats were 
once again exposed to the same conditions for 5 min (test) 
and they were videotaped to score their immobility (floating 
without struggling, using small movements to maintain the 
head above water), swimming (actively moving limbs more 
than is required to maintain the head above water), and 
climbing (active forepaw movements in and out of the water, 
often directed at the wall of the tank).23 Customized software 
(Red Mice, Cádiz, Spain) was used to analyze the videos and 
to determine the predominant behavior at 5-s intervals. The 
total counts for each behavior during a 5-min test were aver-
aged and although longer periods of immobility are taken 
as an indication of depression-like behavior, changes in the 
time spent climbing or swimming have been correlated with 
alterations in the availability of noradrenaline and serotonin, 
respectively.23 As a positive control of antidepressant activ-
ity in the FST, the antidepressant desipramine (20 mg/kg; 
Sigma-Aldrich, St Louis, MO) was administered intraperi-
toneally to naive rats at 23.5, 5, and 1 h before testing. The 
behavioral tests were separated by a 3-day interval.
Western Blotting
Fresh tissue samples from the ipsilateral SC segments 
L3–L6, PGi, LC, and PFC regions were collected at 4, 
14, and 28 days after injection of the CFA or vehicle. All 
the samples were processed for Western blotting and after 
the tissue was lysed, an aliquot (50 μg) was separated on 
a 10% polyacrylamide gel and then transferred to a poly-
vinylidene difluoride membrane (BioRad, Hercules, CA). 
After washing in  Tris-buffered saline containing 0.1% 
Tween-20 (TBST), the blots were blocked with 5% bovine 
serum albumin (Sigma) in TBST and probed overnight at 
4°C with rabbit  anti-phospho-ERK1/2 (1:5,000; Acris Anti-
bodies, Herford, Germany), mouse-anti ERK1/2 (1:2,000; 
Cell Signaling Technology, Danvers, MA), and mouse anti-
tubulin (1:250,000; Sigma) antibodies diluted in 5% bovine 
Table 1. Descriptive Statistics and Exact P Values for the Repeated-measures ANOVA
Control MA
P Value  
(Repetead-measures ANOVA)
Student– 
Newman–Keuls  
Post Hoc TestBasal (a) First Week (b) Second Week (c) Third Week (d) Fourth Week (e) Basal (f)
First  
Week (g)
Second  
Week (h)
Third  
Week (i)
Foruth  
Week (j) Arthritis Time Interaction
Weight (g) 303.7 ± 13.3 (6) 329.8 ± 10.7 (6) 352.3 ± 9.7 (6) 374.8 ± 9.3 (6) 388.9 ± 9.1 (6) 296.7 ± 18.1 (6) 293.2 ± 14.9 (6) 324.8 ± 14.8 (6) 345.2 ± 16.3 (6) 358.7 ± 14.9 (6) 0.1812 0.0000*** 0.0178* ns
Temperature (°C) 37.5 ± 0.1 (6) 37.5 ± 0.1 (6) 37.1 ± 0.3 (6) 37.3 ± 0.1 (6) 36.9 ± 0.2 (6) 37.3 ± 0.3 (6) 37.1 ± 0.1 (6) 38.3 ± 0.2 (6) 37.1 ± 0.2 (6) 37.2 ± 0.2 (6) 0.1562 0.0191* 0.0014** c/h (P = 0.0008)
Paw volume Ip (ml) 1.7 ± 0.0 (6) 1.8 ± 0.0 (6) 1.8 ± 0.0 (6) 1.8 ± 0.0 (6) 1.8 ± 0.0 (6) 1.7 ± 0.0 (6) 3.4 ± 0.2 (6) 3.4 ± 0.2 (6) 3.5 ± 0.2 (6) 3.4 ± 0.2 (6) 0.0000*** 0.0000*** 0.0000*** b/g (P = 0.0001); 
c/h (P = 0.0001);  
d/i (P = 0.0001);  
e/j (P = 0.0001)
Paw volume Ctr (ml) 1.7 ± 0.0 (6) 1.8 ± 0.0 (6) 1.8 ± 0.0 (6) 1.8 ± 0.0 (6) 1.8 ± 0.0 (6) 1.7 ± 0.0 (6) 1.7 ± 0.0 (6) 1.7 ± 0.0 (6) 1.8 ± 0.0 (6) 1.8 ± 0.0 (6) 0.6992 0.0994 0.1439 ns
Inflammation score 0.0 ± 0.0 (6) 0.0 ± 0.0 (6) 0.0 ± 0.0 (6) 0.0 ± 0.0 (6) 0.0 ± 0.0 (6) 0.0 ± 0.0 (6) 2.8 ± 0.4 (6) 3.5 ± 0.1 (6) 3.6 ± 0.3 (6) 3.4 ± 0.3 (6) — — — —
Ankle-bend score 0.0 ± 0.0 (6) 0.0 ± 0.0 (6) 0.0 ± 0.0 (6) 0.0 ± 0.0 (6) 0.0 ± 0.0 (6) 0.0 ± 0.0 (6) 19.3 ± 0.7 (6) 17.8 ± 1.0 (6) 20.0 ± 0.0 (6) 20.0 ± 0.0 (6) — — — —
Paw withdrawal Ip (g) 223.8 ± 17.0 (6) 196.3 ± 4.5 (6) 222.5 ± 6.0 (6) 223.8 ± 7.1 (6) 218.8 ± 7.9 (6) 212.5 ± 23.4 (6) 125.0 ± 8.6 (6) 161.3 ± 7.4 (6) 158.8 ± 10.5 (6) 143.8 ± 5.3 (6) 0.0000*** 0.0004*** 0.5470 b/g (P = 0.0005); 
c/h (P = 0.0032);  
d/i (P = 0.0039);  
e/j (P = 0.0004)
Paw withdrawal Ctr (g) 248.8 ± 17.9 (6) 218.8 ± 9.6 (6) 225.0 ± 13.3 (6) 252.5 ± 17.8 (6) 238.8 ± 9.0 (6) 267.5 ± 20.7 (6) 210.0 ± 9.3 (6) 222.5 ± 6.6 (6) 257.5 ± 26.0 (6) 220.8 ± 15.0 (6) 0.9179 0.0244* 0.8047 ns
Values expressed as mean ± SEM for each experimental group followed by the sample size (n). In the post hoc column, c/h (P = 0.0008) means that  
at the 2nd week, controls were statistically different from monoarthritic rats with a P value of 0.0008.
*P < 0.05, **P < 0.01, and ***P < 0.001.
Ctr = contralateral; Ip = ipsilateral; MA = monoarthritis; ns = no significancies.
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serum albumin–TBST. After thorough washing, these pri-
mary antibodies were detected by incubating for 1 h at room 
temperature with IRDye 800CW goat anti-rabbit (green) or 
IRDye 680LT goat anti-mouse (red) secondary antibodies 
(1:10,000; LI-COR®, Lincoln, NE). After three final washes 
with TBST, the antibody binding was detected by using a 
LI-COR Odyssey® two-channel quantitative fluorescence 
imaging system (LI-COR®). Digital images of Western blots 
were analyzed by densitometry using the ImageJ free access 
software (National Institutes of Health, Bethesda, MD). The 
data were expressed as pERK1/2 expression levels relative to 
those of total ERK1/2, as no significant differences in the 
loading control (tubulin) were observed. As no differences 
in pERK1/2 expression were observed between the ipsilateral 
and contralateral sides for the PGi, LC, or PFC, these values 
were combined and averaged.
Topical Diclofenac Administration
To induce analgesia, 10 mg of sodium diclofenac (equiva-
lent to 1 g of commercial Voltaren Gel®; Novartis, Basel, 
Fig. 1. Time course of the development of inflammation and nociceptive behavior in control and monoarthritic rats. (A) General 
parameters of health: weight and temperature. (B) Parameters of inflammation: paw volume and inflammation score. (C) Param-
eters of nociception: allodynia (ankle-bend score) and hyperalgesia (paw withdrawal threshold). All values are expressed as the 
mean ± SEM: **P < 0.01, ***P < 0.001 monoarthritis (MA) versus corresponding controls, repeated-measures ANOVA followed by 
Student–Neuman–Keuls post hoc test for each time point. n = 6 per experimental group. B = baseline; W = week.
Table 1. Descriptive Statistics and Exact P Values for the Repeated-measures ANOVA
Control MA
P Value  
(Repetead-measures ANOVA)
Student– 
Newman–Keuls  
Post Hoc TestBasal (a) First Week (b) Second Week (c) Third Week (d) Fourth Week (e) Basal (f)
First  
Week (g)
Second  
Week (h)
Third  
Week (i)
Foruth  
Week (j) Arthritis Time Interaction
Weight (g) 303.7 ± 13.3 (6) 329.8 ± 10.7 (6) 352.3 ± 9.7 (6) 374.8 ± 9.3 (6) 388.9 ± 9.1 (6) 296.7 ± 18.1 (6) 293.2 ± 14.9 (6) 324.8 ± 14.8 (6) 345.2 ± 16.3 (6) 358.7 ± 14.9 (6) 0.1812 0.0000*** 0.0178* ns
Temperature (°C) 37.5 ± 0.1 (6) 37.5 ± 0.1 (6) 37.1 ± 0.3 (6) 37.3 ± 0.1 (6) 36.9 ± 0.2 (6) 37.3 ± 0.3 (6) 37.1 ± 0.1 (6) 38.3 ± 0.2 (6) 37.1 ± 0.2 (6) 37.2 ± 0.2 (6) 0.1562 0.0191* 0.0014** c/h (P = 0.0008)
Paw volume Ip (ml) 1.7 ± 0.0 (6) 1.8 ± 0.0 (6) 1.8 ± 0.0 (6) 1.8 ± 0.0 (6) 1.8 ± 0.0 (6) 1.7 ± 0.0 (6) 3.4 ± 0.2 (6) 3.4 ± 0.2 (6) 3.5 ± 0.2 (6) 3.4 ± 0.2 (6) 0.0000*** 0.0000*** 0.0000*** b/g (P = 0.0001); 
c/h (P = 0.0001);  
d/i (P = 0.0001);  
e/j (P = 0.0001)
Paw volume Ctr (ml) 1.7 ± 0.0 (6) 1.8 ± 0.0 (6) 1.8 ± 0.0 (6) 1.8 ± 0.0 (6) 1.8 ± 0.0 (6) 1.7 ± 0.0 (6) 1.7 ± 0.0 (6) 1.7 ± 0.0 (6) 1.8 ± 0.0 (6) 1.8 ± 0.0 (6) 0.6992 0.0994 0.1439 ns
Inflammation score 0.0 ± 0.0 (6) 0.0 ± 0.0 (6) 0.0 ± 0.0 (6) 0.0 ± 0.0 (6) 0.0 ± 0.0 (6) 0.0 ± 0.0 (6) 2.8 ± 0.4 (6) 3.5 ± 0.1 (6) 3.6 ± 0.3 (6) 3.4 ± 0.3 (6) — — — —
Ankle-bend score 0.0 ± 0.0 (6) 0.0 ± 0.0 (6) 0.0 ± 0.0 (6) 0.0 ± 0.0 (6) 0.0 ± 0.0 (6) 0.0 ± 0.0 (6) 19.3 ± 0.7 (6) 17.8 ± 1.0 (6) 20.0 ± 0.0 (6) 20.0 ± 0.0 (6) — — — —
Paw withdrawal Ip (g) 223.8 ± 17.0 (6) 196.3 ± 4.5 (6) 222.5 ± 6.0 (6) 223.8 ± 7.1 (6) 218.8 ± 7.9 (6) 212.5 ± 23.4 (6) 125.0 ± 8.6 (6) 161.3 ± 7.4 (6) 158.8 ± 10.5 (6) 143.8 ± 5.3 (6) 0.0000*** 0.0004*** 0.5470 b/g (P = 0.0005); 
c/h (P = 0.0032);  
d/i (P = 0.0039);  
e/j (P = 0.0004)
Paw withdrawal Ctr (g) 248.8 ± 17.9 (6) 218.8 ± 9.6 (6) 225.0 ± 13.3 (6) 252.5 ± 17.8 (6) 238.8 ± 9.0 (6) 267.5 ± 20.7 (6) 210.0 ± 9.3 (6) 222.5 ± 6.6 (6) 257.5 ± 26.0 (6) 220.8 ± 15.0 (6) 0.9179 0.0244* 0.8047 ns
Values expressed as mean ± SEM for each experimental group followed by the sample size (n). In the post hoc column, c/h (P = 0.0008) means that  
at the 2nd week, controls were statistically different from monoarthritic rats with a P value of 0.0008.
*P < 0.05, **P < 0.01, and ***P < 0.001.
Ctr = contralateral; Ip = ipsilateral; MA = monoarthritis; ns = no significancies.
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Switzerland) was applied topically twice daily for 3 to 5 days 
to the ipsilateral paw of control and monoarthritic rats until 
analgesia was achieved, beginning 21 days after CFA injec-
tion. Pure Vaseline (Acofarmaderm, Acofarma S.A., Barce-
lona, Spain) was applied to the control and monoarthritic 
rats and served as a control of diclofenac application. A plastic 
Elizabeth collar was fixed around the neck of each animal to 
prevent ingestion of the cream/vaseline.24 The effect of diclof-
enac on the signs of inflammation and nociceptive behavior 
was analyzed after the last topical application (see Inflamma-
tion Assessment and Nociceptive Behavioral Assessment sec-
tions). As indicators of paw inflammation, photographs and 
footprints of the hind paw were taken to evaluate the shape 
and area of paw. At the end of the experiment, Western blot 
procedures were performed to evaluate the effect of diclof-
enac in the pattern of ERK1/2 activation in the SC, PGi, LC, 
and PFC. Next, topical application of diclofenac/vaseline 
was repeated in another set of animals to evaluate the effect 
of nonsteroidal anti-inflammatory drug analgesia on pain-
induced affective changes following the protocols described 
in the Anxiety- and Depression-like Behavior section.
To study the possible site of action of diclofenac, an 
additional group of animals was organized to receive local 
topical treatment of diclofenac in the contralateral paw 
(right paw) following the same protocol as described in the 
first paragraph of this section. Thus, the following extra 
experimental groups consisted of control and monoarthritic 
animals receiving vaseline (Cont + VAS and MA + VAS) 
and a group of monoarthritic animals receiving diclofenac 
treatment (MA + DIC). Before and after vaseline/diclofenac 
administration, baseline measures were taken for the assess-
ment of the paw volume, ankle-bend score, and paw-pinch 
test values. Afterwards, Western blot procedures were per-
formed to evaluate the effect of contralateral paw adminis-
tration in the pattern of ERK1/2 activation in the SC, PGi, 
LC, and PFC.
Statistical Analysis
All data are presented as the means ± SEM and all the results 
were analyzed using STATISTICA 10.0 (StatSoft, Tulsa, 
OK) or GraphPad Prism 5 software (GraphPad Software, 
Inc., La Jolla, CA) using either a Student t test (unpaired or 
paired, two-tailed) or a one-way or two-way ANOVA with or 
without repeated measures, followed by the appropriate post 
hoc tests (Student–Newman–Keuls or Dunnett tests). The 
independent variables were monoarthritis (between-groups) 
and treatment (between-groups). The level of significance 
was set at a P value of less than 0.05. Detailed information 
regarding statistical results is shown in tables 1-4.
Results
Monoarthritis as a Model of Chronic Inflammatory Pain
The injection of the vehicle alone (control group) did not 
provoke any inflammatory reaction in rats and these animals 
exhibited a normal behavior. By contrast, stable monoarthri-
tis was induced by CFA injection, with marked inflamma-
tory signs within several hours of induction that persisted 
for 4 weeks. Monoarthritic rats displayed: (1) normal 
body weight gain; (2) normal body temperature, except in 
the second week when a significant increase was observed 
(P < 0.001; monoarthritis vs. control for week 2 by ANOVA 
followed by Student–Newman–Keuls post hoc test; fig. 1A); 
(3) a significant increase in the ipsilateral paw volume evident 
each week (P < 0.001 for each time point; monoarthritis vs. 
control by ANOVA followed by Student–Newman–Keuls 
post hoc test; fig. 1B); and (4) a higher inflammation score 
in the ipsilateral paw that persisted until the fourth week 
(fig. 1B). Significantly, none of these features were observed 
in the contralateral paw of these monoarthritic rats. When 
the movement-induced nociceptive behavior was evaluated, 
CFA injection provoked higher ankle-bend scores (allo-
dynia) throughout the experimental period (fig. 1C) and 
monoarthritic rats exhibited significantly stronger mechani-
cal hyperalgesia in the ipsilateral paw (P < 0.001 for weeks 1 
and 4, P < 0.01 for weeks 2 and 3; monoarthritis vs. control 
by ANOVA followed by Student–Newman–Keuls post hoc 
test; fig. 1C). No painful reactions were observed in the con-
trol rats or in the contralateral paw of monoarthritic rats. 
Descriptive statistics is shown in table 1.
Monoarthritis-induced Anxiety- and Depression-like 
Behavior
To determine whether chronic pain associated with joint 
inflammation induced anxiogenic-like behavior, the rats were 
subjected to the marble-burying and EZM tests at several time 
points during the development of monoarthritis (fig. 2A). 
Unlike MA4D rats, more marbles were buried by MA14D (P 
< 0.05 by one-way ANOVA followed by Dunnett post hoc test) 
and MA28D (P < 0.01 by one-way ANOVA followed by Dun-
nett post hoc test) rats compared with the marbles buried by their 
corresponding controls, indicative of  anxiety-like behavior.
In the EZM maze test, there was no difference in the per-
centage of time spent in the open arms between control rats 
and MA4D or MA14D rats. However, MA28D rats spent 
significantly lesser in the open arms than by their corre-
sponding controls (P < 0.001 by one-way ANOVA followed 
by Dunnett post hoc test), again indicative of the develop-
ment of anxiety-like behavior. No changes in locomotor 
activity were detected between groups in the EZM, ruling 
out a motor component in the effects observed.
The FST was performed to evaluate the possible devel-
opment of depressive-like behaviors (fig. 2B), in which 
MA28D but not MA4D or MA14D rats exhibited signifi-
cantly higher immobility scores compared with the scores of 
their corresponding controls (P < 0.05 by one-way ANOVA 
followed by Dunnett post hoc test). Moreover, this effect was 
accompanied by a significant decrease in climbing behavior 
(P < 0.05 by one-way ANOVA followed by Dunnett post 
hoc test), but there were no significant changes in swimming 
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behavior. As expected, desipramine treatment diminished 
the rat’s immobility (P < 0.01 vs. corresponding control, 
Student t test) and significantly increased their climbing 
behavior (P < 0.01 vs. corresponding control, Student t test). 
Descriptive statistics is shown in table 2.
Monoarthritis-induced ERK1/2 Activation in the  
SC–PGi–LC–PFC Pathway
The expression of pERK1/2 was evaluated as an indicator of neu-
ronal activity in the SC, PGi, LC, and PFC in the early, middle, 
and late phases of monoarthritis development (fig. 3). In the 
ipsilateral side of the SC, significant increases in the expression 
of pERK1/2 were observed at 14 (P < 0.05 by one-way ANOVA 
followed by Dunnett post hoc test) and 28 (P < 0.001 by one-way 
ANOVA followed by Dunnett post hoc test) days after monoar-
thritis induction when comparing with that in control groups. 
No significant changes were observed at 4 days of monoarthri-
tis disease. In addition, no significant changes in pERK1/2 were 
observed at 4 or 14 days after monoarthritis induction in any of 
the brain areas analyzed. By contrast, significantly more pERK1/2 
was observed in the PGi (P < 0.05 by one-way ANOVA fol-
lowed by Dunnett post hoc test), LC (P < 0.01 by one-way 
ANOVA followed by Dunnett post hoc test), and PFC (P < 0.05 
by one-way ANOVA followed by Dunnett post hoc test) at 28 
days after monoarthritis induction compared with that in the 
corresponding controls. Descriptive statistics is shown in table 2.
Effect of Topical Administration of Diclofenac on 
Nociceptive Behavior
As expected, topical application of diclofenac to the ipsi-
lateral paw decreased the inflammation and increased the 
pain threshold of that paw, without producing any signifi-
cant change in body weight or body temperature (fig. 4). 
Although a small edema was observed in monoarthritic rats 
that received diclofenac (P < 0.01, control + diclofenac vs. 
monoarthritis + diclofenac by two-way ANOVA followed 
by Student–Newman–Keuls post hoc test), this was substan-
tially smaller than that seen in those that received vaseline 
(P < 0.001, monoarthritis + vaseline vs. monoarthritis + 
diclofenac by two-way ANOVA followed by Student–New-
man–Keuls post hoc test: fig. 4B). A similar effect on the 
inflammation score was observed (fig. 4B) and the ankle-
bend score of monoarthritic rats that received a topical 
application of diclofenac was significantly lower (P < 0.001, 
monoarthritis + vaseline vs. monoarthritis + diclofenac by 
two-way ANOVA followed by Student–Newman–Keuls 
Fig. 2. Anxiety- (A) and depressive- (B) like behavioral responses to monoarthritis and schematic representation (C) of the para-
gigantocellularis (PGi)–locus coeruleus (LC)–prefrontal cortex (PFC) pathway. (A) Increased anxiety was observed in MA28D rats 
in the marble-burying test (left), as indicated by an increase in burying behavior relative to the controls. Similarly, MA28D rats 
spent more time in closed areas of an elevated zero maze (center), instead of exploring the open areas, a hallmark of anxiety-like 
behavior. Measurement of the total distance travelled indicated that there were no changes in locomotor activity in the elevated 
zero maze (right panel). (B) The modified forced swimming test was used as an index of depressive-like behavior/pro-depressive 
activity, indicated by an increase in the immobility time of MA28D rats with respect to controls. Naive rats treated with the an-
tidepressant desipramine were used as positive controls of antidepressant activity in all the tests. Values are expressed as the 
mean ± SEM: *P < 0.05, **P < 0.01, and ***P < 0.001 monoarthritis versus control, one-way ANOVA followed by Dunnett post hoc 
test. n = 5 to 6 per experimental group; **P < 0.01, desipramine versus control; unpaired Student t test (two-tailed). (C) Scheme 
illustrating the PGi–LC–PFC nociceptive pathway, originating in the inflamed paw, passing through the dorsal root ganglion neu-
rons (DRGs) to spinal cord (SC) neurons, where it crosses the medial line and finally ascends to the supraspinal structures. AU 
= arbitrary units; CFA = complete Freund’s adjuvant; MA = monoarthritis.
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post hoc test), reflecting a higher nociceptive threshold, 
although this score remained significantly higher than that 
observed in control animals (P < 0.001 for the inflamma-
tion score and P < 0.01 for the ankle-bend score, control 
+ diclofenac vs. monoarthritis + diclofenac by two-way 
ANOVA followed by Student–Newman–Keuls post hoc 
test: fig. 4C). Diclofenac treatment also increased the force 
supported by the ipsilateral paw of monoarthritic rats 
(P < 0.001, monoarthritis + vaseline vs. monoarthritis + 
diclofenac by two-way ANOVA followed by Student–
Newman–Keuls post hoc test), completely abolishing 
mechanical hyperalgesia (fig. 4C). Although not quanti-
fied, photographs and footprints revealed a clear improve-
ment in paw posture and weight loading in the affected 
paw after diclofenac treatment (fig. 5). Descriptive statis-
tics is shown in table 3.
Effect of Diclofenac on Anxiety- and Depression-like 
Behaviors
Diclofenac administration had significant effects on 
 monoarthritis-induced anxiety- and depression-like behav-
iors. In the EZM, monoarthritis-induced anxiety-like 
behavior was reversed by diclofenac treatment (P < 0.05, 
monoarthritis + vaseline vs. monoarthritis + diclofenac by 
two-way ANOVA followed by Student–Newman–Keuls 
post hoc test; fig. 5A), yet no changes in locomotor activity 
were produced in this paradigm (fig. 5A). Similarly, mono-
arthritis-induced depression-like behavior was successfully 
reversed by topical diclofenac administration, as revealed 
by the  significant differences in immobility time between 
groups (P < 0.05, monoarthritis + vaseline vs. monoarthri-
tis + diclofenac by two-way ANOVA followed by Student–
Newman–Keuls post hoc test; fig. 5B). The climbing behavior 
displayed by the monoarthritic rats receiving vaseline showed 
a tendency to decrease compared with the respective control 
group (P = 0.056 control + vaseline vs. monoarthritis + vase-
line, by two-way ANOVA followed by Student–Newman–
Keuls post hoc test; fig. 5B). Descriptive statistics is shown 
in table 3.
Effect of Diclofenac on pERK1/2 Expression in the SC, PGi, 
LC, and PFC
Local inflammation produced a significant increase in the 
expression of pERK1/2 levels in the ipsilateral SC as wit-
nessed in monoarthritic rats treated with vaseline as com-
pared with that in the corresponding controls (P < 0.001, 
monoarthritis + vaseline vs. control + vaseline by two-way 
ANOVA followed by Student–Newman–Keuls post hoc test). 
Analgesia through application of diclofenac to the inflamed 
paw significantly reduced pERK1/2 levels (P < 0.001, mono-
arthritis + vaseline vs. monoarthritis + diclofenac by two-
way ANOVA followed by Student–Newman–Keuls post hoc 
Table 2. Descriptive Statistics and Exact P Values for the One-way ANOVA
 
  Control (a) MA4D (b) MA14D (c) MA28D (d)
Desipramine 
(e)
P Value  
(One-way 
ANOVA)
P Value  
(Student  
t Test,  
Unpaired,  
Two-tailed)
Dunnett  
Post hoc  
TestArthritis
Marbles 
buried (n)
16.7 ± 0.7 (6) 16.3 ± 0.8 (6) 19.0 ± 0.4 (6) 19.8 ± 0.2 (5) — 0.0016** — a/c (P = 0.0344); 
a/d (P = 0.0065)
Time in open 
arms (%)
36.8 ± 3.7 (6) 28.1 ± 3.4 (6) 29.8 ± 4.7 (6) 13.2 ± 2.9 (6) — 0.0020** — a/d (P = 0.0007)
Distance 
travelled 
(AU × 104)
12.8 ± 0.6 (6) 10.1 ± 1.1 (6) 10.1 ± 1.1 (6) 12.1 ± 1.9 (6) — 0.2732 — ns
Immobility  
(mean 
counts)
38.3 ± 3.7 (6) 42.0 ± 3.6 (6) 41.0 ± 1.4 (6) 51.3 ± 2.0 (6) 17.7 + 3.5 (6) 0.0228* a/e  
(P = 0.0021)
a/d (P = 0.0112)
Climbing 
(mean 
counts)
19.2 ± 4.0 (6) 14.7 ± 2.8 (6) 16.5 ± 1.5 (6) 7.5 ± 1.7 (6) 36.2 + 3.1 (6) 0.0371* a/e  
(P = 0.0072)
a/d (P = 0.0167)
Swimming 
(mean 
counts)
3.5 ± 0.8 (6) 3.3 ± 0.8 (6) 2.5 ± 1.1 (6) 1.2 ± 0.4 (6) 6.2 + 1.3 (6) 0.1858 ns ns
pERK1/2 (SC) 1.0 ± 0.0 (8) 2.3 ± 0.5 (12) 3.1 ± 0.7 (11) 5.1 ± 0.8 (8) — 0.0009*** — a/c (P = 0.0314); 
a/d (P = 0.0003)
pERK1/2 (PGi) 0.9 ± 0.0 (6) 1.3 ± 0.3 (6) 0.8 ± 0.3 (6) 1.9 ± 0.4 (6) — 0.0328* — a/d (P = 0.0386)
pERK1/2 (LC) 1.0 ± 0.3 (6) 1.6 ± 0.3 (6) 1.6 ± 0.8 (6) 2.9 ± 0.6 (6) — 0.0114* — a/d (P = 0.0043)
pERK1/2 (PFC) 1.0 ± 0.0 (6) 0.9 ± 0.2 (5) 1.0 ± 0.3 (6) 1.8 ± 0.1 (6) — 0.0092** — a/d (P = 0.0207)
Values expressed as mean ± SEM for each experimental group followed by the sample size (n). For desipramine-positive control, a Student test was per-
formed to directly compare with the control group. In the post hoc column, a/c (P = 0.0344) means that MA14D was statistically different from control rats 
with a P value of 0.0344.
*P < 0.05, **P < 0.01, and ***P < 0.001.
AU = arbitrary units; LC = locus coeruleus; MA = monoarthritis; ns = no significancies; pERK1/2 = phosphorylated extracellular signal–regulated kinases 1 
and 2; PFC = prefrontal cortex; PGi = paragigantocellularis; SC = spinal cord.
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test; fig. 6, A and B) and the significant increase in pERK1/2 
levels in the PGi–LC–PFC pathway of monoarthritic rats 
(P < 0.05, monoarthritis + vaseline vs. control + vaseline 
in the PGi; P < 0.01 monoarthritis + vaseline vs. control + 
vaseline in the LC and PFC by two-way ANOVA followed 
by Student–Newman–Keuls post hoc test; fig. 6, A and B) 
was also successfully restored to control levels after topical 
treatment with diclofenac (P < 0.05, monoarthritis + vase-
line vs. monoarthritis + diclofenac in the PGi and PFC; P 
< 0.01, monoarthritis + vaseline vs. monoarthritis + diclof-
enac in the LC by two-way ANOVA followed by Student–
Newman–Keuls post hoc test; fig. 6, A and B). Descriptive 
statistics is shown in table 3.
Effect of Diclofenac Administration in the  
Contralateral Paw
The results point to the absence of an effect of the contralat-
eral administration of diclofenac (fig. 7) on the paw volume 
Fig. 3. pERK1/2 expression in the spinal cord (SC)–paragigantocellularis (PGi)–locus coeruleus (LC)–prefrontal cortex (PFC) path-
way in response to chronic monoarthritis (MA). (A) In the SC, significant changes were observed in MA14D and MA28D rats. In 
addition, increased ERK1/2 phosphorylation was observed in MA28D rats in the PGi (B), LC (C), and PFC (D). Below the graphs 
are images of the blots showing pERK1/2 (44–42 kDa), tERK1/2 (44–42 kDa), and tubulin (50 kDa) expression for each structure 
from each experimental group. Values are expressed as mean ± SEM: *P < 0.05, **P < 0.01, and ***P < 0.001, MA versus cor-
responding controls, one-way ANOVA followed by Dunnett test. Each column represents the mean pERK1/2 levels from three 
assays performed on samples from independent groups of 2–4 animals. These levels were normalized to the corresponding total 
ERK1/2 values, as no significant changes in tubulin levels were observed. pERK1/2/tERK1/2 = phosphorylated/total extracellular 
signal–regulated kinases 1 and 2, respectively.
Fig. 4. Effect of topical diclofenac application to the ipsilateral paw on inflammation and nociceptive behavior. (A) General 
parameters of health (weight and temperature) were not significantly altered by diclofenac treatment. (B) Paw volume and the 
inflammation score in monoarthritic rats were significantly attenuated by diclofenac treatment. (C) The ankle-bend score was 
significantly lower in diclofenac-treated monoarthritic rats and the paw withdrawal threshold was restored to control levels. Val-
ues are expressed as the mean ± SEM: *P < 0.05, **P < 0.01, and ***P < 0.001, monoarthritis (MA) versus corresponding controls; 
###P < 0.001, MA + vaseline versus MA + diclofenac, two-way ANOVA followed by Student–Neuman–Keuls post hoc test. n = 
6 animals per experimental group.
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(fig. 7A), and paw-pinch threshold (fig. 7C) of the inflamed 
paw (ipsilateral paw), as can be observed by the lack of sig-
nificant changes between the values obtained before the 
treatment and after the treatment, in the group of monoar-
thritic animals receiving diclofenac (paired Student t test). 
However, in the ankle-bend score (fig. 7B), contralateral 
treatment with diclofenac caused a decrease in the values 
obtained after the treatment when comparing with those 
obtained before the treatment (P < 0.01; paired Student t 
test; fig. 7B). Descriptive statistics is shown in table 4.
In addition, quantification of the immunoblots (fig. 8) 
showed that the increased ERK1/2 activation observed in MA 
+ VAS group was maintained in the MA + DIC group in 
the SC (P < 0.01 for MA + VAS and MA + DIC vs. control, 
unpaired Student t test), PGi (P < 0.01 for MA + VAS vs. 
control and P < 0.05 for MA + DIC vs. control unpaired 
Student t test), LC (P < 0.05 for MA + VAS vs. control and 
P < 0.01 for MA + DIC vs. control, unpaired Student t test), 
and PFC (P < 0.05 for MA + VAS and MA + DIC vs. con-
trol, unpaired Student t test). Descriptive statistics is shown 
in table 4.
Discussion
The current findings demonstrate that chronic joint inflam-
mation interferes with sensitivity to noxious stimulation 
and with physiological movement of the inflamed joint, as 
well as profoundly affecting emotional states when the pain-
ful condition is prolonged. Furthermore, we demonstrated 
that chronic pain enhances ERK1/2 activation in certain cen-
tral nervous system regions, specifically in the SC, PGi, LC, 
and PFC. Promoting analgesia through the topical appli-
cation of anti-inflammatory cream successfully attenuated 
nociception, as well the anxiety- and depressive-like behav-
iors observed. Interestingly, this effect was accompanied by 
the normalization ERK1/2 activation in the SC, PGi, LC, 
and PFC.
We initially analyzed here the nociceptive behavior 
produced by joint inflammatory pain with the use of the 
monoarthritis model. As expected, unilateral arthritic inflam-
mation induced constant allodynia and hyperalgesia in the 
ipsilateral paw at all time points studied. The induction of 
monoarthritis was associated with the development of anxi-
ety-like symptoms in the EZM and marble-burying tests. The 
EZM is based on the natural aversion of rodents to bright 
Fig. 5. Effect of topical diclofenac application to the ipsilateral paw on anxiety- and depression-like behaviors induced by 
chronic monoarthritis (MA). (A) Diclofenac treatment abolished the anxiety-like behavior produced by chronic MA, as witnessed 
by an increase in the time spent in the open areas of the elevated zero maze. There were no significant differences between 
experimental groups in the total distance travelled in the elevated zero maze. (B) Topical diclofenac application also eliminated 
MA-induced depressive-like behavior, as witnessed by the decreased immobility in the forced swimming test. (C) Hind paw 
photographs and footprints revealed a clear improvement in the guarding posture in diclofenac-treated monoarthritic rats (Ipsi 
= ipsilateral paw; Contra = contralateral paw). Note the paw position of monoarthritic rats treated with vaseline or diclofenac. 
Values are expressed as mean ± SEM: *P < 0.05 and **P < 0.01, MA vs. corresponding control; #P < 0.05, MA + vaseline versus 
MA + diclofenac; two-way ANOVA followed by Student–Neuman–Keuls post hoc test. n = 5 to 6 animals per experimental group. 
AU = arbitrary units.
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and exposed places, whereas marble-burying behavior gauges 
the level of anxiety-like behavior of a rodent on encounter-
ing unfamiliar and bright objects. In both tests, anxiety-like 
behavior was evident at late disease stages, and in the case of 
the marble-burying test, the anxiety-like behavior was already 
evident at 14 days after monoarthritis induction. We also 
evaluated the time course of depression-like behavior by using 
the FST. This test induces “behavioral despair” in animals and 
abandoning the struggle to escape a stressful environment 
may resemble the psychological concept of “entrapment” 
described in clinical populations.23 MA28D rats displayed 
greater immobility and milder escape behavior (climbing) in 
the FST test. This reduction in climbing behavior was not 
accompanied by changes in swimming behavior, suggesting 
noradrenergic dysfunction. This is mainly due to the fact that 
noradrenaline-selective reuptake inhibitors produce signifi-
cant increases in this behavior in the FST23 indicating that 
a decrease in the climbing behavior suggests a dysfunction in 
the noradrenergic system. More studies are underway to clar-
ify whether this impairment is really occurring. These data 
are in consistent with previous findings,25–27 and with clinical 
data obtained from patients with osteoarthritis,28 indicating 
that chronic inflammatory pain conditions profoundly affect 
emotional states, as also described previously in other rheu-
matic diseases.29 Moreover, the time course for development 
of anxiety and then depression may indicate a certain chrono-
logical development of pain-related mood disorders, which 
was already observed in other pain models.30 Overall, this 
implies that the affective consequences of chronic inflamma-
tory pain evolve over time, probably mediated by long-term 
molecular and neural plastic changes at different brain areas.
Because ERK1/2 have been proposed as promising target 
molecules in the regulation of both pain31,32 and affective dis-
orders,33–35 we investigated whether monoarthritis-induced 
affective disorders were associated with altered ERK1/2 acti-
vation. In the SC, pERK1/2 was not significantly increased 
Table 3. Descriptive Statistics and Exact P Values for the Two-way Analysis
Control MA P Value (Two-way ANOVA) Student– 
Newman–Keuls 
Post hoc TestVaseline (a) Diclofenac (b) Vaseline (c) Diclofenac (d) Arthritis Treatment Interaction
Weight (g) 388.8 ± 9.1 (6) 404.3 ± 8.8 (6) 358.7 ± 14.9 (6) 358.0 ± 5.5 (6) 0.0012** 0.4736 0.4353 a/c (P = 0.0486); 
b/d (P = 0.0200)
Ip
silateral treatm
ent
Temperature (°C) 36.9 ± 0.2 (6) 36.9 ± 0.2 (6) 37.2 ± 0.2 (6) 36.9 ± 0.2 (6) 0.6943 0.4098 0.4098 ns
Paw volume  
Ip (ml)
1.8 ± 0.0 (6) 1.8 ± 0.0 (6) 3.4 ± 0.2 (6) 2.4 ± 0.1 (6) 0.0000*** 0.0002*** 0.0001*** a/c (P = 0.0002); 
b/d (P = 0.0016); 
c/d (P = 0.0002)
Inflammation  
score Ip
0.0 ± 0.0 (6) 0.0 ± 0.0 (6) 3.4 ± 0.3 (6) 1.9 ± 0.3 (6) 0.0000*** 0.0014** 0.0014** a/c (P = 0.0001); 
b/d (P = 0.0001); 
c/d (P = 0.0002)
Ankle bend  
score Ip
0.0 ± 0.0 (6) 0.0 ± 0.0 (6) 20.0 ± 0.0 (6) 5.4 ± 1.8 (6) 0.0000*** 0.0000*** 0.0000*** a/c (P = 0.0001); 
b/d (P = 0.0011); 
c/d (P = 0.0002)
Paw withdrawal 
Ip (g)
218.6 ± 7.8 (6) 218.6 ± 9.4 (6) 143.8 ± 5.3 (6) 212.6 ± 10.0 (6) 0.0001*** 0.0005*** 0.0005*** a/c (P = 0.0002); 
c/d (P = 0.0002)
Time in open  
arms (%)
44.3 ± 2.6 (6) 36.1 ± 3.1 (6) 27.8 ± 4.0 (6) 38.7 ± 3.2 (6) 0.0465* 0.6783 0.0084** a/c (P = 0.0017); 
c/d (P = 0.0132)
Distance  
travelled  
(AU × 104)
14.0 ± 1.5 (6) 14.2 ± 2.4 (6) 9.8 ± 1.2 (6) 9.3 ± 1.7 (6) 0.0170* 0.9356 0.8669 ns
Immobility  
(mean counts)
35.8 ± 3.3 (6) 34.0 ± 3.2 (6) 47.0 ± 1.3 (5) 38.3 ± 1.6 (6) 0.0077** 0.0578 0.2045 a/c (P = 0.0180); 
c/d (P = 0.0294)
Climbing  
(mean counts)
22.3 ± 3.2 (6) 24.5 ± 3.5 (6) 12.6 ± 1.1 (5) 19.5 ± 2.1 (6) 0.0145 0.1120 0.4201 ns
Swimming  
(mean counts)
2.0 ± 0.8 (6) 1.3 ± 0.5 (6) 0.4 ± 0.4 (5) 2.2 ± 1.3 (6) 0.6629 0.5328 0.1760 ns
pERK1/2 (SC) 1.0 ± 0.0 (6) 1.7 ± 0.4 (5) 5.0 ± 0.5 (5) 2.5 ± 0.5 (5) 0.0000*** 0.0444* 0.0010** a/c (P = 0.0002); 
c/d (P = 0.0006)
pERK1/2 (PGi) 1.1 ± 0.1 (6) 1.2 ± 0.4 (6) 3.0 ± 0.9 (6) 1.0 ± 0.1 (6) 0.0730 0.0984 0.0472* a/c (P = 0.0338); 
c/d (P = 0.0466)
pERK1/2 (LC) 1.0 ± 0.0 (6) 1.0 ± 0.1 (6) 1.9 ± 0.3 (6) 1.2 ± 0.1 (6) 0.0083** 0.0287* 0.0800 a/c (P = 0.0082); 
c/d (P = 0.0096)
pERK1/2 (PFC) 1.0 ± 0.0 (6) 1.6 ± 0.3 (6) 3.1 ± 0.6 (6) 1.4 ± 0.3 (6) 0.0225* 0.1730 0.0076** a/c (P = 0.0052); 
c/d (P = 0.0150)
Values expressed as mean ± SEM for each experimental group followed by the sample size (n). In the post hoc column, a/c (P = 0.0486) means that 
MA + vaseline group was statistically different from control + vaseline group with a P value of 0.0486.
*P < 0.05, **P < 0.01, and ***P < 0.001.
AU = arbitrary units; Ip = ipsilateral; LC = locus coeruleus; MA = monoarthritis; ns = no significancies; pERK1/2 = phosphorylated extracellular signal–
regulated kinases 1 and 2; PFC = prefrontal cortex; PGi = paragigantocellularis; SC = spinal cord.
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at 4 days after monoarthritis induction but was significantly 
increased at both 14 and 28 days after monoarthritis. Indeed, 
other authors showed that 2 and 4 days of inflammation were 
not accompanied by increased ERK1/2 activation in the SC.
36 
The significant increase of pERK1/2 observed at 14 and 28 
days may be related with increased metabolic activity which 
was already demonstrated by Schadrack et al.,37 at least for 
the 14 days of monoarthritic time point. The onset of affec-
tive symptoms was accompanied by increased pERK1/2 levels 
in the PGi, LC, and PFC of monoarthritic rats, in agree-
ment with previous reports of increased pERK1/2 expression 
in the rat PGi 7 days after the induction of neuropathic 
Fig. 6. Effect of topical diclofenac application to the ipsilateral paw on the pERK1/2 in the spinal cord (SC)–paragigantocellularis 
(PGi)–locus coeruleus (LC)–prefrontal cortex (PFC) pathway. (A) Graphs depict the changes in the pERK1/2 expression in re-
sponse to chronic monoarthritis (MA). Diclofenac administration significantly reduced pERK1/2 levels on the ipsilateral side of 
the SC and it reversed the increase in pERK1/2 observed in the PGi, LC, and PFC. (B) Images of the blots showing pERK1/2 
(44–42 kDa), tERK1/2 (44–42 kDa), and tubulin (50 kDa) expression for each structure from each experimental group. Values are 
expressed as the mean ± SEM: *P < 0.05, **P < 0.01, and ***P < 0.001, control versus MA; #P < 0.05, ##P < 0.01, ###P < 0.001, 
MA + vaseline versus MA + diclofenac; two-way ANOVA followed by Student–Neuman–Keuls post hoc test. Each column rep-
resents the mean pERK1/2 levels of three assays performed on samples from independent groups of 2–4 animals. These levels 
were normalized to the corresponding total ERK1/2 values, as no significant changes in tubulin levels were observed. C = con-
tralateral; Cont = control; DIC = diclofenac; I = ipsilateral; pERK1/2/tERK1/2 = phosphorylated/total extracellular signal–regulated 
kinases 1 and 2, respectively; VAS = vaseline.
Fig. 7. Effect of the topical administration of vaseline/diclofenac to the contralateral paw on the paw volume (A), ankle-bend 
score (B), and paw withdrawal threshold (C). Valued expressed as mean ± SEM. Comparisons between the values obtained 
before and after the treatment, for each experimental group, were performed by using a paired Student t test. **P < 0.01. Cont 
= control; DIC = diclofenac; MA = monoarthritis; VAS = vaseline.
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pain.38,39 We observed increased ERK1/2 activation in the LC 
after chronic monoarthritis, possibly due to increased excit-
atory input from the PGi. Interestingly, CFA injection has 
been shown to induce a sharp increase in LC pERK1/2 after 
5 min that disappears 7 h later,40 and indeed, we observed 
no changes in pERK1/2 in the early stages after CFA admin-
istration. By contrast, pERK1/2 expression was consistently 
increased 28 days postadministration, coinciding with 
altered nociceptive behavior and the onset of anxiety and, 
especially, depressive states. These findings suggest that the 
LC is involved in both acute pain and the subsequent devel-
opment of pain-induced affective disorders. Finally, ERK1/2 
activation was also enhanced in the PFC region 28 days after 
CFA administration. The PFC is one of the most impor-
tant projection targets of LC noradrenergic terminals, and 
increased pERK1/2 expression in this area has been correlated 
with anxiety- and  depressive-like behaviors.9,10,13,35 Another 
interesting observation was that the pattern of ERK1/2 activa-
tion at supraspinal level was bilateral, which means that uni-
lateral inflammation of the ankle produced both ipsilateral 
and contralateral phosphorylation of ERK1/2 in the PGi–
LC–PFC pathway. This was already shown in other pain 
studies,38,39 and particularly, such lack of lateralization of 
ERK1/2 phosphorylation was common in studies regarding 
Fig. 8. Effect of the topical administration of vaseline/diclofenac to the contralateral paw in the pattern of ERK1/2 activation in the 
spinal cord (SC)–paragigantocellularis (PGi)–locus coeruleus (LC)–prefrontal cortex (PFC) pathway. Below the graphs, there is a 
representation of the immunoblots showing the differences between experimental groups. Values expressed as mean ± SEM. 
*P < 0.05 and **P < 0.01 by unpaired Student t test versus the control group. Cont = control; DIC = diclofenac; MA = monoarthri-
tis; pERK1/2/tERK1/2 = phosphorylated/total extracellular signal–regulated kinases 1 and 2, respectively; VAS = vaseline.
Table 4. Descriptive Statistics and Exact P Values for the Student t Test
Before Treatment After Treatment
P Value (Paired 
Student t Test)
Control MA Control MA
Vaseline (a) Vaseline (c) Diclofenac (e) Vaseline (b) Vaseline (d) Diclofenac (f)
Paw volume  
Ip (ml)
1.9 ± 0.0 (6) 3.6 ± 0.2 (7) 3.3 ± 0.2 (7) 2.0 ± 0.0 (6) 3.9 ± 0.2 (7) 3.2 ± 0.2 (7) ns
C
ontralateral treatm
ent
Ankle-bend 
score Ip
0.0 ± 0.0 (6) 17.9 ± 1.5 (7) 17.1 ± 1.5 (7) 0.0 ± 0.0 (6) 18.6 ± 0.9 (7) 12.1 ± 1.8 (7) e/f (P = 0.0038)
Paw  
withdrawal 
Ip (g)
227.5 ± 8.8 (6) 150.0 ± 9.8 (7) 150.0 ± 8.7 (7) 246.3 ± 8.8 (7) 142.5 ± 4.3 (7) 161.8 ± 9.4 (7) ns
P Value (Unpaired 
Student t Test)
pERK1/2 (SC) — 1.0 ± 0.0 (6) 3.9 ± 0.9 (6) 2.9 ± 0.5 (6) b/d (P = 0.0072);  
b/f (P = 0.0023)
pERK1/2 (PGi) — 1.0 ± 0.0 (6) 1.3 ± 0.1 (6) 1.9 ± 0.3 (6) b/d (P = 0.0039);  
b/f (P = 0.0198)
pERK1/2 (LC) — 1.0 ± 0.0 (6) 1.4 ± 0.1 (6) 2.2 ± 0.3 (6) b/d (P = 0.0174);  
b/f (P = 0.0013)
pERK1/2 (PFC) — 1.0 ± 0.0 (6) 3.6 ± 1.1 (6) 2.5 ± 0.5 (6) b/d (P = 0.0157);  
b/f (P = 0.0427)
Values expressed as mean ± SEM for each experimental group followed by the sample size (n). e/f (P = 0.0038) means that MA diclofenac before treatment 
was statistically different from MA diclofenac after treatment with a P value of 0.0038.
Ip = ipsilateral; LC = locus coeruleus; MA = monoarthritis; ns = no significancies; pERK1/2 = phosphorylated extracellular signal–regulated kinases 1 and 2; 
PFC = prefrontal cortex; PGi = paragigantocellularis; SC = spinal cord.
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pain-related anxiety paradigms.9,10,13 Taken together, these 
findings suggest that alterations in the levels of pERK1/2 may 
be one of the molecular mechanisms that underlie the onset 
of chronic pain–induced affective disorders.
One of the most remarkable findings of the current 
study was that the blockade of nociceptive inputs affected 
 monoarthritis-induced anxiety- and depression-like behavior. 
As indicated elsewhere, administration of sodium diclofenac 
ointment attenuated inflammation and pain,41,42 as well as 
reducing pERK1/2 levels in the lumbar SC. Significantly, the 
induction of analgesia was accompanied by the disappearance 
of anxiety- and depression-like behaviors, suggesting that senso-
rial pain inputs are the source of affective alterations in chronic 
monoarthritis. Importantly, the increased ERK1/2 activation in 
the PGi–LC–PFC pathway on monoarthritis induction was 
successfully restored to control levels by diclofenac treatment, 
indicating that the increased ERK1/2 activity in these regions is 
a consequence of the nociceptive inputs. Based on its increased 
expression only when anxiety- and  depression-like behaviors 
are present, we propose that sustained altered pERK1/2 expres-
sion in the PGi–LC–PFC pathway in chronic monoarthritis 
is probably more closely related to the development of pain-
related affective disorders than with nociception itself. How-
ever, further studies in other areas widely involved in facilitating 
or inhibiting nociception, such as the periaqueductal gray, ros-
tral ventromedial medulla, and dorsal reticular nucleus, will be 
necessary to confirm this hypothesis.
To study the possible site of action of diclofenac, we evalu-
ated the effect of administering vaseline/diclofenac in the 
contralateral paw. Behavioral studies showed that diclofenac 
administered into the contralateral paw modify neither the 
paw volume nor the hyperalgesia level, but a slight reduction 
was observed in the ankle-bend score. Nevertheless, when 
studying the effect of contralateral application of diclofenac 
on the expression of pERK1/2 in the PGi, LC, and PFC, no 
significant changes were observed with respect to its control 
group of monoarthritic rats receiving vaseline on the contra-
lateral paw. Hence, these data suggest that topical application 
has a low systemic effect that would explain the small effect 
in the ankle-bend test. Indeed, previous data have shown that 
local administration (cream, gel, or dermal patch) produces 
a very low systemic effect when compared with that in oral 
administration.43–45 However and of relevance for our study, 
pERK1/2 expression is not modified in any of the brain areas 
studied; so, it seems unlikely that a central effect produced 
may be involved in all the pain-related features restored by 
diclofenac treatment. Overall data suggest that diclofenac 
might be peripherally acting and that the blockade of the noci-
ceptive inputs originated in the inflamed paw is able to restore 
pERK1/2 expression levels in the brain areas studied. However, 
it is important to note that further studies will be necessary to 
discern the peripheral and/or central effect of diclofenac in the 
reversal of all the monoarthritis-related features.
Although the translation of findings from animal mod-
els to humans must always be approached with caution, 
we believe that our findings have interesting parallels in 
the clinical setting. Thus, we propose that achieving effec-
tive pain relief reverses the molecular changes induced by 
chronic pain. This hypothesis is consistent with the data 
from patients with osteoarthritis in whom successful arthro-
plasty reverses thalamic atrophy.46 Furthermore, the current 
findings suggest that effective analgesia also benefits other 
symptoms (anxio-depressive behaviors) that, although not 
directly related to sensorial pain, have been identified as 
major contributors to a worse patient outcome. Finally, it 
is important to note that neuroelasticity (i.e., reversal of an 
effect on removal of the stimulus) is observed at the onset of 
anxio-depressive symptoms. It is possible that a critical win-
dow exists after which inducing such reversal will be more 
difficult, or no longer feasible, due to additional changes 
in neuronal architecture. These findings have important 
implications for the  ongoing debate regarding the optimal 
therapeutic approaches to treating patients with arthritis 
(pharmacological vs. surgical strategies).
The delayed onset of monoarthritis-induced affective 
pathologies suggests that peripheral pain inputs induce some 
reorganization in the central nervous system. Our study 
demonstrates that affective behavioral changes are accom-
panied by ERK1/2 activation in the PGi–LC–PFC pathway. 
Moreover, these findings indicate that successful analgesia 
can reverse sensorial and affective pain-induced changes.
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Abstract 
Background: Chronic pain exponentially increases the risk of suffering emotional disturbances, such as 
those characterized by persistent anxiety, although the mechanisms underlying this co-morbidity are 
unknown. Prolonged arthritis can produce anxiety-like behavior in rats, along with enhanced 
phosphorylation of the extracellular signal-regulated kinase 1/2 (pERK1/2) in the Locus Coeruleus (LC). 
Therefore, we propose that ERK1/2 activation in the LC plays a crucial role in pain-related anxiety. 
Methods: As a model of painful arthritis, monoarthritis (MA) was induced in rats by injection of 
complete Freund´s adjuvant. We first evaluated the behavioral attributes of pain and anxiety, as well as 
LC function, at an early (1 week) and late-phase (4 weeks, MA4W) of the disease. Subsequently, we 
evaluated the effect of pERK1/2 blockade in MA4W. 
Results: Pain was evident in monoarthritic rats 1 week after induction, although anxiety did not appear 
until 4 weeks later. This late-phase of the disease was accompanied by diminished tonic LC activity, 
which was coupled to exacerbated evoked LC responses to noxious stimulation of the inflamed and the 
healthy paw. When ERK1/2 activation was dampened by intra-LC SL327 administration, the exaggerated 
evoked response of MA4W rats was blocked. Importantly, SL327 did not change pain hypersensitivity 
but rather, it reversed both the anxiogenic-like behavior and the increase in pERK1/2 in the anterior 
cingulate cortex (ACC) of MA4W rats. 
Conclusions: Prolonged monoarthritis produced anxiety-like behavior, ERK1/2 activation and impaired 
electrical activity in the LC. Blockade of pERK1/2 in the LC reduced pERK1/2 expression in the ACC 
and relieved anxiety.  
Keywords: Locus coeruleus, anxiety, pain, arthritis, ERK1/2, anterior cingulate cortex 
 
Introduction 
Chronic pain (CP) is now considered an 
independent disease, with repercussions that reach 
far beyond hypersensitivity. Many studies have 
emphasized that CP exponentially increases the 
risk of suffering emotional disturbances, such as 
those characterized by persistent anxiety and low 
mood, generating a vicious circle that magnifies 
and exacerbates the painful experience (1-3). In the 
case of arthritis, pain is produced joints 
inflammation and it is estimated that more than 
30% of the arthritic population in the U.S. suffer 
anxiety (4). While this co-morbidity is clinically 
well established, the underlying mechanisms 
remain unclear. Similarly to what was found by 
other authors (5-6), we previously reported that 
prolonged experimental arthritis produced anxiety-
like behaviors in rats (7), mimicking the situation 
106 
in patients and providing us with an useful 
experimental tool to assess what causes the anxiety 
that develops some time after pain begins. By 
studying phosphorylated isoforms of extracellular 
signal-regulated kinase 1/2 (pERK1/2) as a marker 
of plasticity, we have found that long-term arthritis 
enhances pERK1/2 expression in the Locus 
Coeruleus (LC) and its projection area, the 
prefrontal cortex (7), strongly suggesting that this 
pathway is implicated in the effects of arthritis.  
The noradrenergic-LC system is a bilateral pontine 
nucleus that modulates pain perception through an 
intricate network of projections. It is widely known 
that noxious or inflammatory stimuli activate LC 
descending innervations to the spinal cord to 
promote the feedback inhibition of pain (8-10). 
However, there is little information available about 
the ascending LC projections to the prefrontal 
areas where the emotional consequences of CP 
might be modulated (11-12) (Figure 1A). Indeed, 
the LC is the only source of noradrenaline in the 
anterior cingulate cortex (ACC), a key structure for 
pain-related negative emotions (13-14). Therefore, 
the LC may modulate the sensorial and affective 
features of CP (7, 15-16). 
In the present study we have used an animal model 
of chronic inflammatory pain (monoarthritis, MA) 
to evaluate the characteristics of LC discharge 
following noxious stimulation at an early (non-
anxious phenotype) and late (anxious phenotype) 
phase of disease development. Furthermore, as 
ERK1/2 activity has been implicated in long-
lasting synaptic plasticity in several areas involved 
in pain processing (e.g., the spinal cord and ACC: 
17-18), we also studied the behavioral and 
electrophysiological effects of the pharmacological 
inhibition of ERK1/2 activation at the LC level. 
 
 
Materials and Methods 
Animals and Experimental Design 
Two hundred male Harlan Sprague-Dawley rats 
(200-300g, University of Cádiz - 
ES110120000210) were used in this study (22 ± 1 
ºC, 12 h light/dark cycles, lights on at 08:00 AM, 
food and water ad libitum). All the experimental 
work was carried out in compliance with the 
European Communities Council Directive 
2010/63/EC, Spanish Law (RD 1201/2005) and the 
ethical guidelines for investigation of experimental 
pain in animals (19). The experimental protocols 
were approved by the Institutional Ethical 
Committee. 
Behavior (Group 1) and electrophysiological LC 
activity (Group 2) were evaluated in control rats, 
and one (MA1W) or four weeks (MA4W) after 
inducing inflammation. The effect of intra-LC 
administration of a pERK1/2 inhibitor (SL327) on 
LC electrophysiological activity and behavior was 
evaluated in control and MA4W rats (Groups 3 
and 4 respectively). Furthermore, 
immunohistochemistry studies were performed in 
parallel groups (Group 5: Figure 1B). 
 
Monoarthritis induction and behavioral 
assessment 
MA was induced under isoflurane (Abbott, Spain) 
anesthesia (4% to induce, 2% to maintain) by 
injection into the left tibiotarsal joint (ipsilateral) 
of a complete Freund's adjuvant (CFA, 50 µL) 
solution containing 30 mg of desiccated 
Mycobacterium butyricum (Difco-Laboratories, 
USA) diluted in the vehicle solution (3mL paraffin 
oil, 2mL saline and 500µL Tween® 80: 20). 
Control rats were injected with the vehicle 
solution. Animals that developed polyarthritis were 
excluded from the study.  
 
The paw-pinch test was used to evaluate 
mechanical hyperalgesia (21). Briefly, increasing 
pressure was gradually applied to the dorsal side of 
the paw using a graded motor-driven device (Ugo 
Basile, Italy), beginning with 30 g of pressure. A 
reduction in the pressure that provokes withdrawal 
indicates mechanical hyperalgesia. Two measures 
were taken in both the ipsi- and contralateral paws 
with a 5 minute of interval between each. 
 
Anxiety-like behavior was evaluated in the 
elevated zero maze (EZM) (7). It consists of a 
black circular platform divided into four quadrants 
of equal length: two opposing open quadrants with 
1 cm high clear curbs to prevent falls; and two 
opposing closed quadrants with black walls. A 5 
min trial under the same lighting conditions began 
by placing the animal in the center of a closed 
quadrant. Spontaneous Motor Activity Recording 
and Tracking (SMART, Panlab S.L. Spain) 
software was used to analyze the percentage of 
time the rat spent in the open arms and the total 
distance travelled by each rat. Increases in the time 
spent in the closed areas are correlated with 
anxiety-like behavior. 
 
LC Electrophysiology 
As the ascending pain pathway is mainly 
contralateral (22), single-unit extracellular 
recordings of LC neurons contralateral to the 
injected articulation were obtained (Supplement 1, 
Figure 1A, 15, 23). When a single LC unit was 
isolated, the spontaneous basal discharge 
(baseline) and the sensory-evoked response of LC 
neurons was studied (Figure 2A). Sensory-evoked 
LC responses (n=5) were induced by manually 
applying mechanical pressure for 1s to the 
ipsilateral or contralateral paw (paw compression, 
PC) using a surgical forceps. The sensory evoked-
response, the duration (D) of the response and the 
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suppression period (SP) were quantified after each 
PC (Figure 2B). The post-compression tonic 
activity was measured over an interval of 70 
seconds, 30 seconds after each PC. Changes in 
sensory-evoked discharge and post-compression 
discharge were expressed as a percentage of the 
baseline for each neuron and averaged across 
recordings.  
 
In another set of experiments, a calibrated pipette 
alongside the recording micropipette (24) and 
containing a solution of the inhibitor of ERK1/2 
phosphorylation, SL327 (4.17 mM: S4069, Sigma-
Aldrich, St Louis, MO), was used to explore the 
effect on LC activity (Figure 1A – Group 3).  
 
Intra-LC drug administration 
Five days before completing the 4 weeks of MA, a 
guide cannula was implanted into the contralateral 
(right side) LC at the following coordinates 
relative to lambda: anteroposterior=-3.7 mm, 
mediolateral= -1.1 mm, and dorsoventral -6.2 mm, 
below the brain surface in anaesthetized rats 
(Supplement 1 and (25)). Following at least 5 days 
recovery post-surgery, animals received SL327 
(0.7 µg) dissolved in DMSO at a final 
concentration of 4.17 mM. The behavioral tests 
were performed within 10-25 minutes of drug 
administration.  
 
Immunohistochemistry 
Immunohistochemistry was performed on free-
floating sections of the LC and ACC as described 
in Supplement 1 (26-27). Labeling was visualized 
on an optical microscope (Olympus BX60, Spain) 
equipped with a U-MNU filter system (Olympus 
DP71, Spain) and quantified using Image J 
software (National Institutes of Health, Bethesda, 
Maryland). 
 
Statistical analysis  
All the data are presented as the means ± SEM and 
the results were all analyzed using STATISTICA 
10.0 (StatSoft, OK, USA) or GraphPad Prism 5 
software (GraphPad Software, CA, USA), using 
either Student´s t-test (unpaired or paired, two-
tailed), or a one-way or two-way analysis of 
variance (ANOVA) followed by the appropriate 
post-hoc tests (Bonferroni or Dunnett's tests). The 
independent variables were monoarthritis 
(between-groups), paw or drug (between-groups: 
Table S3). Fisher’s exact test was used to evaluate 
the incidence of burst activity. Significance was 
accepted at p<0.05. 
 
Results 
Nociceptive and anxiety-like behavior 
In MA rats, the ipsilateral paw withdrawal 
threshold is significantly lower than that of control 
rats (p<0.001 for MA1W and MA4W: Figure 1C), 
indicative of mechanical hyperalgesia. In addition, 
MA4W rats spent significantly less time in the 
open arms of the EZM than control rats, indicative 
of anxiety-like behavior (p<0.001: Figure 1D), 
although no such changes were observed with 
MA1W rats. Moreover, no significant changes 
were observed in the total distance travelled in the 
EZM, indicating that locomotor activity was not 
impaired in the MA rats (Figure 1E).  
 
Spontaneous activity of LC neurons 
Data from 57, 36 and 37 neurons were recorded 
from 19 control, 11 MA1W and 17 MA4W rats, 
respectively. The basal spontaneous LC activity 
was significantly lower in MA4W rats than in 
controls (p<0.01: Figure 1F), and there tended to 
be less burst activity in the MA rats (both 1W and 
4W, p=0.059 and p=0.056 vs control, respectively: 
Figure 1G). However, the number of spikes per 
burst did not differ among the experimental groups 
(Figure 1H). 
 
Activity of LC neurons evoked by ipsilateral paw 
compression  
The electrophysiological profile of the sensory-
evoked response was assessed during ipsilateral 
paw compression (Figure 2A and 2B, and Table 
S1). The application of 5 sequential stimulations 
did not significantly alter any parameter studied of 
the sensory responses evoked in any group (S1 vs. 
S5 for control, MA1W and MA4W, p>0.05). 
However, the evoked activity in MA4W rats was 
significantly stronger than that of control and 
MA1W rats, reaching significance in the last 
stimulation (p<0.05 vs. control: Figure 2C and 2K-
2M). This reinforcement was particularly evident 
when analyzing the averaged data of all 5 
stimulations, which reflected the significant 
increase in this parameter in MA4W rats (p<0.001 
vs. controls: Figure 2D). This analysis also 
revealed a significantly weaker evoked response in 
MA1W rats than in the control rats (p<0.05: Figure 
2D). Furthermore, the duration of the response also 
increased in MA4W, particularly following 
stimulations S3 (p<0.01), S4 (p<0.05) and S5 
(p<0.001 vs. control: Figure 2E). Likewise, a 
significant increase in duration was observed in 
MA4W rats when the averaged data of all 
stimulations was compared with the controls 
(p<0.001: Figure 2F). Finally, no significant 
differences were observed in the suppression 
period between the experimental groups (Figure 
2G and 2H).  
 
We also explored the tonic LC rate after each 
noxious stimulus, expressed as the percentage 
change from the basal firing rate (post-
compression tonic activity: Figure 2B). In the 
control group, a slight decrease of 12.2% in tonic 
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activity was observed with each application of 
mechanical stimulation, while the MA1W group 
hardly changed its spontaneous firing pattern in 
response to sequential stimulation. By contrast, an 
increase in tonic activity of about 16.5% was 
observed with sequential paw compressions in 
MA4W rats, with significant differences observed 
between the MA4W and control rats following 
each paw compression (p<0.05 for S1; p<0.01 for 
S1 and S5; p<0.001 for S3 and S4; Figure 2I). 
Moreover, there was a significant increase in the 
averaged post-compression tonic activity in 
MA1W and MA4W rats compared with the 
controls (p<0.05 and p<0.001, respectively: Figure 
2J).  
 
LC neuron activity evoked by contralateral paw 
compression  
After 5 successive ipsilateral paw compressions, 
one compression was applied to the non-inflamed 
contralateral paw (Figure 2A). As expected, no 
sensory response of the LC was evoked when a 
noxious stimulus was applied to the contralateral 
paw of control rats (Figure 2N and 2O). However, 
when the same procedure was applied to 
monoarthritic rats after either one or four weeks of 
inflammation, a sensory-evoked response was 
observed that was particularly evident in MA4W 
rats (Figure 2O). Indeed, burst activity was 
stronger in MA1W rats (p=0.052) and significantly 
higher in MA4W rats (p<0.05) than in control rats 
(Table S1: Figure 2N). No significant differences 
were detected between the MA1W and MA4W 
rats. 
 
TH and pERK1/2 expression in the LC  
Since increased use of noradrenaline is 
accompanied by TH upregulation (28), we 
evaluated the TH expression in the LC. As 
expected, TH immunolabeling was observed in the 
cytoplasm and dendrites of noradrenergic neurons. 
At the caudal level, the number of neurons 
expressing TH per section increased significantly 
in MA4W rats compared with control animals 
(p<0.01 and p<0.05 for ipsi- and contralateral 
sides, respectively: Figure 3A and 3G). Similar 
results were obtained when considering the entire 
rostro-caudal extension (total portion, p<0.05 for 
ipsi- and contralateral sides: Figure 3C), although 
no differences were observed in the rostral domain 
(Figure 3B) in MA1W rats or when comparing the 
ipsi- and contralateral sides. This increased TH 
expression in the LC of MA4W animals was 
confirmed in western blots (Figure S1F). Similar 
results were obtained when pERK1/2 was 
evaluated in the LC, where immunolabeling was 
detected in the cytoplasm, nucleus and in the 
dendrites, as well as in a large number of fibers 
surrounding the LC neurons (26). Again, no 
differences were observed between the ipsi- and 
contralateral LC. In MA4W rats in the density of 
pERK1/2 labeling increased significantly in the 
caudal portion of the LC compared with control 
animals (Ipsilateral, p<0.001; Contralateral, 
p<0.001: Figure 3D and 3H), as well as in the 
rostral domain (Ipsilateral, p<0.01; Contralateral, 
p<0.001: Figure 3E and 3I), and along the entire 
rostro-caudal extension (Ipsilateral, p<0.001; 
Contralateral, p<0.001: Figure 3F). These data 
suggest that prolonged inflammatory pain 
produces greater activation of the ERK cascade in 
the LC (MA4W). Moreover, a slight increase in 
pERK1/2 expression was detected in the 
contralateral LC of MA1W rats when the entire 
rostro-caudal extension was considered (p<0.05: 
Figure 3F). 
 
Electrophysiological effect of intra-LC SL327 
microinjection 
Next, we studied the effect of SL327 on the LC 
discharge evoked by ipsilateral paw compression 
in control and MA4W rats (Group 3, Figure 1B). 
After noxious stimulations S1, S2, S3 and S4, a 
dose of SL327 (8.35 - 33.39 pmol) was 
administered into the LC and the evoked response 
was measured. SL327 administration did not 
significantly modify the responses provoked by S1 
administration in control animals (evoked 
response, duration, suppression period and post-
compression tonic activity: S1 vs. S2-S5, p>0.05: 
Figure 4A-D), yet SL327 produced a dose-
dependent decrease in the evoked discharge after 
each noxious stimulus in MA4W rats, which was 
particularly evident at S5 (S1 vs S2-S4, p>0.05; S1 
vs. S5, p<0.01: Figure 4A). Additionally, we found 
that the evoked discharge produced in MA4W and 
control rats receiving SL327 differed significantly 
after S4 and S5 (control vs. MA4W for S4 and S5, 
p<0.05 and p<0.01, respectively). However, the 
duration of the response in control and MA4W rats 
was not modified by microinjection of SL327 
(p>0.05). Overall, these results suggested that 
SL327 decreased the duration of the response that 
had been significantly increased in MA4W rats 
(Figure 4B). Regarding the effect of SL327 in 
suppressing LC neurons after ipsilateral paw 
compression, a dose-dependent increase was 
observed in MA4W that was statistically different 
from the basal S1 value once 33.39 pmol had been 
administered (S5: S1 vs. S5, p<0.01: Figure 4C), 
and when compared with control animals receiving 
the same dose (control vs. MA4W, p<0.001: 
Figure 4C). Finally, microinjection of SL327 
produced a significant decrease in the post-
compression tonic activity in MA4W compared 
with the basal S1 value (S1 vs. S3-S5, p<0.001: 
Figure 4D), and with the control animals receiving 
the same dose (control vs. MA4W, p<0.05 for S3, 
S4 and S5: Figure 4D, detailed information can 
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also be found in Table S2). Representative 
oscillography traces can be found in Figure 4E.  
 
Effect of intra-LC SL327 administration on 
nociception, anxiety and pERK1/2 expression in 
the ACC 
Having verified that SL327 (4.17 mM) can revert 
the pERK1/2 in the LC to control levels (Figure 
S1D, Supplementary material 1), we assessed the 
behavioral effects of this inhibitor. The significant 
decrease in the pain threshold observed in the 
ipsilateral paw of MA4W rats before 
microinjection of SL327 (Pre-drug: p<0.05 vs. 
contralateral paw: Figure 5A) was still evident 
after administering the inhibitor (SL327 vs 
contralateral paw, p<0.01: Figure 5A). Hence, 
pERK1/2 inhibition appeared to have no effect on 
the ipsilateral and contralateral paw withdrawal 
threshold in MA4W rats. However, when their 
anxiety-like behavior was assessed, microinjection 
of SL327 reverted the shorter times spent by 
MA4W rats in the open arms (p<0.05, MA4W 
saline vs. MA4W SL327: Figure 5B), indicating an 
anxiolytic effect. No changes were observed in 
control animals receiving SL327 and moreover, no 
significant changes were observed in the total 
distance travelled (Figure 5C).  
 
Subsequently, we explored the effect of intra-LC 
SL327 administration on pERK1/2 expression in 
the ACC (Figure 5D). A bilateral increase in the 
number of pERK1/2 immunoreactive cells was 
found in layers II-III of the ACC of MA4W 
animals compared to their respective controls, both 
at the rostral and caudal levels of the nucleus 
(p<0.05, MA4W vehicle vs. control vehicle: 
Figure 5D and 5F). Interestingly, microinjection of 
SL327 into the LC of MA4W rats successfully 
reverted the number of cells expressing pERK1/2 
in layers II-III of the ACC to control levels (Figure 
5D and 5F), while no significant changes were 
observed in the control animals that received 
SL327. The pERK1/2 immunoreactivity in neurons 
was confirmed by the co-localization with NeuN 
(Figure S1G). 
 
Discussion 
This study shows that pain-related anxiety in 
monoarthritic rats is accompanied by altered 
electrophysiological activity in the LC and an 
increase in pERK1/2 in both the LC and ACC. 
Furthermore, pharmacological blockade of 
pERK1/2 at the LC level reversed these alterations. 
Therefore, this study provides direct evidence of 
how alterations in the LC provoke ERK1/2 
activation in the ACC, leading to pain-related 
anxiety.  
In agreement with our previous data, we show that 
the pain threshold decreases significantly in MA 
rats in the first week of inflammation, although 
these animals do not display emotional changes 
(7). Hence, MA1W rats serve as a control for pain 
in the absence of emotional changes given that the 
anxiogenic phenotype was established after 4 
weeks of MA. Electrophysiological LC studies in 
the early (MA1W) and late phase (MA4W) of the 
monoarthritis showed a significant decrease in the 
firing rate in MA4W rats and a tendency towards 
weaker burst activity in MA1W and MA4W rats. 
In addition, significant increases in TH expression, 
the rate-limiting enzyme for the synthesis of 
noradrenaline, were only evident in MA4W rats, 
suggesting an increase in the demand for this 
neurotransmitter. This is consistent with the altered 
climbing behavior in the forced swimming test 
observed previously in MA4W rats (7), which 
could reflect a diminished availability of 
noradrenaline in the face of a stressful situations 
(29-30). Indeed, the electrophysiological 
recordings of the tonic activity of the contralateral 
LC neurons in monoarthritic conditions may 
reflect a deficiency in noradrenergic transmission.  
 
We also evaluated the sensory-evoked activity of 
LC neurons by applying several noxious 
stimulations to the paw. As expected and in 
agreement with previous studies, contralateral LC 
neurons are potently activated by noxious 
stimulation of the hind paw in control and MA 
animals. This is consistent with the activation of 
the contralateral spinoreticular tract (Figure 1A) 
(31). However, a greater evoked discharge rate 
was found in prolonged (MA4W) but not in earlier 
(MA1W) monoarthritis, suggesting an exaggerated 
response to nociceptive inputs in the late-phase. 
An analogous increase in the evoked response and 
in TH expression was observed in chronic 
neuropathic rats under social stress (16) and in a 
rat model of post-traumatic stress (32), suggesting 
that prolonged monoarthritis may produce similar 
changes in the LC as those observed in stressful 
conditions. Thus, the increased responsiveness in 
prolonged monoarthritis might enhance pain 
transmission upon noxious events and have 
repercussions on signaling to the corticolimbic 
areas. LC activation releases moderate amounts of 
noradrenaline to coordinate arousal, attention and 
vigilance (33-34). However, hyperactivation of LC 
circuits may lead to excessive noradrenaline 
release, an effect that could provoke anxiogenic-
like behavior (11).  
 
Interestingly, paw compression of the healthy paw 
(contralateral) evoked an LC response especially in 
long-term arthritic animals (MA4W). Hence, the 
plasticity associated with CP in cortical and sub-
cortical areas might fully or partially reflect a 
disturbance to the ascending sensory pathways. 
This is a very interesting because it agrees with the 
bilateral changes found when exploring TH, 
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pERK1/2 and the noradrenaline transporter in 
animal models of CP where the injury is produced 
on one side of the body (7, 15, 35). Nevertheless, 
as the contralateral paw was stimulated after 
several stimulations of the injured paw, this effect 
may be secondary to the stimulation of the injured 
paw. Nevertheless, we conclude that the ipsilateral 
LC is electrophysiologically activated in CP 
conditions, i.e. transmitting information to higher 
structures, when in healthy conditions it remains 
silent.  
 
Consistent with our previous western blot studies 
(7), here we also show an enhancement of 
pERK1/2 in MA4W by immunohistochemistry. 
We also explored the effect of the pharmacological 
blockade of ERK1/2 phosphorylation (SL327 
microinjections) on contralateral LC activity, 
which reverted the alterations to sensory-evoked 
parameters and post-compression activity after 
prolonged inflammation to control levels or even 
beyond. Importantly, this effect only occurred in 
pathological conditions and SL327 did not produce 
any significant change in the control rats. We also 
assessed whether SL327 administration to the 
contralateral LC had a repercussion on the 
manifestation of anxiety and pain in MA4W rats, 
evaluating these effects on mechanical 
hyperalgesia and anxiety-like behavior. 
Interestingly, while anxiety behavior reverted to 
control levels, the mechanical hyperalgesia 
remained unchanged. Furthermore, the 
corticotropin-releasing factor (CRF) is a widely 
known anxiety-related neuropeptide that modulates 
LC activity (36) and we have recently shown that 
the microinjection of a CRF antagonist into the 
contralateral LC reverted both the anxiogenic-like 
behavior and the pERK1/2 levels in the LC but it 
did not modify pain threshold (37). This suggests 
that enhanced ERK1/2 phosphorylation linked 
with CRF signaling in the contralateral LC at 
prolonged times of the monoarthritis disease is 
more related with the emergence of “affective-
behaviors”. Furthermore, these data demonstrate 
that pain-related anxiety is dissociated from the 
perception of the sensory component of pain. This 
result sheds light on the link between pain 
hypersensitivity and secondary mental effects. In 
this sense, it was recently shown that gabapentin 
administration produces analgesia but it does not 
rescue the impaired attention produced by 
neuropathic pain (38-39). Hence, pain-related 
affective and cognitive impairment does not appear 
to be due to the inherent stress provoked by the 
painful experience but rather, it may be attributed 
to a permanent alteration to a specific circuit. 
 
We also explored the effect of intra-LC SL327 
administration on pERK1/2 activation in the ACC. 
The ACC is one of the largest components of the 
limbic system and it is known to play an important 
role in the anxiety- and depressive-like behaviors 
resulting from pain. The ACC critically modulates 
pain-related anxiety in several animal models 
(visceral pain, 18; post-operative pain, 40; 
neuropathic pain, 13), and intraplantar formalin 
injection produces persistent and bilateral ERK 
activation in laminae II-III of the ACC that is 
required to induce pain-related negative effects 
(27). This is consistent with the bilateral increase 
of pERK1/2 observed in laminae II-III of the ACC 
of MA4W rats. The reduced pERK1/2 activation in 
the ACC provoked by intra-LC administration of 
SL327 is consistent with the reduction of anxiety-
like behavior in MA4W rats. Furthermore, this 
effect was found on both sides of lamina II-III of 
the cortex, suggesting that the effect of LC neurons 
on the ACC is not direct, as most of the LC 
projections to the ACC are ipsilateral (14). As 
such, circuits involving the thalamus (41) or the 
amygdala should be explored or at least cortico-
cortical projections from one hemisphere to the 
other. It should be noted that for the first time, our 
studies show that the LC-ACC pathway is critical 
for pain-induced anxiety. Furthermore, these 
results agree with the neuroanatomical overlapping 
hypothesis, which postulates that a brain region 
(LC) involved in the processing of both pain and 
affective information may be disrupted by CP and 
that this may lead to an alteration in the processing 
of the affective information, thereby triggering a 
secondary effect. 
In an animal model of chronic inflammatory pain 
(monoarthritis), our data shows that rats displayed 
a sharp decrease in their sensorial threshold within 
1 week of induction, although anxiety-like 
behavior did not appear until much later (4 weeks). 
This late phase temporally coincided with a 
decrease of the tonic LC activity but also, with an 
exacerbated evoked LC response to noxious 
stimulation of the inflamed paw. These changes 
were accompanied by enhanced TH and pERK1/2 
expression in the LC. Moreover, when ERK1/2 
activation was blocked pharmacologically in the 
contralateral LC, the exaggerated 
electrophysiological evoked LC response of MA 
rats was impaired. Importantly, ERK1/2 blockade 
did not modify pain hypersensitivity but rather, it 
reversed the anxiogenic-like behavior, as well as 
normalizing pERK1/2 expression in the ACC. 
Thus, we provide direct evidence of how a sub-
cortical structure decreases ERK1/2 activation in 
the ACC, leading to relief from pain-related 
anxiety. 
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Figure Legends 
 
Figure 1: A) Schematic representation of the classical anatomical pathways involved in pain transmission 
from the paw to the supraspinal centers, passing through the spinal cord, the LC and reaching the PFC 
(ascending pathway, contralateral) as well as the direct projection originated in the LC to the spinal cord 
(descending pathway, ipsilateral). B) Schematic representation of the experimental design. C) Mechanical 
hyperalgesia was confirmed by a decrease in the withdrawal threshold of the ipsilateral paw of MA1W 
and MA4W rats when compared to the ipsilateral paw of control rats: ***p<0.001 by two-way ANOVA 
followed by Bonferroni post-hoc test. D) The percentage time spent in the open arms of the elevated zero 
maze (EZM) decreased significantly in MA4W rats, indicating anxiety-like behavior: ***p<0.001 by one-
way ANOVA followed by Dunnett’s post-hoc test. E) The total distance travelled in the EZM was no 
different between the experimental groups. F) The spontaneous firing discharge of LC neurons decreased 
significantly in MA4W rats: **p<0.01 by one-way ANOVA followed by Dunnett’s post-hoc test. G) 
There was a tendency towards a decrease in the incidence of spontaneous burst activity in MA rats, 
although the number of spikes/burst was maintained (H). AU, Arbitrary units; CFA, complete Freund’s 
adjuvant; Contra, Contralateral; IHC, immunohistochemistry; Ipsi, Ipsilateral; LC, Locus Coeruleus; MA, 
monoarthritis; PFC, Prefrontal cortex; SC, spinal cord. 
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Figure 2: Sensory-evoked responses of LC neurons to sequential ipsilateral paw compression followed 
by contralateral paw compression in control, MA1W and MA4W rats. A) Schematic representation of the 
protocol used for electrophysiological recordings of the phasic activity of LC neurons. B) Representative 
oscillography trace of a typical LC neuron’s response to paw compression. C) The evoked response, was 
not significantly altered during the five paw compressions (S1-S5), although it was significantly higher in 
the S5 of MA4W animals that in the controls. D) The overall data showed that this response decreased 
significantly in MA1W rats and that it increased significantly in MA4W rats. E) After S3, S4 and S5, the 
duration of the response increased significantly in MA4W rats when compared with the controls. F) The 
overall data showed that the duration of the response increased significantly in MA4W rats. G-H) The 
period of suppression was no different between the experimental groups. I) The percentage change in the 
tonic activity relative to the basal values after each paw compression was significantly altered in MA4W 
rats when compared with the control group. J) These changes were also observed when analyzing the 
overall data for this parameter. In addition, the MA1W rats also revealed a significant increase when 
compared with the control group. The statistics represented in the graphs C, E, G and I are *p<0.05, 
**p<0.01 and ***p<0.001 by One-way ANOVA for each stimulation followed by Dunnett’s post-hoc 
test. The statistics represented in the graphs D, F, H and J are *p<0.05, **p<0.01 and ***p<0.001 by one-
way ANOVA followed by Dunnett’s post-hoc test. K-M) Oscillography traces representing the LC 
response in S1, S3 and S5 in control, MA1W and MA4W rats. N) The incidence of evoked burst activity 
increased in the MA animals. O) Oscillography traces representing the LC response to contralateral 
stimulation in control, MA1W and MA4W rats. C, contralateral stimulation; D, duration; ER, evoked 
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response; FR, firing rate; MA, monoarthritis; PC, paw compression; S1-S5, stimulation 1-5; SP, 
suppression period. 
 
 
Figure 3: The number of TH immunoreactivity cells (A-C) and the mean values for pERK1/2 (D-F) in 
the caudal, rostral and total portions of the LC, and representative photomicrographs showing TH (red, G) 
and pERK1/2 labeling (gray, H and I) in the LC: *p<0.05, **p<0.01 and ***p<0.001 by two-way 
ANOVA followed by Bonferroni post-hoc test. Scale bar=100µm. AU, Arbitrary units; C, contralateral; I, 
ipsilateral; MA, monoarthritis; pERK1/2, phosphorylated extracellular signal-regulated kinase 1/2; TH, 
tyrosine hydroxylase. 
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Figure 4: Effect of SL327 microinjection into the LC on electrophysiological parameters. A) The 
microinjection of SL327 significantly decreased the sensory-evoked response of MA4W rats. B) No 
significant effects were observed on the duration of the response. C) SL327 microinjection significantly 
increased the period of suppression. D) SL327 microinjection significantly decreased the change in the 
tonic activity relative to the basal values: +p<0.05, ++p<0.01 and +++p<0.001 by one-way ANOVA 
followed by Dunnett’s post-hoc test comparing S2-S5 vs. S1; *p<0.05, **p<0.01 and ***p<0.001 by 
repeated measures followed by Bonferroni post-hoc test comparing control vs. MA4W. E-H) 
Representative oscillography traces for S1 and S5 in control and MA4W rats. I-J) Representative 
examples of the firing of LC neurons upon intra-LC administration of SL327 to control and MA4W rats. 
FR, firing rate; MA, monoarthritis; S1-S5, stimulation 1-5. 
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Figure 5: Effect of SL327 microinjection into the LC on the behavior (A-C) and on pERK1/2 expression 
in the anterior cingulate cortex (ACC: D-F). A) SL327 microinjection into the LC had no effect on the 
paw withdrawal threshold but it did reverse the anxiety-like behavior in MA4W rats (B), without 
affecting locomotor activity (C). D) There were significantly fewer cells expressing pERK1/2 in the 
rostral and caudal ACC of MA4W rats receiving SL327 when comparing with MA4W rats that received 
the vehicle alone: *p<0.05 by two-way ANOVA followed by Bonferroni post-hoc test. E) Representative 
coronal rat brain sections showing the localization of the rostral and caudal ACC. F) Representative 
photomicrographs showing pERK1/2 labeling in the layers II-III of the ACC of control and MA4W rats 
that received an intra-LC microinjection of vehicle or SL327. Scale bar = 100µm. ACC, anterior cingulate 
cortex; C, contralateral; Cg1, cingulated cortex area 1; Cg2, cingulated cortex area 2; IL, infralimbic 
cortex; I, ipsilateral; MA, monoarthritis; pERK1/2, phosphorylated extracellular signal-regulated kinase 
1/2; PrL, prelimbic cortex; S1-S5, stimulation 1-5. 
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Electrophysiological recordings of the LC neurons 
As the ascending pain pathway is mainly contralateral (1), single-unit extracellular recordings of LC 
neurons from the brain hemisphere contralateral to the injected articulation were obtained. Anaesthesia 
was induced by a single intraperitoneal injection of chloral hydrate (400 mg/kg) and maintained using a 
perfusion pump (60 mg/kg/h) (2). Rats were placed in a stereotaxic frame (David Kopf, Tujunga, CA, 
USA), with the nose down to obtain a 15° angle (Figure S1A) and body temperature was maintained at 
37°C with a heated pad. The recording electrode was lowered into the LC contralateral to the inflamed 
hind paw (anteroposterior: -3.7 mm, mediolateral: -1.1 mm relative to lambda; 5.0-7.0 mm from brain 
surface after dura removal; (3)). Well-established criteria described elsewhere (4) were used to identify 
LC neurons: long-duration action potential (>2 ms), spontaneous firing at a regular rhythm, a slow firing 
rate between 0.5 and 5 Hz, and characteristic spikes with a long-lasting positive-negative waveform 
(Figure S1C). The signal was amplified with a high-input impedance amplifier and discriminated spikes 
were fed into a PC and processed using CED Micro 1401 and Spike2 computer software (Cambridge 
Electronic Design, Cambridge, UK).  
 
When a single LC unit was isolated (Figure 2A), the spontaneous basal discharge (baseline) was recorded 
for, at least, 2 min and the following parameters were calculated: firing rate (Hz), the incidence of burst 
activity, and the number of spikes per burst. A LC cell was considered to exhibit burst firing when it 
displayed at least two spikes with an initial interspike interval below 80 ms and with subsequent 
interspike intervals higher or equal to 160 ms (5). The sensory-evoked response of LC neurons was 
studied after stable basal spontaneous firing by manually applying mechanical pressure to the ipsilateral 
or contralateral paw (paw compression: PC: Figure 2B) for 1s using a surgical forceps. This sensory-
evoked discharge was followed by a suppression period (SP) (6-9). This type of PC does show neither 
sensitization nor habituation with repeated trials in naive animals (10). For each recorded neuron, PC was 
applied 5 times with 100s of interval (Figure 1B). In order to prevent paw damage, no more than 4 
neurons were studied per rat. The sensory evoked-response, the duration (D) of the response and the SP 
were quantified after PC. The post-compression tonic activity was measured in an interval of 70 seconds, 
thirty seconds after each PC. Changes in sensory-evoked discharge and post-compression discharge were 
expressed as a percentage of the baseline for each neuron and averaged across recordings. At the end of 
the experiment, a Pontamina Sky Blue mark was deposited by applying a 5 μA cathodic current through 
the recording electrode and subsequently the site of recording was histologically verified (Figure S1B). 
Only measurements from cells within the LC area were included in this study.  
 
A calibrated pipette glued adjacent to a recording micropipette (11) with a solution containing 4.17 mM 
of SL327, an ERK1/2 phosphorylation inhibitor (S4069; Sigma-Aldrich, St Louis, MO), was used to 
explore the effect of pERK1/2 inhibition on electrophysiological LC activity in another set of experiments 
(Figure 1A – Group 3). This compound was dissolved in a vehicle solution of 50% dimethyl sulfoxide 
(DMSO) and 50% of Dulbecco’s buffered saline containing: NaCl 136.9 mM, KCl 2.7mM, NaH2PO4 
8.1mM, KH2PO4 1.5mM, MgCl2 0.5mM, and CaCl2 0.9 (pH = 7.40). Pulses of pressure (50-150ms) 
were applied with a Picospritzer™ II (General Valve Corporation, Fairfield, NJ, USA) to inject the 
compound. The injected volume was measured by monitoring the meniscus movement in the pipette 
which was previously calibrated so that each pulse corresponded to the injection of 2 nl of solution. The 
vehicle solution did not alter the LC electrical activity in control or MA rats.  
 
Intra-LC drug administration 
Five days before completing the 4 weeks of MA, rats were anaesthetized with intraperitoneal injection of 
ketamine (100mg/kg) and xylazine (20mg/kg), and placed in a stereotaxic instrument with the head tilted 
at a 15º angle to the horizontal plane (nose down). A guide cannula (22 gauge, 15mm length) was 
implanted in the contralateral (right side) LC at the following coordinates relative to lambda: 
anteroposterior=-3.7 mm, mediolateral= -1.1 mm, and dorsoventral -6.2 mm below the brain surface (3). 
After positioning, the guide cannula was fixed to the skull and anchored to stainless screws with 
polyacrylic cement. A stainless steel wire was inserted into the guide cannula to prevent occlusion. 
Following at least five days of postsurgical recovery, animals were gently immobilized with a cloth and 
the steel wire was cut. Microinjection was performed by lowering a removable injector with 1mm longer 
than the guide tip connected to a 10μL Hamilton syringe (7). Animals received 0.7 µg of SL327 dissolved 
in DMSO to obtain a 4.17mM solution. The injection volume was 0.5µL. DMSO was used as a vehicle, 
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since no behavioral changes were observed when compared to rats receiving saline. The microinjection 
lasted for 30 seconds and the injector remained inserted for more 60 seconds to allow drug spreading. The 
behavioral tests (paw pressure and EZM tests) were performed within 10-25 minutes after drug 
administration. Random animals in all groups were selected for histological confirmation of the 
localization of the implanted cannula (Figure S1E). 
 
Immunohistochemistry 
Control, MA1W and MA4W rats were anaesthetized with 8% chloral hydrate (400 mg/kg) and were 
immediately perfused through the ascending aorta with 250 mL of oxygenated Tyrode’s solution followed 
by 750 mL of paraformaldehyde 4% in phosphate buffer (PB), 0.1M pH 7.2. Brains were removed and 
processed for free-floating immunohistochemistry. Sections of 30µm of thickness containing the LC 
region were immunorreacted against TH (raised in sheep, 1:2000; Abcam, UK) or against the 
phosphorylated isoforms of ERK1/2 (raised in rabbit, pERK1/2; 1:500; Acris antibodies, Germany), as 
described elsewhere (12). Immunodetection was achieved upon incubation with the correspondent 
secondary antibody and, in the case of the pERK1/2 protein, an ABC kit followed by incubation in a 3,3'-
diaminobenzidine solution was used. Sections were mounted on gelatin-coated glass slides, and cover-
slipped with a PBS-Glycerol based medium. In parallel, sections containing the ACC region were 
similarly immunorreacted against the phosphorylated isoforms of pERK1/2 and revealed as mentioned 
above. Additionally, several sections containing the ACC region were double immunorreacted against 
pERK1/2 and NeuN (Neuronal nuclear antigen, raised in mouse; 1:500; Millipore, Chemicon, CA, USA). 
This double immunoreaction was revealed using the correspondent fluorescent secondary antibodies: 
alexa® 488 (green) for pERK1/2, alexa® 568 (red) for NeuN. The histological delimitation of the LC and 
the ACC areas was made according to The Rat Brain Atlas of Paxinos and Watson (3). 
 
Positive cells to TH were quantified by counting the number of cellular bodies labelled in all sections 
containing each region analyzed (either the caudal, the rostral or the total), per animal, by using an 
Olympus BX60 microscope coupled to a digital camera (Olympus DP71), and an image software (Cell F 
2.4). The average number of immunoreactive (IR)-cells/section was used for statistical purposes. Similar 
procedures were performed for quantification of the number of positive cells to pERK1/2 in the ACC, 
which was based on what was described elsewhere (13). The expression of pERK1/2 in the LC was 
quantified by densitometry as described before (12). 
 
SL327 dosage adjustment 
A preliminary study was performed to verify the dosage of SL327 required for both electrophysiological 
and behavioral procedures as the volumes necessary in each technique are quite different. Previous 
reports where it was administered, by intracerebroventricular injection, 2ul of a solution of 1nmol/ul of 
SL327, which corresponds to 0.67µg of SL327, were used as reference for dosage adjustment (14). Thus, 
we studied if a similar amount was able to reduce the significant increase of ERK1/2 activation observed 
in the LC of MA4W rats. For that propose, we microinjected in the LC, a DMSO-based solution 
containing 0.7ug or 1.4ug of SL327 and the animals were sacrificed for western blot procedures 15 
minutes after microinjection, as described in the following section. The results obtained are depicted in 
Figure S1 and allowed the establishment of the dose of SL327 to be used in the behavioral assessment. 
However, in the electrophysiological recordings, where a single neuron is recorded at each time, an 
identical formulation was used but the volumes administered at each time were adjusted. 
 
Western blotting 
Fresh tissue samples from the LC were collected from two sets of rats. One set was used for TH 
quantification and included control, MA1W and MA4W rats divided by ipsi- and contralateral sides. The 
other set included control and MA4W rats receiving DMSO, 0.7µg or 1.4µg of SL327. All the samples 
were processed for Western blotting and after the tissue was lysed, an aliquot (50 µg) was separated on a 
10% polyacrylamide gel and then transferred to a polyvinylidene difluoride membrane (PVDF; BioRad, 
Hercules, CA). After washing in Tris-buffered saline containing 0.1% Tween-20, the blots were blocked 
with 5% Bovine Serum Albumin (Sigma, St Louis, MO) in TBST. The blots containing the samples for 
TH quantification were incubated overnight at 4ºC with rabbit anti-TH (1:5,000; Acris antibodies, 
Herford, Germany) and mouse anti-tubulin (1:250,000; Sigma-Aldrich, St Louis, MO). The blots 
containing the samples for pERK1/2 quantification were incubated overnight at 4ºC with rabbit anti-
phospho-ERK1/2 (1:5,000; Acris Antibodies, Herford, Germany), and mouse-anti ERK1/2 (1:2,000; Cell 
Signaling Technology, Danvers, MA) antibodies diluted in 5% Bovine Serum Albumin-TBST. After 
thorough washing, these primary antibodies were detected by incubating for 1 hour at room temperature 
with IRDye 800CW goat anti-rabbit (green) or IRDye 680LT goat anti-mouse (red) secondary antibodies 
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(1:10,000; LI-COR®, Lincoln, NE). After 3 final washes with TBST, the antibody binding was detected 
using a LI-COR Odyssey® two-channel quantitative fluorescence imaging system (LI-COR®, Lincoln, 
NE). Digital images of Western-blots were analyzed by densitometry using the ImageJ free access 
software. The data were expressed as pERK1/2 expression levels relative to those of total ERK1/2. These 
values were combined and averaged.  
 
Antibody specificity control 
In this study, we did not perform any antibody specificity control as the antibodies used are well-known 
for their specificity and widely used in previous studies (7, 12, 15-18).  
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Figure S1 – Supplementary material. A) Schematic representation of the recording electrode’s position. 
B) Pontamine spot (arrow) certifying that the recording electrode was well positioned in the LC. C) LC 
typical spike shape. D) Expression of pERK1/2 (42-44 kDa) in the LC in response to MA or SL327 (0.7 
ug or 1.4 ug) and corresponding images of the western blots for each experimental group (below the 
graph). These levels were normalized to the corresponding total ERK1/2 values as no significant changes 
in tubulin levels were observed: **p<0.01 and ***p<0.001 by one-way ANOVA followed by Dunnett’s 
post-hoc test. E) Histological representation of the unilateral injection sites and cannula placement within 
the LC. F) TH expression evaluated in western blots increased significantly in MA4W rats: p<0.05 by 
two-way ANOVA followed by Bonferroni post-hoc test. Below the graphs are the corresponding images 
of the western blots for each experimental group. G) Photomicrographs showing the co-localization of 
pERK1/2 immunolabeling with NeuN positive neurons in the ACC. The lower row shows higher 
magnification images. Scale bar = 50µm. C, contralateral; I, ipsilateral; LC. Locus Coeruleus; MA, 
monoarthritis; NeuN, Neuronal nuclear antigen; pERK1/2, phosphorylated extracellular signal-regulated 
kinase 1/2; tERK1/2, total extracellular signal-regulated kinase 1/2; TH, tyrosine hydroxylase. 
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Table S1 - Effect of five sequential compressions to the ipsilateral paw followed by one compression to 
the contralateral paw in the phasic activity parameters 
  
S1 S2 S3 S4 S5 C 
I 
(%
) 
Control 100.00 (10/10) 100.00 (10/10) 100.00 (10/10) 100.00 (10/10) 100.00 (10/10) 0.00 (0/7) 
MA1W 100.00 (8/8) 100.00 (8/8) 100.00 (8/8) 100.00 (8/8) 100.00 (8/8) 46.20 (6/13) 
MA4W 100.00 (11/11) 100.00 (11/11) 100.00 (11/11) 100.00 (11/11) 100.00 11/11) 66.70 (6/9)* 
E
R
 (
H
z)
 
Control 4.50±0.54 4.60±0.54 4.50±0.45 4.60±0.60 4.10±0.57 - 
MA1W 3.25±0.53 3.50±0.60 3.38±0.68 3.50±0.82 3.38±0.73 2.17±0.17 
MA4W 6.36±0.89 6.46±0.84 6.46±0.84 6.82±0.90 7.00±0.84 2.83±0.54 
D
u
ra
ti
o
n
 (
s)
 Control 0.57±0.09 0.51±0.05 0.46±0.06 0.46±0.08 0.33±0.07 - 
MA1W 0.33±0.08 0.34±0.06 0.26±0.04 0.35±0.07 0.30±0.07 0.15±0.02 
MA4W 0.88±0.17 0.88±0.20 0.95±0.14 0.95±0.17 0.88±0.13 0.22±0.07 
S
P
 (
s)
 
Control 1.56±0.19 1.49±0.17 1.68±0.19 1.69±0.19 1.62±0.18 - 
MA1W 1.64±0.15 1.65±0.14 1.69±0.20 1.88±0.14 1.57±0.16 1.73±0.13 
MA4W 1.60±0.16 1.46±0.17 1.51±0.24 1.48±0.24 1.39±0.28 1.64±0.30 
%
 C
h
an
g
e 
 Control -6.70+2.22 -9.17+3.23 -13.73+3.10 -15.92+2.93 -15.36+4.44 - 
MA1W 2.04+2.56 1.36+2.36 -0.13+2.58 -0.09+3.73 -2.08+3.12 - 
MA4W 17.04±8.10 17.10±8.67 19.88±7.94 -2.08±3.12 13.29±6.94 - 
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Table S2 - Effect of SL327 on the ipsilateral paw compression response 
  S1 (Basal) S2 (8.35pmol) S3 (16.69pmol) S4 (25.04pmol) S5 (33.39pmol) 
I 
(%
) Control 100.00 (8/8) 100.00 (8/8) 100.00 (8/8) 100.00 (8/8) 100.00 (8/8) 
MA4W 100.00 (6/6) 100.00 (6/6) 100.00 (6/6) 100.00 (6/6) 100.00 (6/6) 
E
R
 (
H
z)
 
Control 5.50±0.60 5.63±0.82 5.63±0.53 6.00±0.68 5.75±0.84 
MA4W 4.33±0.49 3.83±0.54 3.67±0.62 3.33±0.56 2.67±0.33 
D
u
ra
ti
o
n
 (
s)
 
Control 0.51±0.05 0.48±0.06 0.54±0.08 0.57±0.11 0.55±0.08 
MA4W 0.61±0.08 0.51±0.11 0.51±0.04 0.42±0.09 0.48±0.11 
S
P
 (
s)
 Control 1.35±0.12 1.20±0.09 1.25±0.15 1.26±0.08 1.34±0.12 
MA4W 1.40±0.21 1.62±0.20 1.58±0.18 2.33±0.50 3.23±0.94 
%
 C
h
an
g
e Control -5.63±4.39 -6.03±6.17 0.63±8.20 -6.55±8.26 -15.56±9.18 
MA4W 13.92±6.97 -7.43±6.73 -34.44±8.9 -42.14±12.62 -52.10±12.95 
  
Table S3- Statistics of the analysis of variance (ANOVA). 
  Without SL327  With intra-LC SL327 
 S Factor Factor Interaction S (dose) Factor Factor Interaction 
Behavior         
Paw Withdrawal (g)  Fa(2,30)=15.21*** Fp(2,30)=41.22*** Fi(2,30)=6.67**  Ft(1,8)=0.78 Fp(1,8)=17.51** Fi(1,8)=0.32 
% Time in open arms  Fa(2,16)=16.25***    Fa(1,20)=2.70 Fd(1,20)=1.39 Fi(1,20)=5.25* 
Distance Travelled (AUx104)  Fa(2,16)=1.61    Fa(1,20)=0.39 Fd(1,20)=0.28 Fi(1,20)=0.76 
Electrophysiology         
   Tonic activity         
Firing rate (Hz)  Fa(2,127)=5.76**       
Spikes/burst  Fa(2,60)=0.49       
   Phasic activity  One-Way       
Evoked response (Hz) 
S1 Fa(2,26)=4.74*   S1 (Basal) 
Fa(1,48)=6.44* Ft(4,48)=1.31 Fi(4,48)=2.74* 
S2 Fa(2,26)=4.53*   S2 (8.35) 
S3 Fa(2,26)=5.02*   S3 (16.69) 
S4 Fa(2,26)=4.50*   S4 (25.04) 
S5 Fa(2,26)=6.96**   S5 (33.39) 
T Fa(2,142)=30.66***       
RM Fa(2,104) =5.83** Fs(4,104)=0.33 Fi(8,104)=0.63     
Duration (s) 
S1 Fa(2,26)=4.63*   S1 (Basal) 
Fa(1,48)=0.05 Ft(4,48)=0.48 Fi(4,48)=1.39 
S2 Fa(2,26)=3.90*   S2 (8.35) 
S3 Fa(2,26)=11.84***   S3 (16.69) 
S4 Fa(2,26)=6.65**   S4 (25.04) 
S5 Fa(2,26)=11.19***   S5 (33.39) 
T Fa(2,142)=35.45***       
RM Fa(2,104) =11.99*** Fs(4,104)=0.50 Fi(8,104)=0.42     
Suppression period (s) 
S1 Fa(2,26)=0.06   S1 (Basal) 
Fa(1,48)=4.90* Ft(4,48)=5.92*** Fi(4,48)=5.28** 
S2 Fa(2,26)=0.37   S2 (8.35) 
S3 Fa(2,26)=0.22   S3 (16.69) 
S4 Fa(2,26)=0.88   S4 (25.04) 
S5 Fa(2,26)=0.30   S5 (33.39) 
T Fa(2,142)=1.32       
RM Fa(2,104) =0.61 Fs(4,104)=0.43 Fi(8,104)=0.23     
% change according to basal firing rate 
S1 Fa(2,26)=4.78*   S1 (Basal) 
Fa(1,80)=3.15 Ft(4,80)=12.21*** Fi(4,80)=8.96*** S2 Fa(2,26)=4.74*   S2 (8.35) 
S3 Fa(2,26)=8.72**   S3 (16.69) 
S4 Fa(2,26)=12.63***   S4 (25.04) 
 The F values with their associated degrees of freedom were expressed as Fa (df of arthritis, residual), Fs (df of stimulation, residual), Fd (df of drug SL327, residual), Fp (df of 
paw, residual), Ft (df of time, residual), or Fi (df of interaction, residual). Significance was represented as *p<0.05, **p<0.01 and ***p<0.001 
 
S5 Fa(2,26)=6.75**   S5 (33.39) 
T Fa(2,142)=36.05***       
RM Fa(2,104) =8.39** Fs(4,104)=3.51** Fi(8,104)=1.09     
  Factor Factor Interaction  Factor Factor Interaction 
Immunohistochemistry         
   TH in LC         
Caudal  Fa(2,34)=9.21*** Fp(1,34)=0.46 Fi(2,34)=0.09     
Rostral  Fa(2,34)=1.33 Fp(1,34)=0.36 Fi(2,34)=0.47     
Total  Fa(2,34)=8.12** Fp(1,34)=0.25 Fi(2,34)=0.02     
   pERK1/2 in LC         
Caudal  Fa(2,32)=25.58*** Fp(1,32)=0.04 Fi(2,32)=1.28     
Rostral  Fa(2,32)=18.14*** Fp(1,32)=0.17 Fi(2,32)=0.03     
Total  Fa(2,32)=27.29*** Fp(1,32)=0.00 Fi(2,32)=0.76     
   pERK1/2 in ACC         
Caudal         
     Ipsilateral Fa(1,12)=3.56 Fd(1,12)=0.33 Fi(1,12)=4.75* 
     Contralateral Fa(1,12)=4.36 Fd(1,12)=0.41 Fi(1,12)=6.39* 
Rostral         
     Ipsilateral  Fa(1,13)=5.46* Fd(1,13)=2.79 Fi(1,13)=4.54  
     Contralateral Fa(1,13)=5.08* Fd(1,13)=4.63 Fi(1,13)=4.90* 
Regulation of the activity of the Locus coeruleus-noradrenergic system in 
chronic pain 
Porto, 
2015 
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ABSTRACT  
Background: The corticotropin-releasing factor (CRF) is a stress-related neuropeptide that modulates 
Locus Coeruleus (LC) activity. As LC has been involved in pain and stress-related patologies, we tested 
whether the pain-induced anxiety is a result of the CRF released in the LC.  
Methods: Complete Freund's adjuvant (CFA)-induced monoarthritis (MA) was used as inflammatory 
chronic pain model. α-helical CRF receptor antagonist was microinjected into the contralateral LC of four 
weeks MA animals. The nociceptive and anxiety-like behaviors, as well as phosphorylated extracellular 
signal-regulated kinases 1/2 (pERK1/2) and CRF receptors expression were quantified in the 
Paraventricular Nucleus (PVN) and LC. 
Results: MA rats manifested anxiety and increased pERK1/2 levels in the LC and PVN, although the 
expression of CRF receptors was unaltered. α-helical CRF antagonist administration reversed both the 
anxiogenic-like behavior and the pERK1/2 levels in the LC.  
Conclusions: Pain-induced anxiety is mediated by CRF neurotransmission in the LC through ERK1/2 
signaling cascade.  
 
Keywords: Anxiety; Corticotropin-releasing factor; Locus Coeruleus; Pain; pERK1/2. 
 
INTRODUCTION  
Corticotropin-releasing factor (CRF) is a 
neuropeptide released from neurons in the 
paraventricular nucleus (PVN) of the 
hypothalamus that activates stress-related 
hypophysial structures (Bale and Vale, 2004). 
Extrahypophysial CRF operates as a 
neurotransmitter in several brain areas, influencing 
different actions related to the stress response 
(Valentino and Wehby, 1988). Also, it may 
exacerbate many chronic diseases, in particular, 
those involving severe pain like arthritis (Zautra et 
al., 2007), a prevalent inflammatory condition. 
Equally, the emergence of anxiety due to persistent 
pain is a negative factor commonly reported by 
arthritic patients (Gyurcsik et al., 2014), 
representing in itself a stressful situation (Hummel 
et al., 2010) and inducing similar effects to other 
stressors (Vierck et al., 2010). Indeed, it is 
estimated that up to 20% of patients with arthritis 
will develop depression and/or anxiety (Covic et 
al., 2012). Although inflammatory pain is a 
stressor that may modulate the hypothalamic-
pituitary-adrenal (HPA) axis (Bomholt et al., 
2004), the neurobiological features and behavioral 
repercussion of such association remain poorly 
understood.  
CRF acts at different sites in important regulatory 
pain structures, directly implicating this molecule 
in pain modulation (Lariviere and Melzack, 2000). 
In particular, the Locus Coeruleus (LC), the major 
noradrenaline source in the brain, is one important 
target for CRF neurotransmission (Valentino and 
Van Bockstaele, 2008). Besides its important role 
in modulating ascending and descending pain 
pathways, the LC also represents a convergent 
nucleus that is correlated with adaptive responses 
to stress (Valentino and Van Bockstaele, 2008). 
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Thus, the activity of CRF in the LC could 
influence chronic inflammatory pain and it would 
not be unreasonable to hypothesize that the onset 
of emotional changes produced by pain might be 
the result of stress-induced CRF release. 
The extracellular signal-regulated kinases 1/2 
(ERK1/2) cascade is a strong candidate to mediate 
the effects of CRF in pain and it is known to 
participate in CRF receptor signaling in neuronal 
cells (Hauger et al., 2006). In addition, CRF 
administration into the LC region promotes c-Fos 
and ERK1/2 activation in the prefrontal cortex 
(Snyder et al., 2012). Accordingly, we 
demonstrated that animals suffering chronic 
inflammation also display an anxio-depressive 
phenotype, with an enhancement of ERK1/2 
activation in the prefrontal cortex (Borges et al., 
2014).  
To evaluate whether CRF neurotransmission in the 
LC triggers the development of anxiety in chronic 
inflammation (e.g., a model of rheumatoid 
arthritis), an antagonist of the CRF receptors was 
microinjected into the LC and the nociceptive and 
anxiety behavior, as well as the activation of 
ERK1/2 in the LC, were evaluated. 
METHODS 
Animals 
Harlan Sprague-Dawley male rats (250-300g) were 
provided by the Experimental Unit of the 
University of Cádiz (registration No. 
ES110120000210). Animals were housed 2-4 per 
cage with ad libitum access to food and water, and 
kept under controlled conditions of lighting (12h 
light/dark cycle), temperature (22 ºC) and humidity 
(45-60%). The protocols followed the European 
Communities Council Directive of 22 September 
2010 (2010/63/EC), Spanish Law (RD 1201/2005) 
and the ethical guidelines for investigation of 
experimental pain in animals (Zimmermann, 
1983), and they were reviewed and approved by 
the Institutional Ethical Committee for animal care 
and use.  
 
Monoarthritis model of inflammatory pain 
Monoarthritis (MA) was induced as described 
previously (Butler et al., 1992), injecting the left 
tibiotarsal joint of rats anaesthetized with 
isoflurane (4% to induce and 2% to maintain: 
Abbott, Spain) with 50 µL of complete Freund's 
adjuvant (CFA) solution, containing 30 mg of 
desiccated Mycobacterium butyricum (Difco 
Laboratories, USA), paraffin oil (3 mL), saline (2 
mL) and Tween
®
80 (500 µL). Animals that 
developed polyarthritis were excluded. The control 
rats were injected with the vehicle solution 
(paraffin oil, saline and Tween
®
80). The 
experimental design is represented in 
Supplementary Fig. S1a. 
Surgery and intra-LC drug administration 
Animals were anesthetized with an intraperitoneal 
injection of ketamine (100 mg/kg) and xylazine 
(20 mg/kg), and placed in a stereotaxic apparatus 
with the head tilted at an angle of 15ᵒ to the 
horizontal plane. A guide cannula (22 gauge, 15 
mm length) was implanted into the contralateral 
LC (lambda: AP=-3.2 mm, ML -1.1 mm, and DV -
6.2 mm; Fig. 1a and Supplementary Fig. S1b) and 
was fixed with skull screws and dental cement. A 
stainless steel wire was inserted into the guide 
cannula to prevent occlusion. Five days after 
recovery, animals were immobilized and the steel 
wire was cut. Microinjection was performed by 
inserting an injector cannula (30 gauge) that was 1 
mm longer than the guide cannula (i.e.: 16 mm). 
Animals received 28 ng or 34 ng of α-helical 
CRF(9-41) (αCRF) dissolved in sterile water (0.5 
µL; Sigma Aldrich, Ref. C246), which blocks the 
CRF I and II receptors, inhibiting the endogenous 
CRF activity. Sterile water was used as a vehicle. 
Behavioral tests or sacrifice for western blot 
procedures were performed 10-25 minutes after 
drug/vehicle administration (see Supplementary 
Material and Fig. S1a). As no differences between 
doses were observed in terms of pERK1/2 
expression, the behavioral effects were analyzed in 
animals receiving the 28 ng αCRF. Behavior was 
assessed in groups of 6 animals and random 
animals were selected for histological verification 
of the cannula implantation.  
 
Health parameters, nociceptive and anxiety-like 
behavior  
The body weight (g) and rectal temperature (°C) 
were recorded weekly and nociceptive mechanical 
allodynia (automated von Frey test) and 
hyperalgesia (paw-pinch test) were assessed as 
described in the Supplementary Material. Anxiety-
like behavior was evaluated in the elevated zero 
maze (EZM) test, which consisted in a black 
circular platform divided into four quadrants, with 
two opposing open quadrants with 1 cm high clear 
curbs to prevent falls and two opposing closed 
quadrants with 27 cm high black walls. A 5 min 
trial under the same lighting conditions began with 
the animal placed in the centre of a closed 
quadrant. The SMART software was used to 
analyze the time spent in the open arms and the 
total distance travelled by each rat. Increases in the 
time spent in the closed areas were correlated with 
anxiety-like behavior (Borges et al., 2014).  
 
Immunohistochemistry 
Another set of control and MA rats (4 weeks) was 
used for quantification of the expression of 
pERK1/2 in the PVN and CRFI/II receptors in the 
LC (Supplementary Material). 
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Statistical analysis 
All data is represented as mean ± SEM and were 
analyzed using STATISTICA 10.0 or GraphPad 
Prism 5 software, using either an unpaired Student 
t test (two-tailed) or one-way, two-way or repeated 
measures analysis of variance (ANOVA), followed 
by the appropriate post-hoc tests. The level of 
significance was considered as p<0.05. 
 
RESULTS 
Effect of MA on health parameters and nociceptive 
responses 
The behavior of control animals was normal, with 
no signs of an inflammatory reaction. CFA 
injection produced a stable MA, with the signs of 
inflammation restricted to the injected joint and 
evident a few hours after induction, persisting into 
the fourth week. The weight gain of MA rats was 
significantly lower than that of the control animals 
1 and 3 weeks after CFA injection (repeated 
measures, Bonferroni; p<0.05: Fig. 1b), while their 
body temperature remained normal during the 
experiment (Fig. 1c). Regarding the pain threshold, 
a significant decrease in the withdrawal threshold 
of the ipsilateral paw was evident when compared 
with the contralateral paw, indicative of 
mechanical hyperalgesia (repeated measures, 
Bonferroni test; p<0.05 for week 1, 2 and 4, 
p<0.01 for week 3: Fig. 1d). Additionally, there 
was a significant decrease in the paw withdrawal 
threshold to von Frey stimulation by the 
ipsilateral-inflamed paw of MA rats when 
compared with the contralateral paw, indicative of 
mechanical allodynia (repeated measures, 
Bonferroni test; p<0.001: Fig. 1e). 
 
Effect of intra-LC microinjection of an α-helical 
CRF receptor antagonist on the pERK1/2 levels in 
the LC 
The administration of the α-helical CRF receptor 
antagonist in the LC normalized the pERK1/2 
values in MA4W rats at both doses of the 
compound used (one-way ANOVA, Dunnett’s 
test;; p>0.05 MA4W 28ng and MA4W 34ng vs 
control; Fig. 1f), suggesting that CRF acts through 
the ERK1/2 signaling cascade in LC neurons. 
 
Effect of intra-LC microinjection of an α-helical 
receptor antagonist on MA-induced pain 
In the paw withdrawal threshold, a significant 
increase in pain sensitivity was observed when the 
ipsilateral paw was compared with the 
contralateral paw in the MA4W rats before (pre-
drug, two-way ANOVA, Bonferroni test; p<0.001) 
and after microinjection of the αCRF into the LC 
(two-way ANOVA, Bonferroni test; p<0.01: Fig. 
1g). Thus, the intra-LC administration of the α-
helical CRF receptor antagonist (28 ng) had no 
significant effect on the paw withdrawal threshold 
of MA4W rats (p>0.05; Fig. 1g). In the force 
threshold, microinjection of the αCRF receptor 
antagonist into the LC had no effect on the 
ipsilateral sensitivity to innocuous stimulation. 
Indeed, the significant decrease in the force 
supported by the ipsilateral paw of MA4W rats 
when compared to the contralateral paw was 
present before and after administration of the drug 
(two-way ANOVA, Bonferroni test; p<0.001: Fig. 
1h). 
 
Effect of intra-LC microinjection of an α-helical 
CRF receptor antagonist on MA-induced anxiety. 
In the EZM, MA4W rats that received the vehicle 
alone (MA4W-vehicle) spent significantly less 
time in the open arms than control animals, 
indicative of anxiety-like behavior (two-way 
ANOVA, Bonferroni test; p<0.05: Fig. 1i). By 
contrast, those animals that received an intra-LC 
microinjection of the αCRF receptor antagonist 
(MA4W-αCRF) spent significantly longer time in 
the open arms when compared to the MA4W-
vehicle animals (two-way ANOVA, Bonferroni 
test; p<0.05: Fig. 1i). No effect of microinjecting 
the αCRF receptor antagonist into the LC was 
observed in the control rats. Moreover, no 
differences were observed in the total distance 
travelled in the EZM (Fig. 1j), ruling out any 
influence of locomotor impairment on the 
experimental results. Regarding the number of 
entries into the open arms, the MA4W-vehicle rats 
appeared to enter these arms less frequently than 
the control animals that received the vehicle alone, 
although this difference was not significant. No 
such difference was observed in the MA4W-αCRF 
rats (Fig. 1k).  
 
Expression of CRF receptors in the LC and 
pERK1/2 in the PVN 
When the expression of the CRF I and II receptors 
was studied in the LC, no differences were 
observed between the control and MA4W rats 
(Fig. 2a, b and c). Most of the neurons expressing 
CRFI/II receptors also expressed TH, indicating 
their noradrenergic nature and demonstrating that 
the CRFI/II receptors were expressed by neurons 
in the LC area (Fig. 2d).  
The expression of pERK1/2 was also studied in the 
PVN of the hypothalamus in order to determine the 
activity of this structure as a readout of CRF 
stimulation in the central nervous system. 
Interestingly, an increase in pERK1/2 was 
observed in MA4W rats compared with control 
rats (unpaired Student’s t-test; p<0.001: Fig. 2e-g).  
 
DISCUSSION 
This study shows that the action of CRF on LC 
neurons is involved in the development of anxiety-
like symptoms associated with prolonged 
inflammatory pain. As expected, four weeks after 
CFA injection, rats displayed signs of pain and 
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anxiety, consistent with previous reports (Borges 
et al., 2014). We also observed a significant 
increase in ERK1/2 phosphorylation in the LC, in 
accordance with previous data (Borges et al., 
2014), and this increased ERK1/2 activation in the 
LC seems to be related with the development of 
anxiety-like behaviors in chronic inflammatory 
conditions. This raises the question as to what 
produces this increase in ERK1/2 activation in the 
LC when painful conditions develop. CRF is a 
molecule linked with the endocrine and behavioral 
response to stress (Bale and Vale, 2004), and the 
role of CRF in different pain conditions has been 
studied (Lariviere and Melzack, 2000), although 
not its effects after prolonged times of 
inflammation (e.g., 4 weeks). Here, we studied the 
PVN nucleus, a CRF-producing structure, and we 
found that pERK1/2 levels increase in MA4W rats 
when compared with control rats, suggesting that 
PVN hyperactivation occurs in association with 
chronic inflammatory pain. As the PVN and LC 
have reciprocal excitatory connections (Perez et 
al., 2006), we hypothesized that this would 
underpin the ERK1/2 activation in the LC of 
MA4W rats. Indeed, the LC is rich in CRF 
receptors (Reyes et al., 2006; Mousa et al., 2007) 
and it has already been shown that CRF activates 
LC neurons (Valentino and Foote, 1988). Here, we 
found no significant differences in CRFI/II 
receptor expression in the LC of control and 
MA4W rats, which indicates that while enhanced 
neurotransmission might originate in the PVN 
when chronic inflammatory pain is established, it 
is not accompanied by changes in the expression of 
the CRFI/II receptors in the LC. The co-
localization of CRFI/II receptors with the TH 
protein, as described previously (Reyes et al., 
2006), confirmed the specificity of this labeling. 
To better understand how CRF neurotransmission 
influences the role of the LC in nociception and 
anxiety behavior, an antagonist blocking the CRF 
receptors was microinjected into the contralateral 
LC. This strategy was adopted in order to study the 
ascending pain pathway passing through the LC 
given its important projections to corticolimbic 
areas (Fig. 1a). The dose of the α-helical CRF 
antagonist used was based on previous studies 
(Mousa et al., 2007), and at both 28ng and 34ng 
this antagonist successfully dampened pERK1/2 
expression in the LC of MA4W rats. Thus, the 
effects of the lower dose alone (28 ng) were 
evaluated on behavior. This procedure had no 
effect on pain sensitivity in the ipsilateral/inflamed 
or contralateral paws of MA4W rats. 
In contrast, microinjection of the α-helical CRF 
receptor antagonist reverses the anxiety-like 
behavior observed in MA4W rats without 
interfering with locomotor activity. Indeed, the 
decrease in the time MA4W rats spent in the open 
arms was no longer observed when they received 
this antagonist. These results suggest that the 
increased CRF neurotransmission in chronic 
inflammatory conditions enhances the LC driven 
activation of corticolimbic areas, which may be 
responsible for the development of anxiety. 
Indeed, it has already been shown that CRF 
infused into the LC increases anxiety, a behavioral 
effect of CRF associated with increased 
noradrenergic neurotransmission in LC terminal 
areas like the amygdala and hypothalamus (Butler 
et al., 1990; Weiss et al., 1994). Moreover, the α-
helical CRF receptor antagonist prevents the 
development of anxiety induced by a neuropeptide 
Y receptor antagonist, while not producing any 
significant change when administered in a non-
anxious state (Kask et al., 1997; Donatti and Leite-
Panissi, 2011). Similarly, we did not find a 
significant effect of the α-CRF antagonist in 
control non-inflamed animals. Overall, the effects 
in the ipsilateral paw and on anxiety-like behavior 
in MA rats are consistent with studies showing that 
administration of the α-helical CRF receptor 
antagonist to the basolateral or central nuclei of the 
amygdala has no effect on the nociceptive 
threshold but that it reduced innate fear behavior 
(Donatti and Leite-Panissi, 2013). Nevertheless, 
the lack of changes in nociception might be related 
to the use of a broad-spectrum CRF antagonist that 
blocks, nonspecifically, the signaling of CRF1 and 
CRF2 receptors. Indeed, when NBI27914, a 
specific CRF1 receptor antagonist, was 
microinjected into the amygdala, the withdrawal 
thresholds of the arthritic rats, as well and the 
anxiety-like behavior, were reversed (Ji et al., 
2007).  
Concluding, CRF signaling through the ERK1/2 
cascade in the LC appears to be an important 
mechanism directly related with anxious behavior 
associated with chronic inflammatory conditions. 
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FIGURES AND LEGENDS 
 
Fig. 1: a) Schematic representation of the anatomical pathways implicated. Briefly, the contralateral LC 
indirectly receives inputs from the inflamed paw (red dashed line; ascending pathways) and, 
subsequently, the information is sent to corticolimbic areas. Additionally, the LC sends direct projections 
to the spinal cord (blue straight line; descending pathways). b) Body weight of the control and MA rats. c) 
Body rectal temperature of control and MA rats. d) Mechanical hyperalgesia represented by a significant 
decrease in the paw withdrawal threshold of the ipsilateral paw of MA rats. e) Mechanical allodynia 
represented by a significant decrease in the force threshold of the ipsilateral paw of MA rats. *p<0.05, 
**p<0.01 and ***p<0.001; repeated measures followed by a Bonferroni post-hoc test comparing control 
vs MA for the same week (b and c) or comparing the ipsilateral vs contralateral paw for the same week (d 
and e). f) Graph depicting the expression of pERK1/2 in the LC after intra-LC administration of the αCRF 
receptor antagonist, showing that the significant increase of pERK1/2 in MA4W animals was no longer 
observed when this antagonist was administered: *p<0.05 (one-way ANOVA followed by Dunnett’s 
post-hoc test). g) Graph showing that the local administration of the αCRF antagonist had no significant 
effect on mechanical hyperalgesia in MA4W rats. h) Graph showing that local administration of the α-
helical CRF antagonist had no significant effect on mechanical allodynia in the ipsilateral paw of MA 
rats. **p<0.01 and ***p<0.001 (two-way ANOVA followed by Bonferroni post-hoc test). i) Graph 
showing that the time spent in the open arms decreased in MA4W rats receiving the vehicle alone but this 
effect was successfully reversed by administration of the αCRF antagonist. *p<0.05 (two-way ANOVA 
followed by Bonferroni post-hoc test). j) Graph showing that local administration of the α-helical CRF 
antagonist had no significant effect on the total distance travelled in the elevated zero maze. k) Graph 
 136 
showing that local administration of the α-helical CRF antagonist reversed the decrease in the number of 
entries into the open arms observed in MA4W rats receiving the vehicle alone. B=Baseline; LC=Locus 
Coeruleus; αCRF=antagonist of the corticotropin-releasing factor receptor I and II; W=Week; 
MA=Monoarthritis. 
 
Fig. 2: Expression of CRFI/II receptors in the LC of control and MA4W rats. a) and b) Photomicrographs 
showing the expression of CRFI/II receptors in control and MA4W rats, respectively. c) Graph showing 
that there were no significant changes between control and MA4W rats in terms of CRFI/II receptor 
expression in the LC. d) Immunofluorescence photomicrographs showing that almost all the neurons 
expressing CRFI/II receptors (green) are noradrenergic neurons, since they co-localize with TH 
immunolabeling. e) Graph showing the increase in pERK1/2 expression in the PVN nucleus of MA4W 
rats: ***p<0.001 (unpaired two-tailed Student’s t-test). f) and g) Photomicrographs of pERK1/2 
expression in control and MA4W rats, respectively. Scale bar=100µm. AU=Arbitrary units; W=Week; 
MA=Monoarthritis. W=Week; MA=Monoarthritis. 
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Supplementary material  
 
Nociception 
Mechanical allodynia was evaluated using an electronic version of the von Frey test (Dynamic Plantar 
Aesthesiometer, Ugo Basile, Italy), applying an increasing vertical force (from 0 to 50 g) to both the ipsi- 
and contralateral paws over a period of 20 s. In addition, the presence of mechanical hyperalgesia was 
tested using the paw-pinch test (Randall and Selitto, 1957). Increasing pressure (from 30g of pressure) 
was gradually applied to the dorsal side of the paw using a graded motor-driven device (Ugo Basile, 
Italy). A 250g cut-off was used to prevent damage to the paw. In both tests, three measures were taken on 
each paw at 5 min intervals and the average value was used. 
 
Western blotting 
Fresh tissue samples from the contralateral LC of a preliminary group including control, MA4W-vehicle 
and MA4W-α-CRF rats (28 ng or 36 ng) were obtained after sacrificing them by decapitation, 10-25 
minutes after administration. After the tissue was lysed, an aliquot of the sample (50 µg) was separated in 
a 10% polyacrylamide gel and then transferred to a polyvinylidene difluoride membrane (PVDF; BioRad, 
Spain). After washing in TBST (Tris-buffered saline containing 0.1% Tween-20), the membranes were 
blocked with 5% Bovine Serum Albumin (BSA; Sigma, Spain) in TBST and probed overnight at 4 ºC 
with a rabbit anti-phospho-ERK1/2 (1:5,000; Neuromics, USA) and a mouse-anti ERK1/2 (1:2,000; Cell 
Signaling; Izasa, Spain) antibody diluted in 5% BSA-TBST. After thorough washing, these primary 
antibodies were detected by incubating for 1 hour at room temperature with IRDye 800CW goat anti-
rabbit (green) or IRDye 680LT goat anti-mouse (red) secondary antibodies (1:10,000; Bonsai Advanced 
Technologies, Spain). After 3 final washes with TBST, antibody binding was detected using a LI-COR 
Odyssey® two-channel quantitative fluorescence imaging system (Bonsai Advanced Technologies, 
Spain). Digital images of the Western blots were analyzed by densitometry using the Image J free access 
software and the data were expressed as the pERK1/2 expression relative to the total ERK1/2. Three 
assays were performed on LC samples from 3 rats per group.  
 
Immunohistochemistry (IHC) 
Control and MA rats 4 weeks after CFA injection (MA4W; N=5 per group) were anesthetized with 8% 
chloral hydrate (400mg/kg) and they were transcardially perfused through the ascending aorta with 250 
mL of oxygenated Tyrode’s solution followed by 750 mL of paraformaldehyde 4% in phosphate buffer 
(PB, 0.1M [pH 7.2]). Brains were removed and processed for free-floating immunohistochemistry. One in 
five sequential transverse brain sections (30 µm) containing the PVN from each rat were washed, blocked 
and incubated with a rabbit antiserum against the phosphorylated ERK1 and ERK2 isoforms (pERK1/2; 
1:1000; 48 hours at 4-8ºC: Neuromics, USA). Immunodetection was achieved with a biotinylated donkey 
anti-rabbit antiserum (1:500; 1 hour; Jackson ImmunoResearch, USA), followed by an ABC solution 
(1:200, 1 hour; ABC Elite kit, Vector Laboratories, UK) and a colorimetric reaction with 3,3-
diaminobenzidine tetrahydrochloride (DAB; 10 min) in 0.05M Tris-HCl buffer containing 0.003% 
hydrogen peroxide (Cruz et al., 2005). Sections were then washed in PBS, mounted on gelatin-coated 
glass slides, cleared in xylene, cover-slipped with DPX and analyzed by light microscopy. Furthermore, 
immunohistochemistry to detect CRF receptors I/II in LC sections was performed following a similar 
protocol with an anti-CRFI/II rabbit antiserum (1:50; Santa Cruz), a biotinylated donkey anti-rabbit 
antibody and streptavidin 488 (1:1000, Invitrogen). Additionally, to co-localize the CRF I/II receptors 
with tyrosine hydroxylase (TH) positive neurons, a sheep anti-TH antibody was used (1:4000; abcam, 
UK), which was detected with an Alexa 568 conjugated donkey anti-sheep antibody (1:1000, Invitrogen). 
The specificity of the antibodies was controlled by omitting the primary antibodies in various sets of 
immunoreactions. 
Quantification of the expression of pERK1/2 in the PVN and CRF I/II receptors in the LC was performed 
by densitometry as described elsewhere (Borges et al., 2013). As no differences were observed in 
ipsilateral side when comparing with the contralateral side, the values obtained in each area were 
averaged and used for statistical purposes.  
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Fig. S1: a) Schematic representation of the experimental protocol followed in this study and b) Schematic 
representation of the local cannula implantation. 
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5. Discussion 
The present thesis focuses on the study of the activity of the Locus coeruleus-
Noradrenergic (LC-NA) system in chronic painful conditions, particularly in chronic 
inflammatory conditions. Indeed, during the development of this work it was 
becoming clear that chronic painful conditions lead to a deep biochemical and 
electrophysiological deregulation of the activity of LC neurons with repercussions on 
the sensory and emotional components of pain. 
The CCI and MA models were used to simulate the neuropathic and chronic 
inflammatory conditions, respectively. We observed that the unilateral constriction of 
the sciatic nerve resulted in a stable mononeuropathy accompanied by increased pain 
sensitivity, such as allodynia and hyperalgesia (Publication I), in accordance with what 
was expected for the CCI model (Bennett and Xie 1988). Similarly, we observed that 
the unilateral injection of the CFA solution into the rats’ tibio-tarsal joint, to induce 
MA, was able to cause reasonably evident inflammatory signs accompanied by an 
increased pain sensitivity of the affected paw. Moreover, the inflammation remained 
stable during the period of experimentation (maximum 4 weeks) and the rats showed 
normal body weight gain, normal body temperature and normal locomotor activity 
(Publication II). Such observations were in accordance with what was expected for this 
experimental model (Butler et al. 1992).  
In the CCI model of neuropathic pain we evaluated the expression of pERK1/2 
and the effect, on this expression, of an acute mechanical noxious stimulation 
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(Publication I). At the time these experiments were performed, few data was available 
regarding the pattern of pERK1/2 expression in supraspinal structures following acute 
or chronic painful conditions, particularly in noradrenergic structures. Using seven days 
SHAM and CCI rats (CCI7D), we showed that, in neuropathic pain conditions, pERK1/2 
expression was increased in the spinal cord, PGi and DRN (Alba-Delgado et al. 2011). 
However, in this study, the spontaneous tonic activity of LC neurons, which was 
measured by electrophysiology procedures, was not significantly changed in seven 
days CCI rats when compared with control rats, in agreement with what had already 
been described (Viisanen and Pertovaara 2007). Additionally, microdialysis studies 
pointed to similar extracellular NA levels in the LC and PFC of control and CCI7D rats 
(Alba-Delgado et al. 2011). Remarkably, at this time-point, CCI7D rats did not display 
any affective/emotional impairment (i.e., anxiety and depression) as a consequence of 
the exposure to the painful situation (Alba-Delgado et al. 2013). Overall, the data 
obtained at this specific time-point of neuropathic disease suggested that ERK1/2 
activation was playing a role in the processing of specific pain conditions although the 
electrophysiological activity of the LC neurons was conserved (Alba-Delgado et al. 
2011). Thus, we expanded our studies to evaluate the pattern of pERK1/2 
immunoreactivity in further supraspinal structures, mainly noradrenergic or 
serotonergic, and spinal cord, and following the application of a noxious mechanical 
stimulation to the hind paw of anaesthetized CCI7D rats (Publication I). The main 
rationale of the procedure was based on the fact that LC neurons might be phasically 
activated by noxious external stimuli (Valentino and Foote 1988). Moreover, painful 
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stimulation was already shown to imply central noradrenergic regulation in patients 
(Chapman et al. 2014). Besides, it was still unknown if, in neuropathic pain conditions, 
pERK1/2 was also expressed/altered in other supraspinal structures implicated in 
sensory, cognitive and affective functions. 
At the spinal cord level, we observed increases in the amount of pERK1/2 
detected ipsilaterally in neuropathic rats, in accordance with data from other authors 
(Ji et al. 1999; Song et al. 2005; Zhuang et al. 2005; Ji et al. 2009; Yu et al. 2013). The 
spinal cells expressing pERK1/2 in consequence of a painful situation were mostly 
localized in the superficial dorsal horn, more precisely, in the superficial laminae 
(lamina I to III), as has already been shown (Cruz et al. 2005). This reflects a certain 
spinal cytoarchitectonic organization, indicating the zone where the nociceptive inputs 
enter.  
Interestingly, in the LC, the data regarding pERK1/2 expression in control and 
CCI conditions was quite unexpected as significant decreases in the expression of 
pERK1/2 in the LC of CCI animals, either stimulated or not, were observed, despite the 
absence of significant electrophysiological changes in the LC neurons of CCI rats (Alba-
Delgado et al. 2011). This suggested there was a higher inhibitory input, probably 
provided by GABAergic input from the PrH or serotonergic input from the DRN that, 
somehow, counterbalanced the excitatory glutamatergic input from the PGi. However, 
the data obtained did not allow any further conclusions and anesthesia-induced 
decreased ERK1/2 activation was barely likely to be the cause (please, consult 
supplementary discussion of Publication I). Later on, further behavioral, 
Regulation of the activity of the Locus coeruleus-noradrenergic system in 
chronic pain 
Porto, 
2015 
 
144 
 
electrophysiological and immunohistochemical studies on the CCI model by other 
members of the team indicated that in fact, the LC-NA system is impaired at longer 
time-points of the disease, and that concomitantly anxiety and depressive-like 
behaviors start developing in those animals (Alba-Delgado et al. 2012; Alba-Delgado et 
al. 2013; Bravo et al. 2013; Bravo et al. 2014). This was the motivation for proceeding 
with the remaining studies in a model of chronic pain with different characteristics and 
etiology, as is the monoarthritis induced by intra-articular CFA, and look out for the 
involvement of the LC-NA system and the associated molecular mechanisms.  
The next step was then to evaluate prolonged inflammatory conditions which, 
in the clinical field, are recognized to be accompanied by the emergence of anxio-
depressive symptoms (Covic et al. 2012). However, despite the knowledge that the 
CFA injection produced clear pain symptoms, such as allodynia and hyperalgesia in the 
injected and adjacent area, at the time these experiments were performed it was not 
that clear if it could trigger the onset of anxio-depressive symptoms, as observed in 
clinical settings. Thus, the next goal was to evaluate the time-course for the 
development of these symptoms using well known behavioral paradigms (see 
Behavioral considerations, below). Interestingly, we observed that four weeks (28 
days) after the inoculation of the CFA solution, rats displayed evident anxiety and 
depressive behaviors. Additionally, anxiety but not depression was also detected at 2 
weeks (14 days) after MA induction using the marble burying test. Although some 
questions remain regarding the validity of this behavioral paradigm for evaluating 
anxiety-like behaviors, as discussed below (see Behavioral considerations), the 
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resulting outcome is nevertheless indicative of an abnormal behavioral state of these 
animals. At this time-point, the data obtained with the elevated zero maze were 
similar between experimental groups, indicating no anxiety-behaviors. At earlier time-
points of MA disease (4 days) no anxio-depressive symptoms were detected 
(Publication II). Overall, it may be argued that a certain chronological cascade of 
events occurs in the development of affective disorders associated to chronic pain, 
where anxiety precedes the emergence of depression. This has already been described 
by other authors (Yalcin et al. 2011). Moreover, the development of anxiety and 
depressive disorders in the CFA model has already been described in mice (Narita et al. 
2006; Maciel et al. 2013) and rats (Kim et al. 2012; Parent et al. 2012). The presence of 
these disturbed mood behaviors was also evident in other models of persistent 
inflammation or neuropathic pain (Alba-Delgado et al. 2013; Amorim et al. 2014; 
Caspani et al. 2014), suggesting that severe painful conditions, independently of their 
etiology, trigger the affective component of pain, although some differences are 
identified regarding the time-course of development of anxiety and depression. 
In order to investigate the possible implication of the LC-NA system and some 
of the associated molecular mechanisms in these MA-induced behavior changes, we 
then quantified the expression of phosphorylated ERK1/2 (Publication II). While at 4 
and 14 days after MA induction no significant differences in the pattern of ERK1/2 
expression in LC were detected, the 28 days’ time-point was accompanied by 
significant increases in ERK1/2 phosphorylation. Indeed the difference in the results 
obtained at the earliest time-points, where the anxio-depressive phenotype had still 
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not been developed neither in the CCI (Publication I) nor in the MA (Publication II) 
models of pain, are quite interesting. In fact, they reinforce that there is a different LC 
modulation in neuropathic or inflammatory conditions, at least at the earliest time 
points of the diseases. It is still lacking the physiological meaning of these events 
because pain is clearly present in both models at these time-points.  
The increased pERK1/2 levels in the LC at 28 days after the induction of MA 
suggests an increased activation of this signaling cascade in chronic inflammatory 
conditions, leading to anxious and depressive behaviors. Further, we explored the 
ERK1/2 activation in the CNS structures that, together with the LC, form an ascending 
pathway, namely in the spinal cord and the PGi, that project to LC, and the PFC, the 
main afferent of LC neurons (Ennis and Aston-Jones 1988; Samuels and Szabadi 2008); 
see section 2.6.2.). In the PGi and PFC an increased pERK1/2 expression was detected 
only at 28 days after MA induction. The increased ERK1/2 activation in the PFC is, 
somehow, expected since it includes the rostral part of the anterior cingulate cortex 
(ACC, (Krettek and Price 1977; Ray and Price 1992)), a structure already shown to be 
implicated in the regulation of the affective and emotional responses to pain (Lane et 
al. 1998; Vogt 2005). Indeed, activation of ERK1/2 in the ACC was already shown to be 
an important contribution to the expression of affective pain (Cao et al. 2009). 
Corroborating this, we then observed that microinjection of SL327, an inhibitor of 
ERK1/2 activation, in the LC was able to reverse the anxiety-like behavior in the 
monoarthritic rats with 28 days after CFA injection (MA4W), as well as restored the 
ERK1/2 activation levels in the ACC of these animals (Publication III). Thus, we were 
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able to conclude that ERK1/2 activation in the PGi-LC-PFC pathway is implicated in the 
signaling events underlying the onset of anxio-depressive behaviors in animals with 
prolonged conditions of chronic inflammatory joint pain. 
In what regards to the pattern of ERK1/2 activation in the spinal cord at distinct 
time-points of the MA conditions, it was already shown that at 4, 7 and 14 days after 
CFA injection, the expression of activated ERK1/2 forms was mostly observed when 
there was application of an ankle bend stimulation (innocuous to control rats) (Cruz et 
al. 2005). In our western blot studies, we also found that 4 days after CFA injection 
were not accompanied by significant increases of ERK1/2 activation in the lumbar 
spinal cord (Publication II). However, on the contrary to what we have found 
(Publication II) and previous reports (Ji et al. 2002; Cruz et al. 2005), other authors 
were able to detect significant increases of pERK1/2 expression 96 hours (4 days) after 
CFA injection into the hind paw (Xu et al. 2008). At a later time-point of disease, 
namely at 14 days after MA induction, our data was not in accordance with Cruz et al, 
(2005) studies. The different procedure used for the quantification of pERK1/2 levels 
may underlie such differences. Indeed, Cruz et al., (2005) quantified the number of 
cells immunoreactive to pERK1/2 per section and per sub-region of the grey matter of 
the spinal cord of animals anaesthetized with sodium pentobarbital. In contrast, we 
quantified pERK1/2 expression levels by western blot in the ipsilateral or contralateral 
sides of the lumbar (L3-L6) spinal cord segments (Publication II), the most important 
segments implicated in chronic painful conditions from the periphery, particularly from 
the hind paws (Rigaud et al. 2008). Thus, although some of the available data regarding 
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ERK1/2 expression in chronic pain conditions are contradictory, they are undoubtedly 
indicative of ERK1/2 implication in pain processing at various levels of the pain matrix. 
The following step was to evaluate if these behavioral and biochemical changes 
were, in fact, a consequence of the prolonged nociceptive inputs from the inflamed 
paw in the monoarthritic condition. Thus, we adopted the strategy of topically blocking 
these nociceptive inputs from the inflamed paw with a potent anti-inflammatory 
cream, as is the commercial diclofenac-based cream Voltaren® emulgel (Publication II). 
The topic application was used in order to avoid the well-known side effects of the oral 
administration and the stress associated with daily intraperitoneal injections, and, at 
the same time, to produce a local analgesic effect, without affecting other body parts. 
As expected, the inflammatory signs (edema) and pain sensitivity of MA rats were 
significantly reduced to control levels. Similar analgesic effects using topic diclofenac 
cream were also observed in other studies (Dawane et al. 2011; Takayama et al. 2011). 
Moreover, in diclofenac-induced analgesia conditions, anxiety- and depression-like 
behaviors were no longer observed in MA4W rats and the increased pERK1/2 levels 
previously observed in MA4W rats were reversed to almost normal levels in the spinal 
cord, PGi, LC and PFC. These data suggested that the anxio-depressive behaviors were 
indeed triggered by the existence of continuous painful input arising from the inflamed 
paw, and when this nociceptive input has been subsided, the affective-associated 
behaviors became improved. Similar data was obtained by Amorim et al., (2014) using 
another experimental model of monoarthritis, the kaolin/carrageenan injected in the 
knee joint. Indeed, these authors showed that 4 weeks after the induction of arthritic 
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conditions, rats displayed and anxiety- and depressive phenotype and that 
amitriptyline, a tricyclic antidepressant used in chronic pain treatment (Jann and Slade 
2007), was able to reverse the hyperalgesia and the anhedonia-like effect, a core 
symptom in depression (Amorim et al. 2014). Additionally, it was also shown that 
tramadol, a potent analgesic compound, was able to reverse the mechanical allodynia 
and anxio-depressive phenotype observed in the CCI condition (Caspani et al. 2014). 
All these studies suggest that drugs that relieve pain have also repercussion on the 
indirect consequences and comorbidities associated to chronic painful states. In our 
Publication II, also the levels of pERK1/2 expression have been restored indicating a 
direct functional correlation between the activation of these signaling cascades in the 
spinal cord-PGi-LC-PFC pathway and the nociceptive-, anxiety- and depressive-like 
behaviors. Indeed, although a systemic effect of the diclofenac cream is not totally 
discarded, as argued in Publication II, it is the topic effect that is producing the central 
changes observed in the pERK1/2 levels, by directly blocking the nociceptive inputs 
from the inflamed paw. Overall, the data obtained in the Publication II lead to the 
conclusion that a chronic inflammatory condition is able to induce affective disorders 
associated with increased pERK1/2 expression in the LC and its afferents and 
projections, and that the blockade of the nociceptive inflammatory inputs is capable of 
reversing all the CFA-induced changes. 
Although the quantification of pERK1/2 expression is a widely used method to 
explore the degree of activation of certain encephalic structures in specific 
experimental conditions, it does not allow going further on in the understanding of the 
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implicated mechanisms and, also, does not allow the interpretation of the two most 
important modes of discharge of LC neurons: the tonic and the phasic modes. In order 
to overcome this barrier, we used electrophysiological procedures to infer about the 
activity of the LC neurons in chronic inflammatory conditions. Thus, in Publication III, 
we evaluated the LC discharge characteristics at baseline and following noxious 
stimulation of the inflamed paw in an early (non anxio-depressive phenotype) and late 
(anxio-depressive phenotype) phase of the disease development. Using rats with 1 
week of MA (MA1W) as a control of a pain condition without emotional changes and 
rats with 4 weeks of MA (MA4W) because of their anxio-depressive phenotype, we 
showed that prolonged time-points of MA were susceptible to deep 
electrophysiological changes in both the tonic and phasic activity of LC neurons. 
Indeed, while tonic activity was significantly decreased at 4 weeks after MA induction, 
the sensory-evoked activity (phasic activity) was significantly increased (Publication 
III). Additionally, the incidence of burst activity was also decreased in MA1W and 
MA4W conditions, although it did not reach the significance level. These results 
suggest a decrease in the spontaneous tonic activity of the LC neurons in prolonged 
monoarthritis. Corroborating this, significant increases in TH expression were found in 
MA4W rats suggesting a noradrenergic dysfunction in terms of demand of this 
neurotransmitter. This is consistent with our finding of an altered climbing behavior in 
the forced swimming test in MA4W rats (Publication II), which can be interpreted as 
altered availability of noradrenaline (Detke et al. 1995; Cryan et al. 2005). Altogether, 
these results indicate an impairment in noradrenergic transmission to the spinal cord 
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(descending pathways) and to the cortical areas (ascending pathways), in chronic 
inflammatory conditions.  
To evaluate the sensory-evoked activity of the LC neurons several noxious 
stimulations were performed in the injured paw while the discharge was recorded in 
the contralateral LC (Publication III). Contralateral LC neurons were activated by 
noxious stimuli in the hind paw in control animals, as expected (Simson and Weiss 
1988; Valentino and Foote 1988), but this activation was exacerbated in MA4W rats. It 
has already been shown that this type of response of the LC neurons has mostly an 
“all-or-none” nature and the magnitude of the response is not altered when the 
pressure of the paw compression slightly varies (Simson and Weiss 1988). Thus, 
overall, the results are greatly suggesting that an increased ratio of the tonic/evoked 
activity, as observed in prolonged monoarthritic conditions (MA4W), enhances the 
pain perception to noxious events, with repercussions on the signaling to the forebrain 
areas. Similar electrophysiological data and TH expression were observed in rats with 
chronic neuropathic pain and under social stress (Bravo et al. 2013) and in a rat model 
of post-traumatic stress (George et al. 2013), suggesting that prolonged monoarthritis 
may produce similar LC changes as those observed in stressful conditions.  
At this point we were speculating if the increased pERK1/2 levels observed in 
the LC of rats with 4 weeks of MA (Publication II and Publication III) were playing a 
role in this sensory-evoked response in MA4W rats. Thus, we explored the effect of the 
pharmacological blockade of ERK1/2 phosphorylation, achieved by intra-LC 
administration of the SL327 compound, on the neuronal activity of the contralateral 
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LC. Although the microinjection of SL327 did not significantly affect the LC tonic 
activity in MA4W rats, it caused a reversion to control levels, or even below, of the 
sensory-evoked parameters that had been found altered in response to the prolonged 
inflammatory condition (Publication III). This suggests that increased ERK1/2 activation 
in the LC is implicated in the sensory-evoked response of LC neurons in rats with 
prolonged monoarthritis (MA4W). Moreover, the microinjection of SL327 reversed the 
anxiety-like behavior to control levels but the mechanical hyperalgesia remained 
unchanged. Thus, it is possible that the changes in the LC neuronal electrophysiological 
activity observed in MA4W animals reflect mechanisms related with the anxiety-like 
behaviors which involve ERK1/2 activation in the LC. In accordance, the absence of 
effect of the SL327 in the electrophysiological activity of control rats is corroborated by 
the lack of behavioral changes in control rats in the elevated zero-maze (Publication 
III). Therefore, altogether these data suggest that increased levels of ERK1/2 
phosphorylation in the LC at the prolonged times of monoarthritis disease are more 
related with the onset of “affective-behaviors” associated with pain. Indeed, the 
present data demonstrate that pain-related anxiety is dissociated from the sensorial 
pain component in an animal model of arthritic pain.  
Finally, we were questioning what extracellular input in the LC would be 
producing increased ERK1/2 activation upon prolonged painful conditions and, 
consequently, would be responsible for the development of anxiety-like behaviors. 
Taking into account that, as mentioned above, the electrophysiological data together 
with the increased TH expression in the LC of MA4W rats were quite similar with what 
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had been observed in stressful conditions (Bravo et al. 2013; George et al. 2013; Bravo 
et al. 2014), we hypothesized that CRF would play a role in these mechanisms 
(Publication IV). In support of this, pain, and particularly the inflammatory pain, was 
recognized as a potent stressor activating the Hypothalamic–pituitary–adrenal axis 
(HPA; Hummel et al. 2010). Furthermore, chronic stress produces persistent ERK1/2 
activation in dendrites of the layers I and II in the PFC (Trentani et al. 2002), precisely 
where we found an increased number of neurons expressing pERK1/2 in MA4W rats. 
Thus, the hypothesis that prolonged painful conditions were producing stress-like 
effects mediated by CRF neurotransmission was highly attractive. Moreover, we 
observed a significant increase in ERK1/2 activation in the PVN of the hypothalamus, 
the main producer of CRF, at prolonged time-points of monoarthritis (MA4W), 
indirectly indicating an increased activity in the CRF-based system. Thus, we 
microinjected a CRF antagonist in the LC and assessed the nociceptive and anxiety-like 
behavior in control and MA4W rats. Similarly to what occurred after microinjection of 
SL327 in the LC, here we also observed a reversion in the anxiety-like behaviors that 
had been observed in chronic inflammatory conditions, without affecting the 
nociceptive threshold. Additionally, the microinjection of the CRF antagonist in the LC 
was also able to reverse the increases in ERK1/2 activation in LC neurons, highly 
pointing to an effect of CRF through the ERK1/2 cascade in the LC (Publication IV). This 
increased CRF neurotransmission in the LC would explain the increased expression of 
TH in prolonged inflammatory conditions, as it was already observed in previous 
studies (Melia and Duman 1991). However, it is well known that CRF activates the LC 
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neurons, as shown by the increase in the tonic discharge of the LC neurons upon local 
CRF microinfusion (Curtis et al. 1997), which could be against our findings of decreased 
tonic discharge in MA4W rats (Publication III). Nevertheless, a dual role for the CRF in 
acute or chronic stressful conditions is, nowadays, documented. Acute stress promotes 
sensitization of the LC neurons to CRF neurotransmission, producing high tonic but low 
phasic activation (Curtis et al. 1995). Indeed, in Publication III, a weak decrease in the 
sensory-evoked response of the LC neurons of MA1W rats was observed, although the 
tonic discharge rate was maintained at normal levels. In contrast, chronic stressors 
that more closely relate to psychopathology, such as repeated auditory stress, 
desensitize LC neurons to CRF (Conti and Foote 1996) and induce intracellular 
trafficking of CRF receptors (Reyes et al. 2014) producing opposite effects to those 
observed in acute stress. Thus, in conclusion, although some studies are still needed to 
clarify the role of CRF in prolonged monoarthritic conditions, altogether the data 
obtained seem to implicate CRF as an important mediator in the onset of anxiety in 
inflammatory painful conditions, through mechanisms that involve the activation of 
the ERK1/2 signaling cascade in the LC. Future experiments, as immunohistochemistry 
and electrophysiology, are planned in order to further understand the effect of 
blocking CRF neurotransmission in anxio-depressive monoarthritic rats. A schematic 
representation of the data obtained using the monoarthritis model of chronic 
inflammation can be found in Figure 10. 
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Figure 10: Schematic representation of the main results obtained using the monoarthritis model of 
chronic inflammation. A) Main features observed in prolonged monoarthritis. B) Results obtained upon 
blocking the peripheral nociceptive inputs with diclofenac topical application, in Publication II. C) Results 
obtained upon inhibition of ERK1/2 activation in the LC by using SL327, in Publication III. D) Results 
obtained upon blockade of the endogenous CRF activity in the LC, in Publication IV. 
 
Behavioral considerations 
The study of pain neurobiology, and of its associated comorbidities, relies in a 
large amount on behavioral data, as happens in many research areas within 
neurosciences. Indeed, the assessment of behavioral changes in nociception, and in 
the case of the present work, the search for anxiety- and depressive-like behaviors, 
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allows to validate the experimental animal pain models under study and to correlate 
molecular and cellular data with function.  
In the present work, the nociceptive tests aimed to assess the nociceptive 
threshold in CFA-injected and CCI rats, confirming that thermal and/or mechanical 
hypersensitivity was increased. The most widely known standard pain assays or 
nociception tests that are used in the pre-clinical pain research, and were used in the 
monoarthritic and CCI animals, consist in applying either noxious (hyperalgesia tests) 
or innocuous (allodynia tests) mechanical or thermal stimuli to an animal’s body part 
(often the hind paw). This procedure leads to a simple behavior that can be scored, 
such as the nocifensive withdrawal or vocalization, and allows assessing evoked 
nociceptive behaviors, as opposed to spontaneous pain. In the monoarthritis model, it 
is also well described another test that evaluates nociception associated to the 
physiological movement of the joints, mimicking the movement that the animal would 
perform during locomotion. Described by Butler and Weil-Fugazza (1994), the ankle-
bend test (or foot-bend test) consists in scoring the animals behavior in response to 
five alternate flexions and extensions of the arthritic joint, in this case the ankle, and 
has been reliably used to test pharmacologically the antinociceptive efficacy of several 
compounds (Neto and Castro-Lopes 2000; Potes et al. 2006; Potes et al. 2006; Pozza et 
al. 2010). As it allows obtaining different information regarding the animals’ well-being 
and nociception, this ankle-bend test was also used in the present work in the 
monoarthritis model. 
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In order to assess the onset of anxiety- and depressive-like behaviors resulting 
from the progression of the chronic pain condition, it was necessary to perform other 
specific behavioral paradigms. In the case of anxiety, the marble-burying and the 
elevated zero maze tests were used. The marble-burying test is based on the fact that 
rodents display a burying behavior (known as defensive burying) in response to an 
aversive or non-aversive but unknown stimulus (De Boer and Koolhaas 2003). This 
behavior refers to the displacement of bedding material using the snout or the 
forepaws in an effort to cover the foreign object (Pinel and Treit 1978). In the context 
of the behavioral test, rodents bury the higher number of glass marbles in response to 
non-aversive stimuli, according to their anxious state. This assay has been used as a 
tool for assessing the anxiety-like behavior mainly due to its sensitivity to several 
anxiolytic drugs (Broekkamp et al. 1986; Njung'e and Handley 1991; Nicolas et al. 2006; 
de Almeida et al. 2014). Nevertheless, some authors argue that the burying behavior 
reflects a repetitive and preservative behavior (obsessive-compulsive) rather than 
novelty-induced anxiety (Thomas et al. 2009).  
The elevated zero maze is another paradigm used for the assessment of 
anxiety-like behavior. It consists of a modification of the elevated plus maze model 
comprising an elevated annular platform with two opposite and enclosed quadrants 
and two open quadrants. The “zero” shape removes any ambiguity in the 
interpretation of the time spent in the central square of the traditional “plus” design, 
allowing uninterrupted exploration. It is based on the fact that when rodents are 
exposed to a novel open and elevated alley, they exhibit a conflict between exploring 
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the new areas or staying in closed and safe areas. Thus, an increase in the amount of 
time spent in the closed areas is correlated with anxiety-like behavior (Shepherd et al. 
1994).  
Depression-like behavior was evaluated using a modified version of the forced 
swimming test (FST), as described previously by Detke et al. (1995). It is based on the 
fact that when confined to a limited space, rodents engage in a vigorous escape 
behavior. When it becomes clear that escape is impossible, these animals adopt an 
immobile posture, performing only the necessary movements required to keep their 
head above the water. Accordingly, in the FST, rats are placed for 15 minutes (pre-test) 
in a clear cylindrical acrylic container filled with tepid water to induce a depressive 
state in these animals. After 24 hours, the rats are once again exposed to the same 
conditions for 5 minutes (test) and they are videotaped to score their immobility 
(floating without struggling, using small movements to maintain the head above 
water), swimming (actively moving limbs more than is required to maintain the head 
above water) and climbing (active forepaw movements in and out of the water, often 
directed at the wall of the tank) (Detke et al. 1995). While longer periods of immobility 
are taken as an indication of depression-like behavior, changes in the time spent 
climbing or swimming have been correlated with alterations in the availability of 
noradrenaline and serotonin, respectively (Detke et al. 1995; Cryan et al. 2005). The 
FST keeps being one of the most used assays for the detection of pro-depressive and 
anti-depressive effects due to its good predictive validity, and it allows a rapid and 
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cheaper way for the assessment of antidepressant activity in a wide range of 
substances and pro-depressive activity in several experimental conditions.  
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6. Conclusions 
The main conclusions of this work are: 
1) The ERK1/2 cascade is differentially activated/deactivated in the spinal cord 
and in the PGi-LC-PFC pathway according to the duration of the exposure to a 
painful condition (acute vs chronic) and the type of pain (inflammatory vs 
neuropathic); 
 
2) Chronic and painful inflammatory conditions are accompanied by the 
development of anxiety and depression which are a direct consequence of the 
increased and persistent nociceptive input due to inflammation; 
 
3) In chronic inflammatory conditions, the ERK1/2 cascade in the LC is implicated 
in the altered perception of the noxious stimulus and modulates the 
development of the observed affective disorders; 
 
4) The normal noradrenergic circuitry is compromised in chronic inflammatory 
conditions triggering the affective component of pain rather than participating 
in the nociceptive response; 
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5) Electrophysiology recordings of LC neurons points to a low tonic activity and 
high phasic activity in chronic inflammatory conditions leading to an anxio-
depressive phenotype; 
 
6) Increased CRF neurotransmission in the LC upon chronic inflammatory 
conditions seems to be one of the mechanisms triggering the activation of the 
ERK1/2 cascade and subsequent effects. 
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